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Abstract
The present study has investigated the possibility o f using pharmacological methods to 
enhance the psychomotor performance o f young, healthy human subjects beyond 
normal levels. Previously reported studies have concentrated on replacing cognitive 
performance in clinical cognitive deficit conditions. However, overall evidence o f drug 
effects, on various aspects o f cognition, suggested that some drugs may be able to 
enhance the psychomotor component o f cognitive performance in normal subjects. Four 
substances which had shown some evidence being putative psychomotor enhancers 
were identified, caffeine, nicotine, Ginkgo biloba extract (GBE) and citalopram 
hydrobromide (CH). Each had a specifically different pharmacology, caffeine and 
nicotine being stimulants but with different sites o f activity, GBE a vasodilator and 
increaser o f cerebral blood flow, and CH a re-uptake inhibitor o f serotonin. Experiments 
were conducted to assess if  their relative pharmacologies were suitable for achieving 
absolute psychomotor enhancement and to assess if currently available substances 
would be genuinely usable as psychomotor enhancers. A  test battery o f relevant and 
valid tests was constructed to cover the performance, physiological and psychological 
aspects o f performance which were likely to be affected. The results showed some 
evidence for absolute psychomotor performance enhancement, with stimulant effects on 
the EEG and some improvement in reaction times and mood with caffeine and nicotine. 
GBE and CH did not show any effects on the tests used. This did not unequivocally 
demonstrate the existence o f psychomotor enhancers but did suggest that active 
stimulation o f the Central Nervous System is a more appropriate approach to increasing
psychomotor performance above normal levels, than increasing the amount o f resource 
for brain function.
0 Philip Wansbrough 1998
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Chapter 1 
Introduction
Background
With the ever-increasing technological complexity o f the working environment, 
human performance is rapidly becoming the rate-limiting step'in task efficiency. To 
improve overall working performance, therefore, it is important to concentrate not only 
on improving the technology with which we all work, but also to improve the normal 
human capability to deal with it. This can be approached from two directions, by 
improving cognitive performance or physical performance. On reviewing the published 
literature on the subject, it became clear that there is a large amount o f work, indeed 
whole journals, dedicated to the improvement o f the latter, mainly driven by the world 
o f sport. Such studies have looked at a wide range o f methods covering all aspects o f 
physical and mental training, equipment and technology to aid training, environment, 
physical attributes for particular sport and, last but definitely not least, drugs. The 
investigation o f improvement in cognitive performance has been slightly more focused 
on drugs although there has been a clear lack o f investigation o f the enhancement o f 
normal cognitive performance by pharmacological means.
One major problem in the search for true cognitive enhancing drugs is that we 
are unaware if healthy humans have a totally efficient cognitive system. If cognitive 
function in normal healthy humans is as efficient as possible, then it would probably not 
be possible to increase performance.
However, the definition o f cognitive performance is not clear. When using the 
term cognition most consider it to be the actual functional processes which occur within 
the brain in order to process an output to a stimulus. Some aspects, however, such as the 
overall accuracy, speed or resolution o f a task can be classified as psychomotor
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performance and are no less important. These can be considered to be representative o f 
die overall processing speed and are the result o f the central cognitive processes. They 
can be subject to change and the ability to attend to the task in-hand will invariably 
affect overall performance. When attempting to improve absolutely, the performance o f 
a cognitive task, ways o f speeding up the motor reaction component, or increasing the 
vigilance in attending to the stimuli are just as valid as improving the central cognitive 
processes in the first place. A  drug capable o f improving the central cognitive processes 
above normal levels should be considered to be a cognitive enhancer (CE). However, 
the majority o f studies o f such drugs conducted in normal subjects have tended only to 
affect the psychomotor aspects o f cognitive performance (see Tables 1.2 - 1.6). 
Therefore, a drug which can improve psychomotor performance above normal levels 
can be considered to be a psychomotor enhancer (PE).
In the author’ s view, using these wider limits in an investigation o f the 
improvement o f cognitive performance as a whole does not make studies which only 
look at making the central cognitive processes more efficient absolutely, or those 
looking at replacing lost neurotransmission activity using drugs illegitimate. It merely 
widens the field o f view o f the same work area. By legitimising all approaches to 
improving performance, work can be categorised more easily and will, therefore, lessen 
the confusion as to which substances are true CEs or PEs.
Some assume that CEs, in the widest context, are only those drags used to 
counteract Alzheimer's disease and other dementias, involving loss o f cognitive 
processes (Calvani and Carta 1991, Shimizu 1991 ). All aspects involved in attaining 
cognitive enhancement are valid in themselves, but they should be viewed together to
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give a clearer overview o f the different approaches being made to improving overall 
cognitive performance.
The idea o f enhancing overall cognitive and psychomotor performance by using 
drugs is not a new one. Indeed some drugs are already used to maintain normal 
performance levels o f fatigued operators in some very specialist working environments 
(Belland & Bissell 1994, Emonson & Vanderbeek 1995). However, the existence o f a 
large number o f different compounds which are alleged to enhance performance has 
resulted in a rather disparate approach to research in this area. The majority o f studies so 
far have concentrated on the use o f CEs and PEs for the reinstatement o f cognition to 
those performance levels lost through age, disease or both. Table 1.1 provides a synopsis 
o f reviews and generic papers published on the subject o f putative CEs. These generally 
concluded that positive behavioural results with CEs in animal studies have not 
necessarily extrapolated to results in humans, CEs did have some efficacy in human 
cognitive deficit conditions, but that current methodologies used in investigation were 
not consistent enough to adequately assess putative CEs for therapeutic purposes or to 
be predictive o f enhancement above normal levels. Overall the literature suggested that 
it is more likely that such drugs will be able to enhance the psychomotor aspect o f 
cognitive performance in normal subjects, rather than the central cognitive processes. 
Therefore, it was decided to concentrate the present study on investigating the effects o f 
putative PEs.
In the author’s opinion, to fully understand the complex processes that are
involved in the human brain and then be able to improve them, study should not be
restricted solely to the alleviation o f deficit in mental performance. Indeed, any
understanding o f how to increase absolute cognitive performance, including using PEs,
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would improve many working situations, with enhanced efficiency or faster, more 
accurate human responses.
In order to set out the programme o f investigation for this study it was important 
to set a specific goal. This has been shown to be especially important in the assessment 
o f CEs (Gamzu 1990). However, in that same paper, it was stated that the therapeutic 
effects o f CE’s are not seen for many weeks after treatment commences and that effects 
in healthy volunteers should not be used as evidence for or against the efficacy o f a CE 
(or PE). In fulfilling the first part o f Gamzu’s suggestion the present study actually 
departed from the latter part by not assuming that PEs were only for therapeutic 
purposes. The goal o f the study was, therefore, to assess if  it was possible to enhance the 
cognitive performance o f young, normal healthy humans beyond normal levels, using 
drugs, i.e. PEs, which are currently available. This was conducted within the context o f 
being able to use such drugs in real world situations.
To set this goal, it was first necessary to look at the moral and every-day 
implications o f enhancing cognitive performance beyond normal levels. An extreme 
example where PEs could be o f future use, such as the use o f drugs by schoolchildren to 
improve exam results, was thought to be undesirable. The argument, however, was not 
thought to be so strong against giving ‘ safe’ PEs to individuals operating in highly 
technical situations e.g. pilots, air traffic control and power plants. Here, an 
improvement in psychomotor performance may save lives. Fast and accurate decision 
making, involving many o f the complex cognitive procedures that the human possesses 
could prevent the human error that is prevalent in accidents. As technology progresses, 
the information load on such operators will grow greater and yet more demands will be
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made on their mental performance. Therefore, the ability to improve psychomotor 
performance to deal with this would improve safety.
In opposition to this view it could be argued that more timely shift rotation 
would allow operators to get sufficient rest in order to perform adequately. Better 
ergonomic design o f the tools could also improve performance. Machine and computer 
technology has advanced greatly in the last decade, and better ergonomic design or shift 
rotation is useful, but there is a point in the equation when the human clearly becomes 
the rate limiting step. Automation is definitely the answer in some situations, but in 
others humans cannot be replaced and, therefore, they will have to perform faster, more 
accurately and for a longer period o f time. The answer in this case may be a PE which, if 
available, would improve cognitive performance before fatigue set in. PEs would not 
necessarily replace those drugs already in use for combating fatigue, but could provide a 
useful ‘boost5 in performance over optimum levels.
From reviewing the papers in Table 1.1 it was clear that there had been a wave 
o f research into producing putative CEs and PEs in the late 19805s and early 1990’ s. 
However, as has been said, these were mainly for the degenerative diseases which cause 
a decline in cognitive function e.g. Senile Dementia o f the Alzheimer’s Type (SDAT). 
One other aspect that became clear on further reading o f the literature was that society 
commonly uses natural psychoactive substances which have alleged psychomotor 
enhancing benefits. It was necessary, therefore, to thoroughly review studies o f both 
pharmaceutical and commonly available substances on healthy humans, and to highlight 
the possible beneficial effects they may have in the working environment.
Another problem existed in that initially, most, if not all, the new drugs
developed to enhance cognitive performance, in the wider context, were targeted at
6
clinical therapies for cognitive deficit. These have sometimes found their way into other 
marketable areas as beneficial side effects were highlighted. In addition, some 
substances, which have been rejected by the clinical professions, have entered the illicit 
trade markets. Wild claims about their efficacy have been made, with little, i f  any good 
quality scientific substantiation (Concar and Coghlan 1993). As these dings exist, 
people will use them and, therefore, we need to understand their modes o f action. It will 
become necessary to investigate the use o f these illicit putative CEs/PEs because, in ill- 
informed hands, they may have unknown detrimental effects on performance or health. 
However this particular issue was not dealt with in the confines o f the present study’s 
goal.
This review aimed to inform the construction o f the present study by assessing 
the state o f research into drugs that are used, or are purported to have a use in the 
enhancement o f healthy human psychomotor performance, above normal levels i.e. PEs. 
Drugs referred to in this study, which are only aimed at alleviating a deficit were known 
as cognitive replacers (CRs).
Work carried out on already widely available psychoactive drugs as well as 
some o f the newer derivatives and developments was assessed. It highlighted the lack o f 
well controlled scientific study o f improvement o f absolute psychomotor enhancement, 
and suggested directions in which the research needs to move. The use o f natural 
compounds to improve performance is widespread and the investigation o f the use o f 
these substances as absolute PEs, and the problems with withdrawal associated 
performance deficits were also emphasised.
7
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Review Strategy
In order to select specific drugs for investigation the literature was further reviewed for 
evidence o f psychomotor enhancing properties in a wide range o f substances. It was 
important to structure the literature review to identify the availability and suitability o f 
drugs for investigation o f the present study’s goal. To do this the current drivers o f 
putative CE and, more specifically, PE development had first to be assessed as well as 
the methods used to prove efficacy. This then allowed a strategy to be devised in 
approaching specific published studies o f such substances.
From the reviews listed in Table 1.1 it appeared that there are currently two main 
areas driving research and development for enhanced cognitive and psychomotor 
performance; medicine and society. The first is obviously o f  great importance for the 
mental health o f the world’s population. The latter, however, is now also increasing its 
demand to develop these drugs, as society wants a performance advantage in 
competition and ever increasing professional efficiency. In addition, these drugs would 
also provide the advantages o f improved overall cognitive performance and intellectual 
quality in the general population (review Allain 1990i). It is the drugs developed as a 
result o f the latter drive that would be most useful in working situations. At the moment 
most o f the drugs which possibly fall into this category have been developed for medical 
purposes rather than as a direct result o f looking for a PE, During their assessment they 
have probably shown promise and have been legally approved, but, in some cases may 
not have completely fulfilled the requirements for general release as a medication. Other 
substances which have improved psychomotor performance may have been in use so 
long, that they have become a foodstuff or their use is just generally accepted. The
11
present review, therefore, concentrated on results from studies using healthy, normal 
humans as subjects, with drugs that have been approved for testing in humans including 
naturally occurring substances that are in general use.
The development o f PEs for use in non-clinical performance enhancement is 
very difficult. No one doubts that any drug which improves psychomotor performance 
would benefit a large number o f psychiatric and neurological patients. If it could show 
similar effects in normal people, or those with lower than average performance, it would 
also be very valuable in terms o f improving the overall mental performance o f the 
populace. From the literature there seemed to be a general agreement that research in 
both the clinical and non-clinical areas is hampered by the lack o f relevant tests in both 
humans and animal models. A  lack o f well defined pharmacological targets to develop 
drugs for was also apparent (Allain et al 1990a, Allain et al 1990b, Hollister 1990).
It has been suggested that whilst animal models may not exactly replicate the 
results seen in humans in drug research, positive results in animals may serve as 
indicators o f the same in humans (Sanger 1990). This approach involves assessing 
animal cognition in a behavioural way rather than at a neurological level, much the same 
as human processes are. To develop and assess PEs in this manner may allow some 
drugs which show promise, but not actual clinical efficacy, through to a stage o f testing 
on humans. Animal models do not necessarily reflect exact mechanisms at work in the 
human. Some drugs, therefore, will show less efficacy in animals than humans and vice 
versa. This means that some drugs which may be o f use in humans may still be passed 
over at this stage.
New methodologies are therefore important in overcoming the problems with
relating animal and human studies. Increases in computer technology, especially its use
1 2
in physiological measurement, could be one o f the answers. Indeed, it has been 
suggested that the use o f quantitative electroencephalography (qEEG) would be 
essentially the same for both animals and humans and should, therefore, be used in this 
type o f drug assessment (Hall et al 1990). Being a relatively new method, o f course, a 
full profile o f its capability is not available and results should be treated with care.
As a result o f this lack o f standardisation in assessment methods, each o f the 
sections o f this review highlights the methodologies used, so that recommendations 
could be made as to which procedures may be o f use in assessing the use o f putative 
PEs. Once the drugs to be used for the present investigation were identified, the 
methodology for assessment was fomiulated. This is discussed in Chapter 2.
It would seem from these views that the current system for assessing novel PEs 
for both clinical and non-clinical purposes is less than perfect. The latter also has added 
ethical and legal problems. Indeed the FDA (in the US) has suggested that any drug able 
to enhance the cognitive processes o f healthy humans may be illegal (Clinical Pharmacy 
News article June 1992 11 (6) : 467). To assess possible applications o f these drugs it 
would be prudent, therefore, to look at substances which have already gained approval 
for clinical use as well o f those o f natural origin. This review assessed the extent to 
which these putative PEs have been investigated and their results quantified, in normal 
humans.
One major problem was that most o f the work reviewed has been carried out by 
only measuring performance, psychological or physiological responses. Veiy little has 
been conducted using combined techniques and this situation needed to be addressed in 
any investigation o f PEs.
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A  large number o f pharmacological actions can result in indications o f improved 
psychomotor performance. Hence there is a variety o f compounds which could be 
termed as PEs. Classification o f CEs, as a whole, has mainly derived from clinical 
applications and, due to the complexities involved, has resulted in a large variety o f list 
types (Frostl and Maltre 1989, Sarter 1992a,b). These, in the main, can be simplified. 
The classifications used in the present review covered the main pharmacological effects 
thought to be o f use in improving performance in those working tasks which rely on 
psychomotor output. This included drugs which have previously been tested in 
clinical/non-clinical applications and substances o f a natural origin which have been 
reported either to ameliorate decrements in performance or improve performance 
absolutely, with few, if  any, side effects.
Some drugs, produced for clinical purposes, have been reported to aid some 
aspects o f psychomotor performance in normal control groups when compared to 
clinical deficit groups (Wilsher et al. 1979, Hindmarch 1995). Therefore, the effects o f 
these particular drugs in normal healthy humans was included in the review. They 
centred around three main groups, the nootropics, stimulants and neurotransmitter based 
PEs. The other group included was that o f natural extracts as they are in general societal 
use and hence are supported by a large body o f work.
As a whole the present review concentrated on the use o f PEs in healthy
humans. Due to the lack o f work conducted in this area, however, ideas were also drawn
largely from literature produced from work on drug treatments o f cognitive deficit
patients. It has been highlighted that it is difficult to separate the direct drug effects on
the mental state or the underlying cognitive behaviour in mentally disordered subjects
(Judd et al. 1987) and, therefore, care should be taken when extrapolating the results
14
from such subjects onto a normal healthy population. This emphasises the need for more 
research to be conducted in this area and is one o f the main reasons that assessment o f 
PEs has to be conducted in normal healthy subjects. This was the starting point for the 
selection o f drugs to be assessed in the present study.
The use o f these PEs may bring great benefits to performance, especially to 
situations requiring great cognitive effort. Their assessment, therefore, had to be 
conducted carefully and methodically, and performance changes due to their use, or 
abstinence and withdrawal, were taken into account.
Drugs Commonly Used As PEs In Normal Healthy Humans
A large proportion o f the population regularly use two o f the most commonly 
available psychoactive drugs i.e. caffeine and nicotine. These two are dealt with in their 
own section o f this introduction. However, the use o f such substances, as well as illicit 
drugs may have an effect on mental performance during working situations. In addition, 
the well-known problems o f addiction to, and withdrawal from, some substances can 
cause performance deficits. The literature was reviewed to take this into account so that 
substances, selected for farther investigation, would be acceptable for use in normal 
working situations.
It quicldy became clear that the assessment o f purported PE use by normal, 
healthy people in working situations was concentrated within the military community. 
One o f the main problems affecting performance in the military environment is fatigue, 
especially in high mental workload situations such as sustained flying operations (Takla 
et al 1994). Within these situations certain drugs have been used in an attempt at
15
maintaining psychomotor performance. An investigation o f fatigue during flying patrols 
o f 5 - 6 hours over 18 days o f intensive operations looked at subjective reports o f fatigue 
and the common methods o f combating it with caffeine tablets and nicotine gum. 
(Belland and Bissell 1994). It was concluded that most pilots suffered from some form 
o f fatigue and that these substances were useful in maintaining psychomotor 
performance and, therefore, fighting capability. Another recent study surveyed the use 
o f amphetamines in the US Air Force (USAF) during sustained flying operations 
(Emonson and Vanderbeek 1995). 65% o f pilots involved used them, mainly for 
‘ aircrew fatigue’ and ‘mission type’ . 58 - 61% o f pilots who used them thought they 
were beneficial or essential. It was concluded that dextroamphetamine (5mg/4hrs) was 
used without major side effects in tactical flying operations, and enhanced cockpit 
performance and flight safety through reduced fatigue. A  previous laboratory study on 
the effects o f amphetamines on simulated sustained flight concluded that they 
significantly reduced reported fatigue (Neri and Shappell 1992).
Drugs which have been developed for alternative purposes may also be used to 
combat fatigue. Piracetam was the original ‘nootropic’ drug first described by Giurgea 
(1972) and was designed to enhance the mental functioning o f dementia patients. 
Results in this field have been disappointing, but it is thought to have uses elsewhere 
and has been shown to have some effects in normal, healthy humans (see later section 
‘Nootropics’). Kudrin et al 1993 investigated the use o f piracetam, in a daily dose o f 
1.2g for a fortnight following intensive radiotelegraphic training to combat fatigue in 
military personnel (the detailed results, unfortunately, were not quoted in the English 
abstract o f this Russian paper but it indicates the universal appeal for pharmacological 
enhancement o f cognition).
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Most o f the work in this field, however, has been carried out on the maintenance 
o f performance whilst undergoing some form o f environmental stress and the drugs in 
use could be considered CRs rather then PEs. There has been little, if  any, work to 
assess the possibility o f raising already optimum mental performance to a new level. If 
drugs were available that would improve attention span, accuracy o f response and 
reduce the time taken to respond to stimuli, before fatigue set in, then the advantages 
would be great.
With this in mind the literature was then reviewed for research carried out on
substances that are easily available and approved for use by humans. One such study
reported that dietary tyrosine alleviated declines in both neural nor-adrenaline levels and
performance during battle stress (Salter 1989). A  subsequent review concluded that
environmental stress, especially sustained operations in a military environment, causes a
depletion o f brain catecholamine (Owasayo et al. 1992). Tyrosine, an essential amino
acid and precursor o f the neurotransmitter noradrenaline, may be o f some use in
preventing the performance deficits seen under this depletion. However, this work was
again aimed at alleviating a deficit. It was disappointing that there was a distinct lack o f
any good quality scientific research on substances which are regarded as ‘ Smart drugs’ ,
substances both legal and illicit, that have found groups o f users who believe in their
psychomotor enhancing properties (Concar & Coghlan 1993). This raised another very
important issue when investigating putative PEs. Some, such as caffeine and nicotine
are used regularly in everyday life. They are both pharmacologically very active and
their use can lead to dependence. Indeed a survey o f military patients in hospital showed
that about 40 % consumed sufficient caffeine to produce symptoms o f caffeinism with
the most extreme case being presented as a paranoid delusion (Mackay and Rollins
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1989). This indicates that some people may use caffeine to excess and, when deprived, 
will probably suffer decrements in their performance. In addition the amount o f caffeine 
intake that is common in caffeinism can in itself cause performance degradation (Loke
1990). However, due to the almost ubiquitous presence o f the substance it is generally 
regarded as suitable for investigation in controlled conditions.
These examples highlighted the problems that may be encountered when people 
use drugs to enhance their performance. It was felt prudent, therefore, to include any 
details o f possible addiction or side-effects when considering any drug for investigation 
as a PE.
Natural Extracts 
Caffeine
The most prevalent o f all substances in this field with purported PE properties is 
caffeine which has a long history o f consumption for the benefit o f its stimulant 
properties (Barone & Roberts 1984, Bonnet & Arand 1994). It is a natural substance 
contained in a variety o f plants which exist all over the world, and most cultures produce 
some form o f caffeinated foodstuff or beverage for its taste and perceived effects. It 
inhibits phosphodiesterase which is involved in the intracellular metabolism o f cAMP 
and also antagonises many o f the effects o f adenosine on both A l and A2 receptors 
(Robertson & Curatolo 1984). The results o f these actions are CNS stimulation, diuresis, 
cardiac muscle stimulation and smooth muscle relaxation (Dews 1982), although the 
links between mechanism and effect are not yet proven.
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It has also been reported to have a generally positive effect on feelings o f 
alertness and well being (Sawyer et al. 1982, Smith et al. 1992) and to increase alertness 
and energy (Rogers et al. 1992). As a consequence o f these actions caffeine improves 
alertness which, in turn, disturbs sleep. This has led to the studies o f its effects on 
psychomotor performance. Objective measurement o f the effect o f caffeine on 
discrete components o f psychomotor function, however, has produced conflicting 
results. Table 1.2 provides an overview o f the most relevant studies o f caffeine which 
are discussed below. The results were divided into the effects o f caffeine on the 
different aspects o f psychomotor performance that each test assessed. The number o f 
entries in this table raised an interesting point. Caffeine, in the context o f  being a 
putative PE, has been studied to a far greater degree than any o f the other substances 
listed in this review. That in itself is a testimony to the anecdotal evidence o f its 
beneficial effects, but as can be seen the scientific study did not provide unequivocal 
evidence o f PE properties.
In studies o f performance caffeine has been shown to increase regularity o f
letter cancellation performance, but not enhance mental maze learning (Battig et al
1984). It improved all speed-related tasks in a study using short term memory (STM),
mental arithmetic, reading comprehension, serial search and verbal reasoning tasks
(Mitchell and Redman 1992). Caffeine also decreased reaction time in choice reaction
time and short term memory tasks (Kerr et al 1991) as well as off-setting deficits o f
Digital Symbol Substitution (DSS), Symbol Copying (SC), Digit Span (DS) and
Critical Flicker Fusion (CFF) due to the effects o f nocturnal sleep (Nicholson et al
1984). Most people assume that caffeine improves alertness when they are fatigued.
Indeed, it has been reported that caffeine enhances vigilance (Zwyghuizen and
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Doorenbos 1990 Frewer and Lader 1991). However, these results suggested that 
caffeine effects were highly task specific and improved speed rather than cognitive 
processing. This can also be seen in Table 1.2 in the section which lists effects o f 
caffeine on 42 vigilance type tests. In all, 50% o f the results showed no effect o f 
caffeine. O f the 14 that saw an improvement, 5 specifically related it to the speed 
aspect o f the test. Several studies (Bovim et al 1995, Gilliland 1980, Hasenfratz & 
Battig 1994) also showed decrements in performance were produced by doses above 
approximately 300mg. The dose o f caffeine given to subjects in these studies has 
proven to be important. It was concluded from one study that high doses o f caffeine may 
slow the speed o f performance (Loke 1990) and that although caffeine may enhance 
tasks with a high information transfer load, those with a high STM component may be 
impaired (Frewer and Lader 1991, Foreman et al 1989).
The effects o f caffeine on the electroencephalogram (EEG) have been assessed 
in several studies, but the number o f electrodes used, and their sitings have varied 
considerably. In one study, EEG, recorded at the midpoint o f the central area (Cz), was 
showed an increase o f power in the alpha and beta frequency wavebands after talcing 
caffeine (Hasenfratz and Battig 1992). Another, using measurements from Cz and P3 
(Parietal area) sites showed theta and alpha power were decreased with caffeine (Bruce 
et al 1986) whilst alpha and betal power was decreased in channels P3-01 (Occipital 
area) with caffeine when investigating its effect on overnight performance degradation 
(Nicholson et al 1984).
Caffeine has also been shown to have effects on the mood state o f individuals
(Lieberman et al 1987) and have different effects on the same subjects depending on the
time o f day o f ingestion (Smith et al 1991). It appears that whilst caffeine increases
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feelings o f energy, alertness, quick-wittedness and attentiveness (Bruce et al 1986) and 
also those o f elation (Smith et al 1991), higher doses increase anxiety (Loke 1990). It 
would appear, therefore, that caffeine has a stimulant effect on mood state up to a certain 
dose limit (approximately 600mg). Additionally, when investigating the effects o f 
caffeinism it has been shown that moderate to high users (400 - 600mg per day) o f 
caffeine have increased higher trait anxiety and depression scores (Gilliland and Andress 
1981). The use o f various different measures o f mood state and anxiety makes it 
difficult to draw conclusions from this evidence. The mood state questionnaires used in 
these studies have either concentrated on positive or negative measures solely. If, as they 
suggested, caffeine can have both positive and negative effects it would be more useful 
to use a bi-polar mood state score such as that suggested by Lorr and McNair (1982). 
This evidence plus the reduction in psychomotor performance with high doses o f 
caffeine (Loke 1990, Frewer & Laderl991, Foreman et al 1989) does support the theory 
o f a ceiling to the positive effects o f caffeine, beyond which detrimental effects can 
occur.
I f the use o f caffeine, as a PE, was to be investigated, however, one other
problem remained. The majority o f studies have asked subjects to refrain from
caffeinated food and beverages for a set time before testing begins and this has meant
that withdrawal may often confound the findings. Indeed, o f the studies represented in
Table 1.2, only two reduced withdrawal to less than 3 hours and only two did not
withdraw the subjects at all. It has been reported that symptoms o f withdrawal from
regular caffeine usage result in headache, lethargy, drowsiness and anxiety (Griffiths et
al 1988, Van Dusseldorp and Katan 1990) and that these symptoms, including impaired
psychomotor performance, occur between 24 and 30 hours abstinence, decreasing in
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severity over a 7 day period, until cessation (Bruce 1991). Another study concluded that 
onset o f symptoms occurred between 12 and 24 hours and peaked between 20 and 48 
hours (Griffiths et al 1986). This suggests that those studies using subjects abstinent 
from caffeine for more than 12 hours prior to testing, could have seen a reinstatement o f 
performance to normal levels, rather than absolute improvement.
In an attempt to assess the possibility o f caffeine causing absolute improvement 
o f psychomotor performance, a survey study o f the relationship between habitual tea 
and coffee consumption and psychomotor performance was conducted. It was 
concluded that higher levels o f caffeine intake through coffee lead to an improvement in 
simple reaction time, choice reaction time, incidental verbal reasoning and visuo-spatial 
reasoning. A  similar, but weaker, trend was reported with tea consumption (Jarvis 
1993). The confounding variables in this study were obviously kept to a minimum, but 
it did not give any quantification o f caffeine effects on psychomotor performance. Also 
no account was taken for the possibility that populations with higher educational 
standards or other factors may have a tendency to drink more coffee than others.
Overall, it was evident that little work has been carried out on the effects that
doses o f caffeine, over and above the normal daily background level, have on
performance. Previous studies noting an improvement in performance with caffeine may
have seen a withdrawal reinstatement i.e. performance degraded by withdrawal from
caffeine was returned to normal levels on the resumption o f caffeine intake. Also there
may be a ceiling effect above which doses o f caffeine may impair performance.
However, as caffeine has been widely used and studied there were no objections from an
ethical point o f view, and it was concluded as being suitable for investigation as a PE. It
was clear, though, the testing regimen would have to be conducted on non-caffeine
2 2
deprived individuals; the main aspects o f psychomotor performance to be assessed 
would be arousal and speed. Also, the dose used had to be large enough to produce an 
effect but not so high that performance decrements were produced.
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Another ubiquitous natural substance with purported PE properties was nicotine. 
On searching the literature it was found that the effects o f nicotine have been studied in 
normal humans. The results o f this search, concentrating on evidence o f true PE 
propensity were summarised in Table 1.3. Pharmacologically, nicotine acts as a 
neurotransmitter in the body and, therefore, has a number o f both inhibitory and 
excitatory effects. Stimulation o f the autonomic ganglia by nicotine can lead to 
tachycardia, increased cardiac output, increased arterial pressure, decreased 
gastrointestinal motility and decreased sweating (Goodman & Gilman 1985). Central 
effects are a fine balance o f stimulation and inhibition, but it does act as an excitatory 
cholinomimetic in the brain whilst inhibiting spinal reflexes. The effects on mental 
alertness, however, can be paradoxical, calming some users whilst waking others 
(Gilbert 1979, Golding and Mangan 1982). It appears that the subjective aspects o f 
nicotine can be affected either positively or negatively depending on dose and situation. 
It has also been suggested that it may help to alleviate some o f the cognitive deficits 
attributed to Alzheimer’ s disease due to its stimulation o f the cholinergic system (Levin
1992).
The intake o f nicotine has mostly been through smoking or chewing tobacco and 
has long been a pastime o f many cultures around the world. Therefore, a large number 
o f studies investigating nicotine have used smoking as the method administration. It is 
without doubt that smoking is harmful to health, but it has been concluded that nicotine, 
without the smoke, may have some use as a psychomotor enhancing substance in 
normal healthy humans (Sherwood 1993).
Nicotine
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A  number o f studies suggest that habitual smokers require nicotine to maintain a 
set level o f performance, and a decrement is seen if  they are deprived (Tsuda et a. 1996, 
Foulds et al. 1996). Regular smokers, allowed to smoke during a simulated driving task, 
showed less errors compared with those not allowed to smoke (Heimstra et al 1967). 
Smoking also improved rapid information processing (Wesnes and Warburton 1983) 
and the use o f nasal nicotine solution improved finger tapping speed in non-smokers 
(West and Jarvis 1986). Chewing nicotine gum improved psychomotor performance o f 
smokers, but not that o f non-smokers (Hindmarch et al 1990). Placebo conditions in this 
experiment, however, would have resulted in a 30 minute nicotine deprivation for the 
smokers, even though subjects were allowed to smoke normally until the start o f the 
experiment.
Smoking has also been reported to modify the EEG activity o f subjects (Knott 
1989, Pritchard 1991, Hasenfratz & Battig 1994)). Although all the authors both 
reported a decrease in delta and theta power, Knott observed an increase in alpha power 
and frequency, Pritchard observed an increase in dominant alpha frequency and a 
decrease in alpha power and Hasenfratz & Battig reported an increase in alpha 
frequency and beta power. Another study (Roth and Battig 1991) reported increased 
alpha frequency when smoking and also showed an increase in finger tapping rate. One 
common feature, however, o f all these studies was that subjects abstained from 
smoking, for between 1 and 10 hours, before testing. Nicotine half life is around 2 hours 
(Benowitz 1982), and a drop to one third the normal blood level o f nicotine can evoke a 
deprivation reaction in smokers (Russell 1987). EEG changes and performance results 
could therefore, in many studies, be due to the reinstatement o f nicotine levels.
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The arousing and tranquillising properties o f nicotine seem somewhat 
paradoxical (Gilbert 1979, Golding and Mangan 1982). This is reflected in its 
pharmacological action with low doses causing stimulation o f autonomic ganglia and 
high doses, following initial stimulation, causing inhibition (Goodman & Gilman 1985). 
The increase o f arousal and emotion reducing effects mean that different aspects o f 
smoking and/or nicotine will be o f use to different people and may also change within 
individuals, depending on the state o f mind at the particular time o f intake. This needed 
to be taken into consideration when assessing nicotine as a PE. One way o f avoiding this 
would be to use non-smoking subjects.
However, in studies investigating the effect o f nicotine on psychomotor
performance, smoking tobacco has been the commonest method o f delivering nicotine
to its site o f action. This was deemed to be an unsuitable method when non-smoking
subjects were used, from both the ethical and quantitative control aspects. Therefore to
investigate the possible PE effects o f nicotine on non-smokers other methods o f drug
delivery were required. Alternatives that have previously been used are: nicotine tablets
(Wesnes and Warburton 1978), nasal nicotine solution (West and Jarvis 1986) and
nicotine gum (Hindmarch et al 1990). Nicotine patches could also have provided an
alternative route o f administration, but by design give a slow and constant release over a
relatively long period. This would have been be more suitable in the provision o f
nicotine to workers unable to smoke through operational necessity, but was not thought
to be suitable in the assessment o f nicotine as a PE. Swallowed nicotine is a poor means
o f delivery as most o f it is metabolised in the first pass o f the liver (Wesnes &
Warburton 1978). Nicotine gum has been shown to provide systemic levels o f between
0.38 and 1.40mg when 2mg gum has been chewed slowly and steadily for 20 minutes
3 2
(Benowitz 1987).The latter method o f administration was thus deemed to be more 
appropriate for the present study.
One problem which has been encountered is that doses o f nicotine higher than 
2mg (administered via chewing gum), in non-smokers, have nauseous side-effects 
(Hindmarch et al 1990 personal communication). In an investigation o f nicotine as a PE 
when using a single dose regimen, therefore, 2mg would be the largest dose able to be 
given to non-smokers.
In conclusion it was clear from the literature that nicotine is a very active 
compound in terms o f its effects on neural transmission. Evidence o f addiction, 
tolerance and withdrawal is widespread (Sherwood 1993). To fully understand its 
pharmacology further work would need to be carried out on quantifying performance 
deficits seen in abstinent users. In certain working conditions these deficits could have 
serious consequences and the possible use o f nicotine substitutes or a prior withdrawal 
programme to prevent this would need to be investigated. However, that was not in the 
remit o f the current study. Overall the evidence suggested that nicotine had the 
properties to be a PE, but, as with caffeine, care was required in the investigation. 
Subjects had to be non-smokers and the method o f administration could not be via 
tobacco if  the understanding o f the effects o f nicotine on psychomotor performance 
were to be advanced.
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Ginkgo biloba
Ginkgo biloba extract (GBE) is a substance which has had a fan* amount o f 
anecdotal press coverage as a ‘smart drug’ . It is the product o f the leaves o f Ginkgo 
biloba or the ‘Maidenhair’ tree and details o f its farming, extraction and purification are 
described by Drieu (1988). It is an ancient Chinese herbal remedy and is thought to 
possess anti-ageing properties. GBE has found a use as a possible PE in a casual role 
(Concar and Coghlan 1993) and in a therapeutic role as a CR (Braquet 1987, Heiss 
1987, Funfgeld & Stalleicken 1988) . Searching the literature highlighted that there has 
not been a great quantity o f good quality scientific study aimed at investigating the 
effects o f GBE in normal subjects. Therefore, it was not possible to produce a table to 
give an overall view o f the likelihood o f PE effects.
However, there has been a reasonable amount o f work done on assessing the 
pharmacology o f GBE. Indeed the first reports on its chemistry and pharmacological 
activity were seen in the mid-1960s. It was reported as a powerful vasodilator with 
spasmolytic properties which is non-toxic and does not cause hypotension (Peter et al 
1966). Early studies, therefore, concentrated on its activity in vascular disorders. In one 
study it was concluded as having a positive blood flow effect on angioneuropathies and 
angioorganopathies (MuBnug and Alemany 1968). In addition it was reported that in 
postthrombotic syndromes it decreased arterial pressure and dilated peripheral vessels 
(Tronnier 1968). As a large number o f elderly people suffer cognitive dysfunction due to 
insufficient cerebral blood flow it was thought that the properties o f Ginkgo biloba may 
relieve some o f this deficit.
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As it is a natural extract, Ginkgo biloba has several active ingredients. These can 
be divided into two classes, the flavonoids and the terpenes. The extract is standardised 
at 24% flavonoid glycosides (ginkgo-flavone glucosides) and 6% ginkgolides (a group 
o f diteipenes unique to Ginkgo biloba) (Drieu 1988). In addition to vasodilatory 
properties, GBE is also an effective antioxidant (Pincemail and Deby 1988), and a 
Platelet Activating Factor (PAF) antagonist (Braquet 1987, Kiesewetter et al 1992).
By the mid 1980s many investigations o f the beneficial effects o f GBE for 
patients with cognitive and vascular disorders, had been carried out. A  general literature 
review up to and including 1985, in this field, concluded that GBE should benefit a large 
number o f elderly patients in a wide variety o f categories (Warburton 1988). This was 
especially so for those deficits o f a vascular nature, but also in organic and depressive 
causes o f deficit. It also stated that it is a well tolerated medication even at higher than 
recommended doses.
In the investigation o f the effects o f GBE on patients, EEG has been used 
extensively as a measure o f efficacy, as have performance tests. The problem remains, 
however, that the two forms o f assessment have not normally been carried out in 
combination.
One study evaluated the use o f computerised brain mapping in assessing the 
cerebral blood supply insufficiency, and the effects o f GBE as a treatment. Hemispheric 
differences seen in the EEG brain map o f one patient suffering from Parkinson’s 
Disease, were reduced by repeated administration o f GBE (Funfgeld and Stalleicken 
1988).
In another study, where the two types o f measurement were conducted in
conjunction, it was reported that the EEG profile o f subjects with poor initial vigilance
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was improved with GBE, but not in those with good initial vigilance (Geftner et al
1985). It was concluded from this that GBE resulted in hardly any improvement in 
normal subjects. The results o f the performance tasks carried out in the same study, 
however, showed an improvement in reaction times o f all the subjects, when given 
GBE. This illustrates the difficulty in quantifying the effects o f a drug when only using 
one method o f measurement. The conclusions were reached purely on the basis o f the 
EEG change and didn’t take the combined effects o f both tests into consideration.
It was obvious from these results that GBE has a definite beneficial 
pharmacological effect on pathophysiological conditions. This is based around its 
improvement o f blood, and hence metabolic, resources. Most reported changes in 
overall cognitive performance have been in general observer-type scales (Warburton 
1988). Despite the fact that such studies have only shown partial reinstatement o f 
cognitive deficit GBE is probably useful as a CR. Indeed GBE is now prescribed in 
many countries as a protector against cerebral deficiency caused by ageing as well as 
being available ‘over-the-counter’ in pharmacies and health food shops in the UK. It is 
sold as a protector o f the cardiovascular system. The range o f active ingredients o f GBE 
is quite large for a pharmaceutical preparation, but it was felt that the very properties 
which may improve cerebral insufficiency may be one approach to improve mental 
performance in normal, healthy people., i.e. an improvement o f  blood supply and 
metabolic resources may be one method o f increasing psychomotor performance, due to 
increased availability o f resources.
In support o f this, and in one o f the few studies which have used normal 
subjects, a review o f the effect o f GBE on cerebral functional activity (Pidoux B 1988)
mentioned a study on the effects o f GBE on healthy subjects by Krauskopf et al (1983).
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It reported that EEG changes indicated a stabilisation o f spontaneous vigilance at a dose 
o f 240mg and some evidence o f hypervigilance at 600mg. Vigilance plays a central role 
in the capability to attend to performance measure tasks and as such can affect an overall 
performance score. Unfortunately the authors again did not compare the physiological 
measurement with performance measures.
Further evidence o f absolute improvement did exist, however, from one other 
study which only used performance measures. The same higher dose o f GBE, as used in 
Krauskopf s study, had no effect on CFF, CRT or subjective drug ratings, but did 
improve the performance o f the Sternberg memory scanning task (Subhan and 
Hindmarch 1984). It was concluded that the GBE effects in the memory task were 
localised to the serial comparison stage o f the reaction process. This aspect o f 
performance is closely related to vigilance.
The question o f reproducibility o f results in healthy humans is one that needs to 
be addressed due to variable results. One study found that two different formulations o f 
GBE had no effect on CFF, CRT, subjective drug ratings, Sternberg scanning test or 
picture recognition (Warot et al 1991). One o f the extracts, however, prevented the 
decline in results seen in a free recall score with placebo and the other extracts. This 
maintenance o f performance over a period o f time adds to the argument that it may 
improve vigilance, but does bring the exact formulation o f the GBE into question.
In summary, although the literature contained suggestions o f GBE’ s ability to 
improve psychomotor performance in normal humans there has been very little work 
aimed at addressing the point. The component o f performance that it has been 
suggested GBE could improve i.e. vigilance, would probably lend itself to the multi­
tasking attributes required in a wide variety o f working situations. It was therefore felt
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that GBE, being a readily available and safe natural substance, with well documented 
pharmacology, should be assessed as a PE.
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Nootropics
The term nootropic was proposed as a term to describe the pharmacology o f 
piracetam (Giurgea 1972), a drug which enhances some aspects o f cognitive and 
psychomotor performance in dementia patients and has since become almost 
synonymous with the term cognitive enhancer. It has since become the name for a group 
o f compounds with similar pharmacologies. In some cases the same term has also been 
used to classify other compounds which improve cognitive or psychomotor 
performance, but do not fall directly into one o f the previously accepted categories. 
However, this section o f the review looked only at those substances directly related to 
piracetam as other putative PEs were given different classifications.
Despite extensive searching it was apparent that little investigation has been 
made o f the use o f nootropics in normal subjects. It was disappointing to discover that, 
far from being PEs, they were once again more like CRs. Table 1.4 was a short attempt 
to list studies which had used normal subjects, but it was obvious that nootropics have 
not been subject to a highly targeted programme o f investigation as PEs. This was 
surprising, especially as they were the first drugs to be called cognitive enhancers and 
because o f the value to society that could be gained if they were truly efficacious as PEs. 
However, as with some o f the other substances reviewed in the current study anecdotal 
evidence suggests that the positive effects seen in clinical patients with cognitive deficit 
are seen as an indicator o f effects in normal subjects. Indeed piracetam is sold as a 
‘ smart drug’ to would be believers to improve concentration (Concar & Coghlan 1993).
An early review o f the animal and clinical pharmacology and 
pharmacotherapeutics o f  nootropics concluded that they improve some areas o f animal
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cognition and had positive effects in the clinical therapeutics o f dementia cases (Giurgea 
and Salama 1977). A  less favourable conclusion was given when another review 
claimed that, although they may have some therapeutic value in clinical use, they had no 
influence on the behaviour o f normal people (Tacconi and Wurtman 1986). It may have 
been that the latter conclusion was reached as a result o f little work being conducted 
solely on the use o f nootropics in healthy humans. However, latterly other researchers 
have also concluded that the nootropics have little effect on humans (Leonard 1994).
The mode o f action o f nootropics, however, is unclear. It is known that they 
affect three main neurotransmitter systems: dopaminergic; cholinergic and
noradrenergic (Nicholson 1991). In support o f this it has been reported that some 
nootropics reverse the effects o f scopolamine induced memory and learning deficits in 
animals (Leonard 1994). The same was seen in amnesia caused by acetylcholine 
production blockade and it was concluded that both were an indication o f action on the 
cholinergic system (Pepeu and Spignoli 1989). In another cautionary note it was stated 
that this didn’t necessarily translate to an effect on psychomotor performance in 
humans.
With this information it seems doubtful that the nootropic drugs would be o f use 
in improving psychomotor performance o f normal, healthy people. The majority o f 
work has been carried out in animal models and demented patients. Some results have 
been published on the effects seen in normal subjects, but there appears to have been a 
split in the approach to this. Studies have tended to use Electroencephalography (EEG) 
as an indicator o f drug action, but have failed to combine it with task performance 
measurement (Kinoshita 1990, Giaquinto 1986, Schenk 1982).
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However, electroencephalography (EEG), the measurement o f  brain electrical 
activity, has been shown to be a useful measure in the study o f nootropics. It was 
reported that five nootropic substances (meclofenoxate, amantidine, piracetam, 
teniloxazine and WEB - 1881 FU) increased EEG a  activity (particularly above 9.5 
Hz.) in healthy young volunteers (Kinoshita 1990). Activity in the slower and faster 
wavebands decreased, showing this group o f drugs to be different from other 
psychotropics. Whilst activation o f the EEG is usually represented by a decrease in a  
and an increase in p, the reverse appears to have happened in this case. This did not, 
however, mean that the EEG had been ‘deactivated5. The simultaneous reduction o f the 
slower waveband activity suggested a decrease in drowsiness and it could indicate that 
the nootropics may improve the general ability o f a person to receive information, 
without having an alerting effect per se. This would suggest that improvements may be 
seen in vigilance aspects o f performance tests. In addition to this possibility, the effects 
o f WEB 1881 FU were localised to the frontal region, suggesting it may aid in linguistic 
learning and memory processes.
WEB 1881 FU also enhanced several peaks o f the visual Event Related Potential
(ERP - an unconscious brain electrical activity response to a rapid visual stimulus)
during a visual spatial attention task (Munte et al 1989). This indicated an increase in
attention to the stimulus, but no systematic effect on task performance was observed. It
was therefore concluded that the ding effects didn’t extend to early perceptual processes.
Oxiracetam was also shown to increase a  activity and decrease 5 activity, particularly in
the fronto-temporal regions o f the brain, in benzodiazepine-medicated, healthy
volunteers (Giaquinto et al 1986). This supported the previously mentioned findings and
suggested a possible use in improving the psychomotor abilities o f medicated patients,
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without negating the sedative effect on anxiety and neuroses. In addition it possibly 
indicated an ability to improve psychomotor function o f normal healthy people during 
fatigue or if commonly used sedative drugs were still active.
In one study the addition o f a subjective questionnaire to EEG recording 
supported this (Schenk 1982). 9g o f Piracetam administered to healthy volunteers had a 
refreshing effect, decreasing feelings o f fatigue 1 - 2  hours after administration and 
increasing vigilance whilst causing an increase in dominant a  power (10 Hz) and a 
decrease in 8 and 0 activity. The group as a whole seem to have had a similar EEG 
profile which could be linked to increases in attention and vigour. Despite this lack o f 
using performance tests in combination with EEG, some evidence for performance test 
improvement in normal subjects has been reported. The normal control subjects in an 
investigation o f the use o f piracetam as a therapy for dyslexia increased verbal learning 
by 8.6% (Wilsher at al. 1979). This was over and above any placebo effect. The 
evidence o f positive effects o f piracetam in dyslexics from the literature was later 
reviewed (Wilsher 1987) and was generally concluded to improve reading ability.
One study did go some way to showing improvements o f both EEG and
performance tests, but was not carried out on strictly normal subjects (Largergren 1981).
The subjects had cardiac pacemakers fitted which resulted in hypoxia, caused by a slow
Heart Rate (HR). This in turn caused deficits in Critical Flicker Fusion (CFF - an
indicator o f general CNS arousal) and Reaction Time (RT) tests. Piracetam not only
reinstated these deficits but also improved visual discrimination performance over and
above the normal level. Additionally it demonstrated that piracetam may be o f use in
hypoxic stress situations. These results however, had to be treated with some care.
Whilst they seemed to suggest some true psychomotor enhancement, the subjects were
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obviously in the later stages o f serious heart disease and ‘normal’ levels o f psychomotor 
performance were probably affected by other factors.
The sum o f this information suggested that nootropics may be o f use to improve 
attention in situations o f fatigue or other deficit conditions. The lack o f success in 
showing the same improvements in human psychomotor as in animals, however, did not 
suggest that the nootropics were suitable for assessment in the present study. Due to the 
generally positive results in animal studies, though, new developments in the group 
should not be ignored when reviewing for PEs in the future.
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Stimulants
It was mentioned previously that stimulants, such as amphetamines, have been 
used by military forces to stave o ff fatigue induced performance decrements since the 
1960s. It was thought, therefore, that the very properties which could stave o ff 
tiredness, i.e. active stimulation o f the central nervous system (CNS), may be a 
suitable approach for the absolute enhancement o f psychomotor performance. Whilst 
caffeine is regarded as a psychostimulant, it was afforded a complete section o f its 
own in this review due to its prevalence o f use and the quantity o f study which has 
been concentrated on it.
This section concentrated on the amphetamine-like stimulants. In general they 
impede the re-uptake and stimulate the release o f noradrenaline and dopamine, which 
results in a euphoriant and stimulant effect (Leonard 1994). In addition they have 
peripheral effects which cause a rise in blood pressure and an inhibition o f 
gastrointestinal mobility. They have limited use, clinically, for narcoleptics and 
hyperkinetic children. Dexferrfluramine can also be used as an appetite suppressant. 
Due to the nature o f the subjective effect o f amphetamines, they are used as drugs o f 
abuse. This provided problems in including them as potentially usable PEs, even if  the 
effects were unequivocal.
Studies reported in the literature on the objective effects o f amphetamines, and 
other stimulant compounds, on normal non-fatigued humans has been sparse as can be 
seen in Table 1.5. Studies on normal subjects in working environments have been 
mostly concerned with extended military operations and maintaining alertness as 
previously mentioned (Emonson & Vanderbeek 1995, Neri & Shappell 1992). In
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addition, they have been mainly subjective in nature. This has revealed little as to the 
drugs’ effects in normal optimum performance conditions, although some studies gave a 
little insight to this, with results from normal control groups. Such groups have been 
used in clinical assessments o f  the physiological response in comparison to 
‘hyperkinetic’ children. In one case, dextroamphetamine decreased motor activity and 
improved psychomotor performance in normal prepubertal boys. (Rapoport et al 1978). 
Whilst this decrease o f hyperactivity through increased CNS stimulation may have 
seemed paradoxical it, could have been predicted by the commonly known inverted-U 
plot o f  stimulation against activity (Yerkes & Dodson 1908). In another study, it was 
reported that both subject groups had increases in recall o f semantically and acoustically 
processed words (Weingartner et al 1980). Attention was also improved but was 
independent o f  the other changes.
A  few other studies have investigated the effects o f stimulants in normal 
subjects. For instance, given over a two week period, oxcarbazepine, an experimental 
stimulant, improved some aspects o f  performance in normal subjects (Curran and Java
1993). Performance on a focused attention task and a manual writing speed task was 
improved and it also increased feelings o f alertness, clearheadedness and 
quickwittedness. No effect was seen in long term memory assessment. The compound 
was concluded as having a stimulant effect and as such could be considered to be a PE, 
although negative side effects from this group of drugs would probably prevent it from 
being used as such in normal working situations.
The effects o f  pemoline, a weak central nervous system stimulant, on
spontaneous EEG and Event Related Potentials (ERPs - P3 response) have also been
investigated in sleep deprived individuals. It was reported to decrease the power o f  the
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EEG and increased the amplitude o f  the P3 response. These results are consistent with 
an alerting drug. This effect was observed for up to 18 hours and was not affected by 
time o f  day o f ingestion or time since sleep (Wright et al. 1995). This again suggested 
that stimulants are effective in counteracting fatigue and supports the evidence for their 
use in certain working situations.
The overall evidence given by the listing in Table 1.5 indicated that stimulants 
do increase general alertness and arousal as indicated by the results o f  CFF tests and 
mood state questionnaires. They may also have an effect on vigilance. However they did 
not seem to have any effect on long term memory components o f  cognitive performance 
except after sleep deprivation. These results did not give enough information for 
amphetamine like substances to be included in the list o f putative PEs for investigation 
in the present study. Additionally, their use in real world situations, would be limited 
because the effects would disturb the next nights sleep. In the case o f  round the clock 
shifts o f  8 or 12 hours, the next shift would be starting before the effects had worn o ff  
sufficiently to allow reasonable sleep. This highlighted the need to look at all aspects o f  
a drugs effects when investigating PEs because the very properties that make the 
amphetamines effective can have detrimental side-effects.
Amphetamines, o f course, are not the only stimulants which were looked at. A
novel substance which has been suggested as a putative PE was Modafinil, a selective a-
1 receptor agonist with strong stimulant properties. It has been investigated by the
French and Canadian military, and was recommended to be included in any
investigations on sustaining performance (Lyons & French 1991). There is also some
suggestion that it has an effect on the dopaminergic transport system (Mignot et al.
1994). It had seemingly minimum peripheral side effects at therapeutic doses, a low
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abuse potential, did not interfere with sleep, did not appeal' to produce tolerance and 
improved vigilance in sleep-deprived subjects (Lyons and French 1991). In another 
study it alleviated the psychomotor and cognitive impairment caused by sleep 
deprivation in most tasks (Bensimon et al. 1991). Modafinil, therefore, would have 
appeared to be a suitable candidate for investigation as a PE. The reported lack o f  side 
effects (Pigeau & Naitoh 1994) would have removed any problems associated with 
conventional stimulants such as a ‘rebound effect’ or the inability to sleep under the 
drug’s influence and may have made it suitable for controlled use to counteract any 
number o f  fatiguing factors presented by a high stress and workload situations. Its 
ability to improve the performance o f  people involved in normal, non-extended shifts, 
however, has not been investigated. Also, more recent results suggest that Modafinil 
may cause subjects to have over-confidence in their own abilities (Baranski & Pigeau 
1997) which would make it dangerous to use in practical situations. This and the fact 
that it was very difficult to get hold o f  for study, other than as a treatment for 
narcolepsy, excluded it from the present investigation.
In conclusion stimulants would seem to be o f some use in certain very
specialised working environments. They can be used in situations where people are
required to operate tasks for extended time periods. Very little information, however, is
available on how presently available compounds may aid psychomotor performance in
normal, healthy people, operating at normal efficiency. There are some suggestions that
more recently developed drugs may also be able to improve performance in these
conditions. As such they may be useful as a PE as well as alleviating fatigue. However
those which are available at the current time such as d-amphetamine, methamphetamine,
diethylpropion and cocaine had no place in the current study. The possibility o f abuse
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and toxicity, and the negative effects o f  possible over-stimulation were too great to 
include them as usable PEs in the present study.
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Re-Uptake Inhibitor/Neurotransmitter Promoters As PEs
The human brain is a very complex organ using many types o f neurotransmitters 
in subtly different ways. Psychomotor performance is affected by more than one o f  the 
different systems involved. Nevertheless die theory o f  improving cognitive and 
psychomotor performance in normals by providing the brain with greater quantities o f 
different neurotransmitters has arisen. Several groups o f drugs have become defined 
through their modulation o f  the various neurotransmitter systems. That is not to say that 
the aforementioned classes o f drugs do not affect neurotransmitter systems. For this 
section o f the review dings were only included if they were responsible for increasing 
the supply o f  neurotransmitters in one particular system either via inhibition o f  re­
uptake, following neural transmission, or by promotion o f greater neural transmission. 
However, not all types o f these drugs which are used in clinical deficits were included, 
just those which had shown some promise in improving normal psychomotor 
performance. Two main approaches to enhancing psychomotor performance through the 
promotion o f  neurotransmission were identified, the cholinergic and serotonergic 
hypotheses. Both included drugs which were aimed at clinical deficit conditions which 
again meant that the bulk of investigations have heated them as CRs.
Cholinergic
In the early seventies it was proposed that a deficit in acetylcholine (Ach) may 
cause a performance decrement in human memory. This was supported by both 
behavioural data (Crow and Grove-White 1973) and by scopolamine (a cholinergic 
inhibitor) administration in normal subjects (Drachman and Leavitt 1974). In the latter
5 8
study it was suggested that the performance deficit seen with scopolamine was similar to 
that in elderly patients with memory loss. Since then it has been found that Alzheimer’s 
patients do indeed have a reduction in the activity o f the cholinergic system (Wilcock 
1991, Brinkman & Gershon 1983). Tacrine, an anticholinesterase inhibitor aimed at 
restoring this cholinergic deficit was approved for use in the early 1990’ s. It was thought 
that such a treatment could significantly improve the quality o f  patients lives by 
improving their general cognitive state (Knapp et al 1994, Eagger & Harvey 1995). 
However, whilst tacrine was efficacious it did not produce dramatic improvements and 
ultimately did not alter the course o f  the disease (Davis et al 1992, Crismon 1994). 
There were also some reviews which had looked at the effects o f  cholinergic promoters 
in general (Sarter et al 1991a & b.). They concluded that, as with tacrine, some 
cholinergic promoters were effective in treating the cognitive decline symptoms o f 
Alzheimer’ s disease for a period o f  time, but that they did not offer a cure.
Despite this, and the fact that the cholinergic hypothesis is aimed more at 
improving central cognitive processes in clinical situations, the literature was reviewed 
for the effects o f such treatments on the psychomotor performance o f  normal subjects. 
One review, on the measurement o f  the effects o f  cholinergic replacement on memory in 
Alzheimer’s, included their administration to normal adults (Brinkman and Gershon 
1983). It was observed that the most widely employed tests which gained positive 
results, in normal subjects, were word list learning tasks. However the conclusion was 
that a limited amount o f  standardised work did not allow reasonable replication. Also, 
work had been carried out with only a small number o f comparisons across the studies.
Another review, on the cholinergic hypothesis o f  human memory, stated that
normal controls in various experiments had seen mild to moderate increases in memory
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recall, in specific sub-sets o f  subjects, with both a precursor o f Ach (lecithin) and an 
anticholinesterase (tacrine) (Sitaram 1984). Both the studies suggested that 
anticholinesterases (AChes) may improve the memory component o f  cognitive 
performance. However, as with all the substances reviewed, only a few studies have 
been published with respect to AChe as a CE, or PE, in normals. Nevertheless within 
this small group there were two studies which actually observed a psychomotor 
performance deficit with cholinergic drugs in normal subjects. In one study (Tandon et 
al 1993) the AChe, physostigmine, when administered to normal subjects, caused 
psychomotor inhibition. The effects were described by the authors as similar to that 
experienced by schizophrenics i.e. lethargy, apathy etc. Feelings o f  sadness, 
hopelessness, worthlessness or guilt, however were not induced. It was concluded that 
the results supported the theory o f  cholinergic hyperactivity being one mechanism for 
the pathophysiology o f  negative schizophrenic symptoms. They also implied that 
causing extra-availability o f  acetylcholine in normal humans would not enhance 
psychomotor function. It may in fact cause a decrease in performance through peripheral 
side-effects.
The other study showed that a novel muscarinic agonist, RS 86, caused disturbed 
visual accomodation, hypersalivation, sweating and shivering, although it did not have 
any effect on reaction time, picture recognition or EEG.
A recent study also concluded that there has been minimal success with
cholinergic replacement therapy (Blin et al 1994). It stated that it is unknown whether
this is because cholinergic depletion doesn’t contribute to the intellectual decline seen in
Alzheimer’s, or because o f  the lack o f efficacy o f pharmaceuticals to locate their targets.
Other problems with AChes have been that some are short lived (physostigmine) whilst
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others have a potential for liver toxicity (derivatives o f  tacrine) (Balson et al. 1995, 
Watkins 1994).
In conclusion, boosting cholinergic transmission with the current range o f  re­
uptake inhibitors or pre-cursors, in normal people, would probably have a detrimental 
effect on psychomotor performance through peripheral side-effects. Therefore they were 
not included in the selection o f putative CEs for investigation.
Looking at less developed drugs in the literature it was clear that newer 
cholinergic drugs are being aimed at central nervous system selectivity, to avoid the 
peripheral cholinergic effects which may be causing these problems. One o f these SDZ 
ENA 713 has been shown to have no such peripheral side-effects whilst retaining central 
activity in normals (Enz et al 1993). Therefore it could be suggested that the centrally 
active AChes could be one approach to enhancing the cognition o f  normal people. 
However, they were not deemed to be at a sufficiently advanced stage o f  development 
and were not selected for investigation in the present study either. Indeed the usefulness 
o f  the new AChes as CEs will not be able to be determined until full clinical testing has 
been conducted. There is also real problem that, apart from some pre-clinical human 
tests, new AChe drugs are not generally assessed for their effects on the psychomotor 
performance o f  normal humans.
Serotonergic
Serotonin (5-hydroxytiyptamine or 5HT) is another neurotransmitter which has
been suggested to have a role in cognitive processing. This conclusion was reached due
to changes which occur in Central Nervous System (CNS) levels o f  serotonin, its
metabolites and receptors in cognitive deficit illnesses (Costall et al. 1992) and
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especially depression (Leonard 1994). However, it was discovered quite early that 
serotonin has a number o f  different receptors (Gaddum & Picarelli 1957) and more 
recently the number has increased to 5 types each with specific effects (Humphrey et 
al.1993). One approach to resolving the changes in serotonin levels in the CNS, which 
appeared in the early 1990’s, was the use o f 5HT3 receptor antagonists as anti-dementia 
drugs (Costall & Naylor 1991). This was predicated on the hypothesis that serotonin 
could inhibit the release o f acetylcholine via the 5HT3 receptor (Barnes et al. 1989). A 
further step was taken in suggesting that 5HT3 antagonists could improve cognitive 
performance per se. Indeed various derivatives o f  the 5HT3 antagonist drags were 
demonstrated to improve memory and learning in animals (Chugh et al. 1991, Broocks 
A. 1992, Barnes et al 1990), although it was also shown that higher doses could actually 
impair performance (Domeney et al. 1991). Whilst these effects appeared to be fairly 
repeatable they did not extrapolate to studies o f normal human subjects. Several studies 
showed that 5HT3 antagonists did not have any effects on psychomotor performance or 
the EEG (Leigh et al. 1992, Link et al. 1991, Hall & Cueppens 1991). Therefore the 
5HT3 antagonists were not deemed to be suitable as an approach to true psychomotor 
enhancement.
Despite this it was noted that serotonin could influence neurotransmitters and be
influenced in a number o f other ways. One group o f drags, the selective serotonin
reuptake inhibitors (SSRIs) did show some promise. SSRIs increase the amount o f
serotonin available for neural transmission, by preventing its re-uptake into the pre-
synaptic neuron. They are used as antidepressants and have some advantages over the
more traditional tri-cyclic antidepressants, such as reduced anticholinergic and
cardiovascular side effects (Kasper et al. 1994). If used in combination with Monamine
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Oxidase Inhibitors (MAOI), however, they can lead to ‘ serotonin syndrome’ resulting in 
hyperthermia, muscle rigidity and cardiovascular collapse (Hyttel et al. 1995).
Previous work had been carried out on the SSRIs as non-sedative alternatives to 
tri-cyclic antidepressants. One study assessed the EEG profile o f litoxetine (Patat et al.
1994). Single and multiple doses showed dose-related increases in fast p, mainly p2 and 
no changes in 8 or 9. A  slight a  reduction only occurred after repeated doses. Changes 
lasted at least 12 hours and EEG profile did not change after 4 days repeated 
administration, indicating that tolerance did not develop. It was concluded that this 
profile resembles that o f a non-sedative antidepressant normally seen with therapeutic 
doses. The changes in a  and fast p also implied some ability to enhance psychomotor 
performance.
There were not many published studies which had investigated SSRIs in normal 
subjects, but there were a few which are listed in Table 1.6. A  review suggested that a 
number o f drugs in the group o f SSRIs may have excitation and activation effects on the 
Central Nervous System (CNS) (Hindmarch 1995). The evidence was not 
overwhelmingly conclusive, but did indicate some definite possibilities. Table 1.6 
confirms this conclusion in that the main improvements in normal subjects were seen in 
measures o f  arousal and reaction time. These were good indicators o f possible PE 
properties. In fact nine out of twelve studies saw improvement in arousal, the largest 
percentage o f any study listing in the present study, notwithstanding the small number 
o f  studies to draw on. Both paroxetine and sertraline appeared to have these effects, 
although others in the group did not demonstrate the same activity.
A  newer member o f the SSRIs, citalopram hydrobromide, had recently been
brought into use as an anti-depressant at the time o f  the review, although it had not been
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investigated for the possible psychomotor enhancing effects seen with some o f  the 
others o f  the group. It had been shown to be pharmacologically more selective for die 
serotonergic system than the other members o f the group (Hytell et al 1995). This 
suggested diat it may have greater psychomotor enhancing properties. Also, previously 
reported negative effects with some SSRIs were thought to be due to a lack o f  selectivity 
for the serotonergic activity. Indeed some can also affect noradrenaline and 
dopaminergic systems. Therefore, it was concluded that citalopram was suitable to be 
investigated as a putative PE in the current study, although subjects had to be carefully 
screened for contra-indications i.e. previous history o f depression, or use o f  Monamine 
Oxidase Inhibitors (MAOIs).
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Taking a look at the total review, it appeared that there was a general lack o f 
work aimed directly at assessing the possibility o f improving the psychomotor 
performance of normal healthy individuals beyond optimum levels, using 
pharmacological intervention. Most studies o f  the so-called CEs and putative PEs 
concentrated on the clinical aspects o f  pharmaceutical preparations, alleviation o f 
fatigue induced performance decrements, or the problems caused by addiction to natural 
substances with psychoactive properties. This emphasised the need for a targeted 
programme o f research and justified the present study.
Despite this, there was some evidence that it may be possible to improve 
psychomotor performance above normal levels, although it was in no way unequivocal. 
Several drugs improved arousal, vigilance, memory, attention and reading ability in the 
normal control groups o f  clinically based studies, and a few have shown similar 
improvements in normal subject groups as well. A  number of. other studies reported 
putative PEs to improve subjective measures, or cause changes in EEG profiles which 
have been proposed as concomitant with improved psychomotor performance.
One problem has been that a large number o f the studies reviewed have used 
subjects that have been in withdrawal from the substance being investigated i.e. caffeine 
or nicotine, or have been fatigued. This did not give accurate information on the effect 
o f  the drug on a person in an optimal situation and should not have been carried out if 
the study aimed to investigate true psychomotor enhancement. Some studies have 
looked at maintenance o f  performance o f  normal subjects in tiling and stressful 
conditions. If baseline performance could be improved by a PE, before the onset o f
Discussion
7 0
fatigue in working situations, then the use o f drugs to reinstate psychomotor 
performance may not be required. It could be delayed or, if given before fatigue set in, 
could give a performance edge that would make psychomotor performance more 
efficient overall. However the possible advantage produced by PEs in working 
situations is unknown due to the lack o f direction in this research field. The present 
study was aimed at taking the first step towards this by identifying suitable drugs for 
assessment and investigating for reliable results in the laboratory.
It was difficult to choose which o f these drugs should be assessed. Great ethical 
and legal problems would have been encountered if use o f  very novel drugs for 
psychomotor performance enhancement had been investigated. Therefore, this was not 
recommended. Any PE to be used in a working situation must have been thoroughly 
assessed and have very little risk o f  any side-effects. Problems with the health and safety 
o f  the users must have been fully minimised. Despite these barriers, there appeared to be 
a number o f possibly useful compounds, already available. They have been tested 
previously on humans, either for clinical purposes or for other effects. Natural 
substances which have been proposed as PEs are also widely available. Much work has 
been carried out on the down side o f  such substances, but their beneficial effects were 
not fully known in healthy humans. Additionally the problem o f addiction to some o f 
these substances was one that was carefully considered.
The aspect o f  psychomotor performance that requires improvement also directed
the choice o f drug. One current method o f  improving overall cognitive performance in
Alzheimer’s disease (SDAT) is the use o f anticholinesterases (AChe). These inhibit the
re-uptake o f  acetylcholine, a neurotransmitter, increase neural transmission and in some
cases can improve a large number o f cognitive functions. This has been useful in cases
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such as SDAT where decrements in cognition have been attributed to reduced 
cholinergic transmission. The number o f  drags which have been developed to modulate 
the cholinergic system seem to be vast (Sarter 1991). This fact illustrated the focus that 
can be brought to research when it has a specific goal.
However, while this approach may have worked in sub-normal conditions, it is 
doubtful whether fully functioning normal humans would have benefited from their use. 
The argument against this method was supported by evidence that the peripheral effects 
o f  AChe have deleterious effects on performance. Therefore this approach was not one 
recommended for inclusion in the current study. Future developments in producing 
AChe drugs selective to the brain may, however, be worth investigating further although 
not here. However, it was recommended to review this area on a regular basis.
The suggestion o f  being able to improve psychomotor performance also arose 
from several other groups o f drugs. The most common reports o f improvements arose 
from; the stimulants such as d-amphetamine; natural substances i.e. caffeine, nicotine 
and ginkgo biloba and SSRIs. It was thought prudent, therefore, to assess some o f  these 
drugs more carefully, with particular emphasis on their use in normal humans. As this 
had not been carried out on a systematic basis before, and in order to provide a 
framework for looking at new drugs as they are developed, a high quality, relevant 
testing regimen needed to be used.
Most objective studies o f CEs have concentrated on singular measures i.e. 
performance, physiological or psychological and, therefore, have only measured one 
aspect o f  the drug’s action. Drags with psychoactive properties have many actions due 
to the complexity o f the system they are acting upon i.e. the brain. In order to fully
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assess them, a comparison o f drug effects on all three measures, within one experiment, 
was necessary. This gave an indication o f  the drug action taking place, how it affected 
the outcome o f certain performance measures, and how it made the subjects feel.
It was most important that if  these drugs were to be used in working situations 
their full range o f effects must be understood. One compound may have the desired 
effect on a particular component o f  psychomotor performance, but may also have an 
adverse effect on the users’ mood. In this the case the drug could be useless. If the 
performance aspects o f  its action alone were assessed, then a serious mistake could be 
made by sanctioning its use. The present study, as has been said, concentrated on the 
first step o f  investigating the drugs in the laboratory to assess the full range o f  possible 
effects in a safe environment.
This type o f  assessment is relatively straightforward to carry out in a laboratory, 
once a drug has gained approval for human use. Indeed, this stage is a vital stepping 
stone to finding a useful PE. The few truly objective studies carried out so far on 
normal, healthy humans have all been carried in the laboratory, but the relevance to ‘real 
world’ situations, however, has not been established. This is one o f  the most important 
issues which needs to be addressed once a ‘true’ PE has been identified. Taking all the 
studies reviewed into account, it was clear that initial assessment o f  all possible PEs 
must be carried out in the same way, but the tests and measurements used should give an 
indication o f  possible advantages and disadvantages that may be seen operationally, i.e. 
have good face validity.
The literature gave a good cross section o f the type o f test that could be used to
assess putative PEs. Firstly it was felt that a recording and comparison o f brain electrical
activity before and after taking a drug should be made. This gives a profile o f drug
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action which suggests the way in which a drag will work i.e. stimulant, sedative, or 
possible higher function enhancer. The most efficient method for carrying this out was 
felt to be brain electrical activity mapping (BEAM) which allows computer storage and 
statistical analysis o f  all the useful EEG frequency wavebands recorded from scalp 
electrodes on subjects. As more compounds are assessed, information on correlations 
between EEG and other performance measures will increase. In the future this could 
allow anticipation o f  a psychoactive drag’s action before it is fully assessed.
Performance tests reflect the particular aspects o f psychomotor performance that 
would desirable to enhance. It was felt from the evidence seen during the review that 
this should include arousal, attention/vigilance, short term memory (STM) and reaction 
time (RT). The use o f some or all o f these tests would depend on the aspect o f  
psychomotor performance that was purported to be affected by the particular drug being 
assessed. Some performance tests have been used many times and have demonstrated 
their ability to detect drag effects on psychomotor performance (see Chapter 2 for more 
detailed discussion). CFF and CRT are useful and well documented measures o f  
psychomotor performance and as such give a good indication o f the general alertness o f  
a subject, and the speed with which they can react to a simple stimulus. They are easy to 
administer and results can be recorded using a personal computer. Many methods exist 
for the testing o f attention, STM and other higher cognitive functions. The choice o f  
tests to used in the present study are discussed in Chapter 2. It was essential for each o f  
the relevant aspects o f psychomotor performance mentioned to be assessed for each 
particular drug.
7 4
The subjects mood state may also change upon administration o f  a psychoactive 
drug and, therefore, also needed to be assessed. Three questionnaire techniques exist 
which have been seen to be suitable for this purpose, POMS-bi, LARS and State-Trait 
anxiety. The POMS-bi would appear to have a wider range o f  assessment than the latter 
two because it assesses both positive and negative aspects o f mood. As PEs may 
produce either o f  these it would be advisable to assess both, rather than just the negative. 
Therefore it was recommended that the POMS bi-polar questionnaire be used in any 
such assessments, although all three could be used to some extent for this purpose.
Overall it was clear that a targeted programme o f research was required to assess 
the possibility o f  enhancing the psychomotor performance o f  humans above normal 
levels through pharmacological intervention. The review highlighted some evidence that 
this would be possible, but also showed that drugs which have been used for clinical 
deficit conditions such as dementias and other mental illnesses are not necessarily 
suitable for this. Table 1.7 summarises the drugs which were selected for assessment as 
well as the reasons for not selecting some o f  the major pharmaceutical groups o f drugs 
which are available.
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A measurable improvement in psychomotor performance above normal levels in 
the general population would have wide-ranging effects. In certain working situations it 
could improve safety. It could result in faster and more accurate responses to the ever 
increasing information load which is required in most professional occupations, the 
reduction o f  human error, or just the ability to work longer and hairier. It was deemed 
from the review that it was more likely to be able to improve the psychomotor 
performance o f normal subjects rather than Hie central cognitive processes. It was 
thought that this aspect o f  cognitive performance was a legitimate target for 
pharmacological enhancement which would contribute to the improvement o f  overall 
performance.
The review assessed the current state o f research into improving psychomotor 
performance through pharmacological means. This was done to inform the construction 
o f a research study aimed at assessing if it is possible to raise human psychomotor 
performance above normal levels using truly usable drugs.
Evidence was drawn from the literature suggesting that drugs may provide such 
an absolute increase in performance. However, it is less than conclusive and definitely 
not based on the specific aim o f finding a true PE. The majority o f  supposed CEs and 
PEs have been designed to replace deficits in cognitive performance caused by 
dementia, cerebral blood flow insufficiency or psychiatric disorders. This means that a 
lot o f the evidence supporting the viability o f drugs as PEs is not based on their effects 
in normal human subjects, other than those observed by chance.
Conclusions
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It became clear that care needs to be taken when choosing putative PEs to assess. 
It could be suggested that some drugs which have already undergone human testing 
could be potential PEs. However, the testing o f novel drugs for such a purpose would be 
difficult and unsuitable. It is recommended, therefore, that currently available drugs 
which have been suggested to have psychomotor enhancing properties and have already 
been used in clinical environments should be assessed. Not only would this avoid ethical 
and legal problems, but would ensure those drugs with suitable actions would be 
available for use relatively quickly.
Additionally some natural substances have supposed psychomotor enhancing 
capabilities. Research into these compounds has mainly been conducted for the purposes 
o f  assessing toxicity or withdrawal from their habitual use. Any use as PEs has been 
mainly subjective or in a withdrawn state. The overwhelming amount o f  anecdotal 
evidence o f  their efficacy though is such that they should be assessed in the same way as 
the pharmaceutical preparations with similar properties.
Laboratoiy experiments are essential in investigating these compounds but care 
should be taken to ensure that tests used are related to real world activity. It is important 
however that results also be seen in certain tasks within the working environment and 
not just in animal models or laboratory conditions. Therefore, good quality, objective 
investigations o f  different types o f  PEs must be undertaken with specific reference to 
functional requirements.
On the whole there has been insufficient use o f combinations o f  physiological, 
psychological and performance measures in the study o f putative PEs. The use o f 
sophisticated brain electrical activity mapping techniques in the assessment o f  such
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drugs has shown promise and would best be used in conjunction with more traditional 
performance measures o f  psychomotor function, attention and possibly memory. In 
addition, subjective measures o f mood state are important in drug studies, because o f the 
more subtle effects o f  these compounds which may be otherwise undetectable. Careful 
consideration must be given to the testing regimen, when assessing the effects o f  PEs, 
and must include objective and subjective measures. A  more detailed discussion on this 
topic is reported in Chapter 2.
One question in the present study was what particular dose o f each drug should 
be investigated in each experiment. The overall aim o f the study was to assess if  
currently available substances were able to be considered PEs. From the review it was 
felt that there was enough information about the substances in question to pinpoint a 
particular dose which could be expected to be active in each case.
In the case o f caffeine it was important to look at a dose which was large enough 
to produce an effect, but not too high to produce detrimental performance effects. An 
additional problem was that subjects were not withdrawn from caffeine in the first place, 
meaning that they most likely would have taken some caffeine prior to testing. 
Therefore the dose in question had to fall within the “window o f efficacy”  o f caffeine, 
without increasing the subjects total dose to unacceptable levels.
With nicotine it was important to take into consideration that subjects were non- 
smokers and were, therefore, nicotine naive. The highest dose that appeared to be 
acceptable to such subjects was chosen in order to ensure an effect would be observed if 
present, without inducing the nausea that can result from high dose nicotine 
administration (Hindmarch 1996 personal communication).
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The studies for GBE and CH were designed to assess the normally given 
therapeutic dose for each and, therefore, those were the doses chosen as they had been 
shown to be active, but without adverse effects on psychomotor performance. The 
particular issues surrounding dose choice are discussed in the introduction to each 
individual experiment.
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Chapter 2 
Methods and Measures
Introduction
In this chapter the methodology for the series o f  experiments carried out in this 
study is described. The rationale and strategy for choosing each test within the battery 
are discussed in detail, describing past use, validity and reliability.
The choice o f  measurements to use in the assessment o f  psychomotor 
enhancers is wide and must be dictated by known ding action, the aspect o f cognition 
that is being targeted and the required result. Additional tests can be included in test 
batteries to confirm non-affected psychomotor functions or to highlight a particular 
one which may not have been assessed in detail in previous studies. It is also very 
important not to lose sight o f  the interaction o f  psychomotor, physical and emotional 
interaction which occurs when a human responds to a stimulus from the environment. 
Overall human cognition is a complicated series o f  processes which can be affected in 
a varied number o f  ways by the introduction o f  a psychoactive drug. Many attempts 
have been made to provide a diagrammatic representation o f  these processes and how 
they interact. It is important, in order to ensure psychologically relevant information is 
obtained from studies that the effects o f drug action are related to a well defined 
model o f  behaviour (Michon 1976).
In the field o f  psychopharmacology the number o f  tests for assessing drug 
effects on psychomotor performance is so vast, that choosing which ones to use is 
difficult. Hindmarch (1980) previously proposed a formal model o f  cognitive and 
psychomotor performance which provides a framework from which to assess the 
usefulness o f  any choices. A  diagrammatic representation after the model is depicted 
in Figure 2.1
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Figure 2.1 Model o f cognitive and psychomotor performance after Hindmarch (1980)
Therefore, a test battery for the assessment of possible psychomotor enhancers 
can be built around the model. The ways in which the tests proposed for the test 
battery relate to this model are demonstrated in the following sections. Each test is 
then mapped onto particular areas of the model in the concluding section.
Parrott (1991) points out that tests which may be valid within the boundaries 
of a task in the laboratory may not be valid to behaviour in the real world, only to that 
particular behaviour being tested. Hence some tests may only be useful for assessing 
the type of performance being measured. Parrott continues to argue in his series of 
reviews (Parrott 1991a, Parrott 1991b and Parrott 1991c) that all tests should 
demonstrate adequate validity, meaning that a test should measure what it claims to, 
correlate to external criterion and fit in with the rest o f the known evidence.
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demonstrate adequate validity, meaning that a test should measure what it claims to, 
correlate to external criterion and fit in with the rest o f the known evidence. 
Additionally if  tests are in a battery they should cover the range o f  psychomotor 
performance required to be assessed. The diagram in the concluding paragraph 
demonstrates that the tests described in this chapter have been carefully selected to 
ensure that they have good content and face validity for the purpose o f  identifying a 
PE. In addition each test has been previously proven to be sensitive to psychoactive 
compounds.
Assessing the level o f performance o f  each component o f  psychomotor 
performance and how it is affected by drugs absolutely accurately is not only difficult, 
but with technology and understanding at the present time it is near impossible. 
Ideally the activity o f  individual neural networks involved in the sensory, processing 
and motor response to a stimulus require measurement, as well as the result o f  the 
particular task in question. This would provide an accurate neural activity profile and 
ultimate task performance. However, in the presence o f  a vast number o f 
environmental changes, the effect o f  the human’ s memory and learning as well as 
motivational state and personality, the number o f permutations o f  activity is almost 
infinite.
In order, therefore, to assess the efficacy o f  certain drugs in enhancing 
psychomotor performance in a useful manner it is important to use a wide and 
relevant range o f  available techniques and technologies which measure the 
physiological and the psychological parameters involved, as well as the results o f 
performing a particular and relevant task. It is important to remember that in real life
all o f  these aspects o f  cognitive performance add up to producing a sentient human
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being who can react and interact intelligently with the world around them. This means 
that to get a useful and reliable measure o f  psychomotor performance not only must 
the sensory input and functional output o f a response be measured, but also the 
Central Nervous System integration which is required to produce a co-ordinated 
behavioural response (Hindmarch 1982b). Indeed information processing is thought to 
be central to activating behavioural functions (Beck 1985). This integration is most 
difficult to assess as it is affected by the motivational and personality traits o f  the 
human, as well as the state o f  memory and learning. It is, however, one area that a lot 
o f  psychoactive substances exert their effects and is, therefore, o f  prime importance in 
assessing PEs.
In any investigation o f  psychomotor performance the conditions o f 
experimentation must be constantly controlled and the emotional state o f  the subjects 
assessed in addition to the performance tests which are administered. This gives a 
more complete picture o f how performance is affected by the experimental, as 
opposed to, the control condition. The following sections are divided into the three 
areas required for the comprehensive assessment o f  a putative cognitive enhancer as 
identified in Chapter 1: performance tests; physiological (brain electrical activity) 
measurement and objective psychological (mood state) assessment.
Performance (Psychomotor) Tests
The approach taken to determine the tests to be used in the test battery for the 
assessment o f  putative PEs was to divide into the four particular areas o f  performance 
that are the most commonly investigated. The most relevant and useful tests for
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assessing each area o f performance were then identified and are discussed in the 
following paragraphs. Evidence o f  successful use in the past, as well as the simplicity, 
repeatability and validity o f  each were taken into consideration, before assigning a 
particular test to the battery. The details o f  the administration o f  each chosen test are 
then described in a separate section.
i.) CNS activity/arousal
To test the level o f  arousal or CNS activity using a behavioural type o f
performance test is, to say the least, difficult. Many measures o f  alertness require
more than a simple motor response and some processing as well. One particular test,
however, which does only require the simplest o f  motor responses and has been used
extensively for this purpose is Critical Flicker Fusion Threshold (Sherwood & Kerr
1993, Hindmarch 1982, Smith and Misiak 1976). Indeed it has been shown to be
sensitive enough in one study to distinguish different effects o f several common
antidepressants (Hindmarch 1988) and has a much lower coefficient o f variation than
standard visual analogue scales or Digit Symbol Substitution Tests (DSST) (Mannion
et al 1992). In a comparison o f  a known sedating anti-depressant, lorazepam, with a
newer SSRI, paroxetine, which was thought to have no such sedative effects, CFF
threshold was lowered by lorazepam and raised by paroxetine (Kerr et al 1992). In a
review o f  the effects o f nicotine on human psychomotor performance CFF threshold
was reported as being raised with nicotine in 14 out o f 22 studies (Sherwood 1993).
Venlafaxine, another SSRI increased CFF threshold (Saletu et al 1992) whilst
amitriptyline, a tri-cyclic anti-depressant with known sedative properties reduced it
(Kerr et al. 1993). Correlation has also been reported between CFF threshold and
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other methods o f  measuring psychomotor function including EEG (Bobon et al 
1982).This history o f  distinguishing sedative and non-sedative compounds 
demonstrates that CFF threshold is a suitable test to use in the evaluation o f  
psychoactive drugs and hence putative PEs.
The basis o f CFF is that sub-threshold light is perceived as a flicker which will 
become gradually less distinct if  the frequency o f  flicker is increased. This 
phenomenon is thought to be related to a cortical process involved in movement 
detection (Simonson and Brozek). The point at which the light is no longer perceived 
to be flickering is deemed to be the fusion threshold (ascending method). If however 
the light is supra-threshold and the frequency is reduced, the point at which the flicker 
is perceived is deemed to be the flicker threshold (descending method). The mean o f  
the ascending and descending thresholds is the Critical Flicker Fusion Threshold 
(CFFT) (Curran 1991).
CFF has incorrectly been described as a vigilance task (Waller and Lavender 
1980), but it is not actually a measure o f  performance, it is more a psychophysical 
threshold (Wesnes et al 1987). When using the test it is therefore important to ensure 
strictly controlled experimental conditions. If the drug being assessed affects pupillary 
size, an artificial pupil should be used although there was no evidence for its 
requirement in the assessment o f those drugs chosen for investigation in Chapter 1. 
Subjects should also remain at a constant distance from the light source.
Wesnes also states there could be problems with some drugs causing a change 
in response bias i.e. the subjects willingness to make a positive response may be 
altered. This could impact on the technique o f  varying the frequency o f  the light until
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a subject detects a change. Some changes observed with the drug may be due to a 
change in willingness to make a positive response and not as a result o f  a central ding 
action. In the detection o f  drugs to enhance psychomotor performance this would 
actually be a valid result because a drug which restricted a response could be deemed 
as decreasing performance. However, those drugs investigated in the present study are 
generally known to have central actions.
Sherwood and Kerr (1993) describe CFF threshold as one o f  the most widely 
used assessments in human psychopharmacology, Indeed it can generally be regarded 
as an index o f  overall CNS activity (Simonson & Enzer 1941). If each flash o f light 
can be thought o f  as a discreet ‘bit’ o f  information then CFF- is an indicator o f  the 
number o f  bits o f  information that the CNS can deal with. If the threshold is raised the 
information processing rate has increased, because the CNS is able to deal with more 
discreet ‘bits’ o f  information than before. With the increasing frequency o f  flicker the 
lights eventually fuse into solid light as the brain can no longer distinguish between 
‘bits’ o f  information, and hence merges them into one solid ‘bit’ .
The test has advantages, in that it is simple and non-invasive, and has no major 
practice effects. There are a number o f  variables, however, apart from the drug which 
will affect CFF threshold, including age, sex, personality, circadian rhythm etc. This 
again highlights the need for accurate and stringent controls when using CFF as a 
measure o f  drug activity.
A  correlation o f  0.8 has been demonstrated between 10 doses o f  oxazepam, a 
benzodiazepine sedative and CFF thresholds (Kerr et al 1992). In an assessment o f  
test-retest reliability using the limits method described above estimates were between
r = +0.85 r = +0.90 in one study and split half reliability estimates between r = +0.92
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and r = +0.97 in a meta analysis o f 101 subjects as described by Sherwood and Kerr 
(1993) in a review o f psychomotor tests. The same review provides good evidence for 
reliability compared with other CNS arousal measures and also the sensitivity o f  CFF 
for distinguishing between sedative and stimulant compounds. Therefore, it was felt to 
be an appropriate test for use in the present study.
ii.) Reaction Time
Sensorimotor reaction to a critical stimulus can be regarded as the basic skill 
required for, and fundamental to, all overt activity (Hindmarch 1980). The use o f 
reaction time tasks has also been extensively discussed in Hindmarch et al (1988). 
Timing the reaction to a discrete stimulus gives an indication o f  sensorimotor 
performance. The result can also be divided into two components, the attentional and 
response mechanisms, both o f  which can be measured separately. This allows the 
assessment o f their individual contribution to the information processing chain. By 
measuring the time to respond to one o f  a possible number o f  possible stimuli the 
additional activity o f monitoring can be introduced, making it a choice reaction time 
task (CRT). Donders (1969) split the result o f the CRT into three time components, 
recognition reaction time (RRT), motor reaction time (MRT) and total reaction time 
(TRT). RRT assesses the attentional monitoring aspect o f  performance, MRT the 
efficiency o f  the output mechanism whilst TRT is merely the sum o f  the two separable 
components. When used to measure drug effects the CRT can, therefore give an 
indication o f the point in the information processing chain at which the drug is acting. 
It has also been claimed that the two components are related to central and peripheral
processes respectively (Welford 1968), although there is evidence, that under normal 
conditions, there is little or no relationship between the two (Henry 1961). Earlier 
Welford (1958) had shown that as long as the sensory stimulus o f  such a test was 
strong enough the decrement in performance due to ageing was due to the central 
processing o f  information. Overall this makes it ideal for use in the assessment o f  PEs 
in normal healthy subjects.
CRT is, therefore, an ideal gross measure o f changes in psychomotor 
performance, as virtually all simple tasks involve similar responses at some point. If a 
drug significantly alters any or all o f  the CRT components the total time taken to 
complete the task will almost always change as well, although this relationship 
probably doesn’t hold true for more complex tasks.
Nicotine has been demonstrated to increase the speed o f  performance in a dose 
related manner in a rapid information processing task designed to assess reaction time 
and accuracy (Wesnes and Warburton 1983). The experiment was repeated in the 
presence o f  scopolamine and it was found that nicotine attenuated the resultant 
increase in reaction time and decrease in accuracy (Wesnes and Warburton 1984). 
Caffeine has also been shown to improve reaction time in some doses (Lader and 
Bruce 1989, review).
As with any test o f  human psychomotor performance it has to have both 
validity and reliability. Krause and Bittner (1982) carried out repeated measures on a 
CRT task and, after the performance plateau was reached by practice, test-re-test 
reliability coefficients were in excess o f  r = +0.58. Teichner and Krebs (1974) 
discussed the laws governing visual CRT and the fact that measurements o f  CRT
provide information on the constant adjustments made by a subject to adapt to the
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environment in order to attend to several possible stimuli suggests a high degree o f 
construct validity. Although face validity may not be very high, the task is simple 
enough to be relevant to most reactions in the everyday life.
iii.) Memory/Learning
Memory is basically a system whereby sensory information can be stored in a 
way in which it can be retrieved and subsequently used to make a response either in 
the short or long term. As such, all forms o f  information processing require memory 
and, therefore, changes in memory will affect other types o f  processing (Warburton 
and Rusted 1989). Memory itself, however, appears to be split into functionally 
different components which communicate with each other and which all operate either 
in the short or long terni. Short term memory (STM) can be thought o f  as the ‘ central 
processing unit’ o f  the memory ‘ computer’ . In turn it has been proposed that this is 
divided into a working memory component with two slave systems, the articulate loop 
and the visuo-spatial loop (Baddeley 1988), although it probably has other functions 
as well (Allain et al 1993). All memory input passes through the short term memory 
before being discarded, used or stored for the long term. This makes the short term 
memory the obvious target choice for assessing a drug’s effects on the memory 
component o f  psychomotor performance. Indeed it was important to concentrate on 
this aspect o f  memory for the present study. The drugs chosen for investigation in 
Chapter 1 were only thought to be able to improve psychomotor performance, not the 
full central cognitive processes which would be assessed by a more complex test o f 
memory and learning.
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Drugs can impair or improve STM and, when trying to assess such effects, it is 
important to consider whether a person specific or population specific approach is 
required. Once this is decided the types o f  tests to use can be determined. The person 
specific approach is o f  more use in clinical situations where dementia has caused an 
impairment in memory function and the effects o f  a treatment drug are being assessed. 
The degree o f impairment will vary greatly, however, between specific aetiology and 
also between individuals. It is important, therefore, in these cases to have a global 
knowledge o f  normal cognitive function o f  the individual in order to make an 
assessment o f  their personal performance decrement.
It has been recommended that, when assessing cognitive function in dementia 
cases, tests should sample a variety o f functions. They should also be sensitive to 
increases and decreases, be appropriate for the population in question as well as being 
short and repeatable (Ferris and Crook 1983). This list o f  course is also relevant to the 
testing o f normal healthy subjects. When assessing the effects o f  a particular drug on 
the memory function o f  normal healthy subjects, however, a population specific 
approach is more useful as intra-individual differences are not as great.
A wide variety o f memory assessment tests exist, some aimed at getting a 
global view o f memory performance, others at assessing a specific modular 
component o f  the memory system. Observer rating scales are most commonly used in 
patient populations to determine rate o f disease progression or the effectiveness o f  a 
particular drug treatment. They are more suited to the person-specific approach and 
would not be sensitive enough on their own to assess drug effects on normal healthy 
subjects. Indeed scales tend to have a high degree o f ambiguity in the items assessed
as well as a lack o f  detail (Warburton and Rusted 1989). For instance the Sandoz
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Clinical Assessment Geriatric Scale (Shader et al 1974) has only one item related to 
memory.
The Wechsler Adult Intelligence Scale (Wechsler 1958) has been used in 
assessing the effects o f  brain damage and has also been adopted for use in drug trials 
(Warburton and Rusted 1989). However, it has low face validity and interpretability 
due to the fact that changes could be due to any one o f  number o f  aspects o f  
information processing.
Some tests aim at the assessment o f  more specific memory functions. 
Learning is the result o f  the storage o f information and can be inferred from a change 
in performance, although not all changes can be attributed to learning. Learning has 
two specific phases, acquisition and recall. If a drug was to truly improve learning it 
would have improve the acquisition o f  information. The problem remains, however, 
that the only way to assess the acquisition is to measure recall ability. It has been 
found in many drag studies that recall performance is dependent on the same drug 
being present as at the time o f  acquisition (Warburton and Rusted 1989). This 
suggests that the drug may have its main effect on the recall stage although the 
situation is unclear. Several types o f  memory and learning task have been used in the 
assessment o f  drugs. The Rey Verbal Memory Test has been shown to be sensitive to 
the effects o f  stimulants and sedatives (Ban 1969). Simple word recognition tasks 
have shown effects with GBE (Arrigo and Cattaneo 1985) and amitriptyline 
(Branconnier et al 1982). The methods required, however, to ensure good quality 
information on the stage o f  learning that a drug may be affecting is not consistent with
9 2
the present study. To include a test in a battery assessing physiological, psychological 
and performance measures it has to be simple, repeatable and valid.
As short term memory is almost certainly involved in all aspects o f  memory 
function, and is linked to psychomotor performance, it would seem sensible to assess 
the effects o f putative PEs on this particular function. It not only refines the target area 
for assessment, but it is probably the one aspect o f  memory that has the most direct 
application to real everyday events and tasks.
Short term memory scanning was initiated by Sternberg (1966) and is based 
around a reaction time technique to assess the high speed scanning and retrieval o f  
information from the short term memory (STM). The test involves subjects being 
asked to remember if a number being displayed to them was a part o f  a group which 
they observed briefly a short time before. The short time between the so called probe 
numbers and the original set means that the subjects’ short term memory is being used 
to store the original set o f  numbers. The time taken to react to a probe number is 
recorded as well as the accuracy o f  the response.
When the original set size is increased so, generally, is the reaction time. This 
is thought to be because o f  die processing time involved as the subject compares the 
probe to more numbers in the original set. The larger the original set, the more that 
higher memory function is involved in the task. A  small set tends to involve just the 
peripheral reaction processes and this can be particularly sensitive to sedation. A  good 
way o f  seeing both peripheral and higher functions is to produce a multiple run system 
with a randomised presentation o f  both small and large original sets. This would be 
the preferred method for assessment o f  putative PEs, because it may differentiate 
between a drugs peripheral and more central memory effects.
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Again, Sherwood and Kerr (1993) provide a good synopsis o f  reliability, 
validity and pharmacosensitivity o f  this particular test. Indeed it has been extensively 
used in a wide range o f  investigations and has been demonstrated to be able to 
differentiate between a number o f  sedative and stimulant compounds. Therefore, it 
was deemed to be a suitable inclusion in the test battery for those drugs assessed in the 
present study which may have an effect on the STM component o f psychomotor 
performance.
iv.) Vigilance/Attention
Reaction to a stimulus in a task with a low memory component is greatly 
affected by the ability to attend to the stimulus in the first place (Warburton and 
Rusted 1989). If a subject has a low attentional capability at the time when performing 
such a task then it follows that they will not perform as quickly or accurately as when 
their attentional capability is higher. Measuring this capability can be done by the 
administration o f  a simple vigilance task. Generally such tasks consist o f  a long 
duration test session with the subject required to respond to rare signals.
Normally when carrying out a simple performance test subjects can reallocate 
cognitive resources to attend to the task if  required. This masks the effect which may 
occur in real world situations where commonly several tasks may be undertaken at 
once, competing for the subject’ s attention. Additionally most psychomotor tests are 
not sensitive to changes in performance which may occur if other cognitive functions 
are in constant use.
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The method o f getting a subject to cany out a fine motor control task, such as 
tracking a moving point on a computer screen whilst attending to a randomised 
reaction time task requires the subject to divide their attention between the tasks 
(Sherwood and Kerr 1993). It is also more indicative o f  the sort o f  competition for 
cognitive resources which occurs in real world multi tasking environments. Such a 
task would give a useful indication o f  the effects that a psychoactive drug may have 
on divided attention situations. A  compensatory tracking task (CTT) gives a good 
representation o f  real world situations and, therefore, has a high degree o f  face 
validity (Hindmarch 1988). It has also been compared to measures o f  ‘ on-the-road’ 
driving performance and was found to be as capable at detecting drugs which 
impaired driving performance (Hindmarch 1986). In stabilised trials CTT was found 
to have a test-retest correlation o f  r = +0.78 which makes it acceptable for use in 
repeated measures experiments (Kennedy et al 1981).
Physiological measurement (brain electrical activity)
Electrophysiological measurement o f  psychomotor performance or ability is 
difficult especially when using non-invasive procedures. The patterns o f  brain 
electrical activity which correlate to certain cognitive processes are not fully 
elucidated and even those that have been investigated have generally been the more 
gross definitions o f  arousal or sedation. It is important, though, to have a truly 
physiological measure o f drug activity, in order to confirm the centrally acting effects 
o f  any drug being investigated. Brain electrical activity is an important indicator o f 
mental state and cognitive activity (Michel and Lehmann 1993, Saletu et al 1991,
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Bente 1977) and can be correlated to the state o f  arousal (Pierlovisi-Lavaire et al 
1993) Measurement o f  brain electrical activity by EEG is more difficult from scalp 
electrodes than it is from more invasive procedures. Much can be learnt, therefore, 
from animal studies o f  electrophysiological correlates o f  cognitive state and 
performance.
In animals, arousal can be characterised by typical EEG patterns in various 
brain areas (Stumpf and Gogolak), commonly a desynchronisation o f  activity in the 
neocortex and a rhythmic, slow wave theta activity in the hippocampus. This can be 
caused by afferent impulses and also by high frequency electrical stimulation o f  
various brain sites e.g. mesencephalic reticular formation, hypothalamus or amygdala. 
In particular, activation o f  the hypothalamus appears to induce hippocampal theta 
activity and mid-brain formation activation is responsible for neocortical 
desynchronisation. Other systems may also induce changes in the EEG which are 
indicative o f  arousal e.g. the ascending noradrenaline projection from the locus 
coeruleus. There could also be a number o f  different arousal mechanisms. Szerb 
(1967) concluded that spontaneous, afferent and electrical stimulation o f  the 
mesencephalic tegmentum activates two pathways, one accounts for EEG activation 
and the other increases cortical acetylcholine release, during arousal. Vanderwolf 
(1975) suggested two distinct mechanisms for this, one movement and non- 
cholinergic based and the other an immobility and cholinergic based system. The 
latter reference has both support (Whishaw 1976) and reports o f inconsistencies (Usui 
& Iwahara 1977). The median raphe nucleus could also be involved in the inhibition
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o f  the hippocampal theta rhythm, which would suggest a mechanism o f  control over 
the arousal state.
Stumpf and Gogolak conclude their chapter by saying that drug induced 
changes in EEG are only an indication o f  a well defined central effect and that there 
are only a few cases where this has been proven. They emphasise, quite correctly that 
EEG doesn’t yield information about the site or mechanism o f drug action. Even 
modem EEG systems still cannot do that, despite the fact that objective numerical 
data are now very easy to extract from EEG signals. In the future, however, if  enough 
drug effects are profiled in a standardised manner as to produce a library o f  EEG 
effects related to drug action then it may become commonplace to assess the 
therapeutic potential o f  psychopharmacological compounds using EEG .
In another review, this time on human subjects (Bauer 1987), it was concluded 
that CNS stimulants increase alpha and beta activity, decrease the general voltage o f  
the EEG and the amount o f  slow wave activity whilst tricyclic antidepressants (TCAs) 
increase both slow and fast wave activity, as well as the variability o f  frequencies and 
voltage. Specifically they slow the frequency o f  the alpha rhythm.
The action o f  stimulants is due to the potentiation o f  central dopamine activity, 
although different drugs have different modes o f potentiation. It is thought that they 
may act on receptors related to the brain stem ascending reticular activating system 
although this may be an oversimplification o f the mechanism. This difference in 
electrical activity between stimulants and TCAs could be assumed to be examples o f  
arousal and sedation, a commonly reported side-effect o f  TCAs. This underlines the 
importance o f  using a multi-faceted approach in the assessment o f  psychoactive drugs.
The use o f  one, or more seldomly, two types o f measure will probably not pick up the
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more subtle effects o f some drugs and hence miss any correlates o f  brain electrical 
activity other than the more general arousal or sedation. Psychoactive drags could be 
expected to affect both psychomotor performance and mood as well as produce 
distinctive changes to an EEG profile.
One system o f profiling a drugs activity and bioavailability using EEG has 
been developed by Saletu (1987) using certain statistical procedures referred to as 
quantitative pharmaco-EEG. This followed from observations that, as early as 1929, 
soon after EEG was first developed, EEG changes could be described for various 
drags (Berger 1929). Saletu5s chapter goes on to describe the systematic way in which 
pharmacological studies were carried out throughout the following decades, with 
modem computerised methods facilitating easy acquisition and analysis o f  data. It was 
obvious that psychotropic drugs all produce significant effects on the function o f the 
CNS and that drugs with similar therapeutic effects induced similar CNS changes 
which were reflected in similar pharmaco-EEG profiles. Following a 1991 study 
Saletu concluded that EEG and EP brain mapping are highly suitable, inexpensive, 
high time-resolution methods for objective and quantitative evaluations o f  the 
neurophysiological basis o f  dementia and its treatment. The test battery for the present 
study, therefore, included EEG as a physiological measure o f  the effects o f  each drug 
being assessed.
Psychological (Mood State)
O f the three types o f  measures that have been mentioned the most insensitive 
and subjective one is attempting to assess changes in mood state which may occur
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following the administration o f a psychoactive drug with potential cognitive 
enhancing properties. On reviewing the literature on mood state and its assessment it 
is clear that the majority o f  tests which have been developed are designed for clinical 
use. They are targeted squarely at the diagnosis, monitoring and severity measurement 
o f  depression or anxiety in psychiatric patients. Indeed, most research in this field 
appears to assume that assessment o f mood state is only about determining the type, 
depth and longevity o f a depressive mood in such patients. This is obviously far from 
the truth. Psychology has found great difficulty in obtaining satisfactory conceptual 
models o f  mood state (Sherif et al 1980), mainly because o f  the need for subject self- 
reporting, the inability to have remote measuring capabilities and most o f  all the 
extremely complex and unpredictable nature o f human emotions. Robertson (1989) 
gives a particularly comprehensive review and critique o f  the most common 
depression/anxiety assessment methods. From this report it Would appear that the 
systems used can be separated in several different ways.
Physician rated systems tend to be complex with some being time consuming 
as well. This is because they are related to clinical diagnoses and tend to consider 
whole patient care rather than just the emotional aspects that may be o f  more interest 
for the present investigation. Secondly there are observer rated scales which are 
mainly for carers o f patients with depressive illness. They are designed to give a 
global impression o f a patients quality o f  life related to their illness and indeed, they 
serve their purpose well, although again they are probably not what is required for the 
assessment o f  PEs in normal healthy humans. Thirdly are the self rated scales where 
subjects/patients complete a set o f self-assessment questions about how they are
feeling. There are also several sub-divisions that can be made within these groups:
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diagnostic, severity, present state, longitudinal monitoring and change assessment. In 
order to assess a drug with potential cognitive enhancing effects a mood state 
assessment should be a simple scored system which is self rating, sensitive to short 
term, drug induced change, easily repeatable and o f  short duration.
One example o f  a test with some o f  these attributes, included in Robertson’s 
review, is the Mood Adjective Checklist (MACL) (Lorr and McNair 1964). It consists 
o f  5 groups o f  adjectives to describe anger/hostility, vigour/activity, fatigue/inertia 
and depression/dejection. Subjects mark a 4 point scale as to the degree o f  mood 
aspect in the last 24 hours. The depression/dejection assessment o f  this test has been 
correlated (r=0,96 p<0.05) with the commonly used Beck Depression Inventory (BDI) 
(Beck et al 1961) and has been used to assess the effects o f two drugs in a group o f 
epileptic patients, although with little success. Lader and Bruce (1989), however, 
reported that MACL was sensitive to increased anxiety following caffeine 
administration
However, the majority o f  scored mood assessment tests tend to concentrate on 
one polarity o f  mood, e.g. anger. This does not allow for the common sense reasoning 
that there must be an equal and opposite polarity o f  mood. For instance, the opposite 
o f  being angry could be agreeable. This bi-polarity o f mood measures was first 
proposed by Osgood and Suci (1957) who proposed that the affective meaning of 
concepts could be accounted for by three bi-polar dimensions. Critics suggested, 
however, that the use o f  bi-polarity was just convenient for scoring in a rating scale. 
However, Bentler (1969) argued that rating scales were susceptible to extreme 
response bias which reduced their sensitivity. It was found that once the bias had been
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accounted for, the inter-correlations supporting the hypothesis held true. There have 
since been other reports supporting the bipolar hypothesis (Meddis 1972 and Russell 
1979). Indeed Lorr and McNair (1984) have produced a bi-polar form o f their original 
Profile o f  Mood States (POMS) (Lori' and McNair 1971) which used uni-polar mood 
states. Initially studies were conducted to establish which mood states were o f  bi-polar 
form and to replicate them in different populations. The first study (Lorr and Shea 
1979) used college students and assessed five mood dimensions, four bi-polar: 
composed/anxious; energetic/tired; agreeable/angry; optimistic/pessimistic and a fifth 
uni-polar, cheerful. Ratings were scored on a four point scale with the same number o f 
positive and negative categories. Extreme response bias was controlled and the former 
three dimensions were found to be bi-polar whilst the latter three were separated and, 
therefore, uni-polar.
The second study (Lorr and Wunderlich 1980) used high school students who 
were given a slightly modified version o f  the first assessment using the known bi­
polar states as well as a cheerful/dejected dimension. The rating scale was five 
pointed and three dimensions were found to be bi-polar: energetic/tired; 
relaxed/anxious; and optimistic/pessimistic.
The third study used the original POMS (Lorr and McNair 1971) which
measured the same dimensions although on a uni-polar rating scale. The subject group
used was a psychiatric patient sample and used five proposed bi-polar dimensions:
composed/anxious; agreeable/hostile; energetic/tired; elated depressed and clear-
thinking/confused. Using principal components analysis all five dimensions were
confirmed to be bi-polar although a sixth was also identified. As a whole this series
o f  studies led to the production o f  the bi-polar POMS questionnaire which included all
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five o f  the mood state dimensions o f  the latter study as well as a sixth: 
confident/unsure, which was elucidated by further unpublished work.
It is important to describe the history o f  development o f  this particular system 
because it illustrates the thinking behind the use o f  both negative and positive 
elements o f  mood in such a tool. One o f the purposes o f  the present study is to 
develop the assessment o f a test battery which will give a more comprehensive 
assessment o f both the subjective and the objective behavioural results o f  PE use in 
normal, healthy humans. The majority o f techniques used to subjectively assess the 
most complex o f  human traits, emotion and mood, are used in populations where 
something has possibly already gone wrong in this area. The use o f  uni-polar 
assessment methods is, therefore, justified for such situations. PEs, however, will 
probably have a positive effect on certain aspects o f  mood, although they may have 
additional negative side effects. It is important, therefore, to use an assessment tool 
which recognises both positive and negative aspects. The bi-polar POMS is even more 
powerful in that it has both positive and negative measurement o f  particular mood 
states which are statistically proven to be linked. This means that it would be more 
sensitive to the subtle changes in mood caused by the drags to be assessed in the 
present study and was hence chosen as part o f the test battery.
Test battery administration
The tests described above were, therefore, assigned to the test battery. A  few 
general rules covered all experiments, although not all tests were used in each 
experiment. The choice o f  tests to use in each case was dependent on previously
1 0 2
reported effects o f  the specific drug to be assessed, as well as the time available for 
testing to cover the expected pharmacodynamic profile.
To ensure good control o f  variable factors in each experiment a double-blind 
crossover approach was taken. A  specific protocol for each experiment was submitted 
to, and approved by, the DERA Centre for Human Sciences Ethical Committee before 
experimentation began. All subjects were required to sign a consent form after having 
been advised o f  the reason for the experiment and possible side effects o f  the drugs 
they were taking. Subjects took the ding or placebo in two conditions the timescale o f 
which varied between experiments and is discussed independently in the experimental 
chapters. The order in which the conditions occurred was randomised. Subjects were 
practised in the all performance tests and had been fully familiarised with all the 
equipment involved before an experimental run. The test battery was administered in 
the same order in placebo and drug conditions in order to allow comparison o f  effects 
between substances (some minor variation between experiments is discussed in the 
individual experiment chapters). The order was as follows for a complete test battery. 
Order o f  testing was maintained throughout all experiments to retain comparability o f  
the drugs assessed:
1. Eyes Open EEG
2. Eyes Closed EEG
3. Critical Flicker Fusion
4. Choice Reaction Time
5. Sternberg Short Term Memory Scanning Task
6. Compensatory Tracking Task
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7. Profile o f  Mood State questionnaire
Physiological measurement (EEG)
EEG was recorded using aNicolet BEAM II brain mapper (Nicolet Instruments, 
Madison, Wisconsin). This particular system is based on a Sun 386i workstation and 
uses aNicolet SM2000 36 channel solid state amplifier.
Tin electrodes were attached using an Electro-cap system for 20 channels on the 
skull, placement according to the International 10-20 protocol (Jasper 1958), with linked 
ears as reference. Four artefact channels were also recorded using individual tin 
electrodes, two for horizontal eye movement, one for vertical eye movement and one for 
neck muscle activity. Prior to attaching the electrodes the subjects’ scalp was 
vigorously rubbed with an isopropyl alcohol wipe. Careful attention was paid to the ears 
to ensure a good reference contact. Then the skin was abraded under the site o f each 
electrode using Omniprep® gel and a disposable wooden pick. This was removed using 
distilled water and then electrode gel was injected into the dome o f  each electrode. 
Electrical conductivity was checked before each EEG recording and impedances were 
ensured to be <10kQ. In some cases further abrading with a wooden pick was required 
until the required level was attained.
All recording was conducted with subjects seated in a sound attenuated, 
environmentally controlled booth. In the eyes closed state subjects were requested to 
close their eyes, blank their minds and relax, although they were asked to remain alert. 
If subjects appeared to become drowsy the measurement was halted and restarted once
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they had been alerted. In the eyes open state, subjects were asked to concentrate on a 
non-descript screen 2 metres in front o f  them and to refrain from blinking for as long 
as possible. Blink breaks were given if necessary, although the majority o f  subjects 
were able to blink at distinct intervals, enabling easy removal o f the artefacts from the 
EEG trace. Each separate recording included 2 minutes o f  eyes open EEG and 2 
minutes o f  eyes closed EEG. This was to ensure a minimum o f 1 minute o f  artefact-free 
EEG able to be used for analysis for each run. In practice the normal amount able to be 
used was 1 minute 20 seconds.
Performance Tests (Psychomotor)
Performance tests 1) and 2) were presented using a Leeds Psychomotor Tester 
(Psychopharma Ltd. Surrey) and results were recorded on an Olivetti 386 personal 
computer which was situated in the same sound attenuated booth where EEG recording 
was conducted The same computer was used for all four experiments, for these two 
tests:
1) Critical Flicker Fusion Threshold (CFF)
Subjects were required to observe four red light-emitting diodes (LEDs) held in
foveal fixation at lm  and to press a response button, held in the hand during the duration
o f  the test, when lights were seen to pass the flicker fusion threshold. Individual
thresholds were determined using the mean o f three ascending and three descending
scales. Light levels were maintained at a constant level for all runs o f  the test
(Woodworth & Schlosberg 1958). All subjects were equidistant from the presentation
equipment and the subjects5 eyes were kept at a constant subtending angle to the LEDs,
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by means o f an adjustable height chair for all experiments. The Leeds Psychomotor 
Tester was also in the same marked position for all experiments to ensure consistency 
and reliability o f any effects
2) Choice Reaction Time (CRT)
Subjects were required to extinguish one o f six equidistant red lights, from a 
central starting position, by touching the appropriate response button next to the light. 
Lights were illuminated at random and twenty trials were presented in each run. The 
mean CRT for the twenty trials was the response measure taken. The Total Reaction 
Time (TRT) was treated as the sum o f two separable components, Recognition Reaction 
Time (RRT) and Motor reaction Time (MRT) (Donders et al 1969).
Performance tests 3) and 4) were presented and recorded as part o f  the Milford 
Test Battery (Psychopharma Ltd. Surrey).on a Viglen 486 personal computer. This 
computer was sited in the main laboratory, outside the sound attenuated booth, but was 
screened o ff to allow concentration. The same computer was used for all runs o f these 
two tests:
3) Compensatory Tracking Task (CT)
Subjects were required to observe a 14”  Viglen computer monitor and keep a 
‘mouse’ controlled cursor (an equilateral triangle) in line with a target (a similar 
triangle, inverted) moving along a horizontal axis in a pseudo-random fashion, whilst 
simultaneously responding to visual stimuli (filled white circles) presented at random
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in the comers o f  the screen. The task lasted for 300 seconds and 32 visual stimuli 
were presented in each test run.
4) Sternberg STM scanning test (ST)
Subjects were required to observe a set o f test group numbers (1,3 or 5 digits) on 
a 14”  Viglen monitor. Following this presentation series a ‘beep’ indicated the start o f  a 
probe series. 12 probe numbers were presented individually and the subject had to 
decide whether the digit appeared in the original test group or not. A  positive response 
was indicated by pressing the left mouse button and a negative the left. Subjects were 
asked to respond as quickly as possible whilst also being accurate. Incorrect answers 
were immediately followed by a ‘beep’ . Six sets o f presentation series were made in 
each run, two each o f the 1,3 or 5 digits. A  pause and the sign/New series’ preceded 
each new presentation series.
In addition to the number o f  correct responses to both present and absent digits 
average reaction times for each o f  the presentation series group sizes were recorded for:
a. Correct response to a figure present in the original series
b. Incorrect response to a figure present in the original series
c. Correct response to a figure not present in the original series
d. Incorrect response to a figure not present in the original series
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The Profile o f  Mood States Bi-Polar questionnaire (Lorr and McNair 1982) 
gives six scaled scores for factors pertaining to the mood state o f  normal individuals, 
Composed-Anxious, Agreeable-Hostile, Elated-Depressed, Confident-Unsure, 
Energetic-Tired and Clearheaded-Confused. These represent opposite poles o f  the 
same mood factor. Subjects gave a rating, on a four point scale (much unlike this (0), 
slightly unlike this (1), slightly like this (2), much, like this (3)), to 72 adjectives 
which related to their present feelings. This gave a numerical score for each adjective. 
Each factor had a grand score made up from six o f  the adjectives related to the 
positive pole and six to the negative pole. This resulted in a total score o f  between 0 
and 32.
Conclusions
This chapter elucidated the process by which a test battery suitable for the 
assessment o f  putative PEs was devised. It was important to base the present study 
around a model o f  behaviour to ensure that psychologically relevant information was 
obtained (Michon 1976). A  previously reported model to base this around was, 
therefore, adopted (Hindmarch 1980).
A  particular approach for the assessment o f  PE drug effects was identified and 
necessarily concentrated on three distinct areas to ensure a comprehensive coverage o f  
all the types o f  effect that a psychoactive drug with PE properties may have:
Psychological assessment (Mood State)
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a. Performance (psychomotor) measurement
This was split further into four distinct types o f  test from past
evidence: CNS activity/arousal; Reaction time, STM and
Vigilance/Attention.
b. Physiological measurement
c. Psychological assessment
Tests were identified which assess each o f these areas and which have also
been demonstrated to have good reliability and validity. They are:
a. Performance Measurement.
i. Critical Flicker Fusion threshold (CFF), a good index o f  CNS 
activity/arousal (Sherwood and Kerr 1993)
ii. Choice Reaction Time, a measure o f  the basic skill required for 
and fundamental to all overt activity (Hindmarch 1980)
iii. Sternberg Short Term Memory Scanning task, the assessment 
o f  high speed scanning and retrieval o f  information from the 
short term memory (Sternberg 1966)
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iv. Compensatory Tracking task, the assessment o f  the competition 
for cognitive resources by attending to more than one task at a 
time (Sherwood and Kerr 1993)
b. Physiological assessment
The recording o f brain electrical activity by electroencephalogram 
(EEG) has been demonstrated to give a good indication o f  psychoactive 
drug affects (Saletu 1991) and some changes in the profile o f  such 
activity have been correlated with other measures o f  ding effects on 
cognitive performance (Roth & Battig 1991).
c. Psychological assessment
Psychoactive drugs by merit o f  their purpose will inevitably have an 
effect on the mood and motivation o f a person.. Most pen and paper 
assessments o f  mood concentrate on the negative aspects, with the 
exception o f  the bi-polar POMS questionnaire (Lorr and McNair 1982) 
which is sensitive to both positive and negative effects o f  drugs.
Finally, in order to demonstrate that these tests and measures give good 
coverage o f  the proposed model o f cognitive performance, the Figure 2.2 maps the 
particular tests to the relevant area o f the model.
1 1 0
n n a
▲ A
Fig. 2.2 Mapping of chosen tests and measures onto the model o f psychomotor 
performance after Hindmarch (1980).
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Chapter Three 
Investigation of Caffeine as a Putative 
Psychomotor Enhancer
Caffeine containing beverages are used regularly in some form by some 80% o f 
the world’ s population (Dews 1982). This consumption is partly related to the perceived 
effects on performance as well as for taste. Caffeine is generally regarded as improving 
alertness, especially in situations where fatigue or sleep deprivation has already lowered 
performance.
Performance
There have been a number o f  studies to determine whether caffeine is a 
psychomotor enhancer as well as a psychomotor ‘replacer’ . Measurement o f  the effect 
o f caffeine on separate components o f psychomotor function and other measures, 
however, has produced a variety o f  results. Caffeine has been generally reported to 
increase the speed related aspects o f  psychomotor performance (Lienert and Huber 
1966, Battig et al. 1984, Mitchell and Redman 1992). Kerr et al. 1991) as well as off­
setting deficits, due to sleep deprivation (Nicholson et al. 1984). It has also been shown 
to enhance vigilance (Fine et al. 1994, Zwyghuizen and Doorenbos 1990, Frewer and 
Lader 1991), continuous attention (Yu et al. 1991) and alertness (Smith et al 1994). In 
an epidemiological study higher levels o f  caffeine intake through coffee were reported 
to lead to an improvement in simple reaction time, choice reaction time, incidental 
verbal reasoning and visuo-spatial reasoning (Jarvis 1993). A  similar, but weaker, trend 
was reported with tea consumption. Although the caffeine effects were not quantified, 
caffeine did appear to be a psychomotor enhancer.
In short caffeine appears to improve speed rather than cognitive processing.
Also, in cases o f  fatigue or sleep deprivation caffeine has been shown to have some
113
Introduction
beneficial effects (Penetar et al. 1993, Nicholson et al. 1984). The doses involved in 
these studies showing positive effects have been between lOOmg and 400mg. However, 
doses o f  caffeine above 250mg, may also have deleterious effects on specific aspects o f 
psychomotor performance. Single doses in excess o f 600mg may actually slow the 
speed o f  performance (Loke 1990) and tasks with a high Short Term Memoiy (STM) 
component may be impaired by a 250 - 500mg dose (Frewer and Lader 1991, Foreman 
et al 1989). The impairment o f speed o f performance may be due to the hand tremor 
produced by caffeine in the dose range 450 - 800mg (Loke et al. 1985, Ghoneim et al. 
1986 and Chait and Griffiths 1983). It would appear that caffeine has a “window o f 
efficacy” in improving performance.
Electrophysiological effects
As well as performance studies there have been several studies on the effects o f 
caffeine on the electroencephalogram (EEG) (Bruce et al. 1986, Hasenfratz 8c Battig 
1992 8c 1994, Pollock et al. 1981). Comparison between EEG studies are difficult due 
mainly to the different number o f  electrodes, their configurations and the characteristics 
o f  individual equipment.
In one study caffeine increased Alpha (a) and Beta (P) frequencies, and 
increased a  power and decreased p power in the central area (Hasenfratz and Battig 
1992); measurements from central and parietal sites showed log Theta (0) and log a  
power were decreased with caffeine (Bruce et al 1986) whilst a  and pi power was 
decreased in the parietal-occipital areas with caffeine in an overnight performance 
degradation study (Nicholson et al 1984).
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It is interesting to note that in the latter two studies a  power was decreased 
whilst in the former it was increased. Those studies reporting a decrease in a  activity 
also demonstrated an improvement in alertness as measured by performance tests. It 
could, and has, been argued that a decrease in a  is concomitant with an increase in 
alertness (Fink 1968). It has been concluded, however, in other extensive work to 
profile the effects o f  drug types on EEG, that a decrease in a  with concomitant increase 
in Delta (6), 0 and (3 is indicative o f a decrease in vigilance (Saletu 1987). Saletu has 
also concluded that the profile o f  a psychostimulant drug gives a rise in a  and (31 power 
along with a decrease in 6, 0 and the faster wavebands. These paradoxical results are 
difficult to explain as caffeine is thought to be a mild psychostimulant (Nehlig et al.
1992). If caffeine, however, has both positive and negative effects on performance 
depending on dose, it could be argued that the same might be true for the EEG.
Mood Effects
Caffeine also alters mood (Lieberman et al. 1987) and may have different effects 
on the same subjects depending on the time o f day o f  ingestion (Smith et al. 1991). 
Whilst caffeine increases feelings o f energy, alertness, quick wittedness, attentiveness 
(Bruce et al. 1986) and elation (Smith et al. 1991), higher doses do produce anxiety 
(Loke 1990).
The detrimental effects o f  caffeine abuse are also reflected in the ratings o f 
mood, with moderate to high users o f  caffeine having higher trait anxiety and 
depression scores (Gilliland and Andress 1981), although caffeine could be the effect 
and not the cause (Debry 1994) due to the very high daily intake involved.
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Withdrawal
Withdrawal from regular caffeine use can result in headache, lethargy, 
drowsiness and anxiety (Griffiths et al 1988, Van Dusseldoip and Katan 1990). The 
time o f  onset o f  effect on performance occurs after 24 to 30 hours abstinence, with 
symptoms o f psychomotor performance impairment, decreasing in severity and finally 
ceasing over a 7 day period (Bruce 1991). Griffiths et al. (1986), however, found effects 
on performance after 12-24 hours abstinence with a duration o f  impairment o f  between 
20-48 hours.
Subjects receiving acute doses o f caffeine after refraining from caffeine for 12 or 
more hours may have some deficits in performance due to withdrawal. Improvements in 
certain aspects o f  psychomotor performance, in abstinent subjects, therefore, may be a 
reinstatement o f  performance to usual levels, rather than an absolute improvement. 
Indeed in a large number o f experiments investigating the effects o f  caffeine on 
performance subjects have been specifically asked to refrain from caffeine overnight, 
prior to experimentation. This tends raise the question that performance improvements 
seen with caffeine are simply a restitution o f following withdrawal performance. 
However, one experiment has shown improvements in attention, delayed recall and 
problem solving with small doses o f caffeine (Warburton 1995) following only 1 hour 
o f  caffeine withdrawal. A  large proportion o f the population are regular caffeine users. 
Those who work in environments where caffeine is not available may suffer withdrawal 
symptoms. If a subjects’ work requires a high level o f vigilance and fast reaction times a 
then a significant drop in psychomotor performance may compromise the effectiveness 
o f  an individuals work and challenges the safety o f their work schedules.
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It would appear from these results that caffeine can have an effect on 
psychomotor performance measures, EEG and mood state. The majority o f  the studies 
showing beneficial effects, however, have used subjects withdrawn from caffeine which 
may demonstrate a reinstatement o f performance rather than an improvement over 
normal levels. Also it appears that dose o f  caffeine is very important as it appears to 
have a “window o f efficacy” which produces beneficial effects.
The present study, therefore, combined performance, physiological and
psychological measures to assess the possible impact o f caffeine on performance in
subjects who were not withdrawn from caffeine. All subjects were required to maintain
their usual intake o f caffeine containing drinks prior to the study. Time o f  day effects
were minimised by using a similar dosing regimen for all subjects. Normal daily
caffeine intake was recorded as reported and participants were selected on the basis o f
regular and moderate use, to ensure a similar predisposition to caffeine and its effects on
all measures. The dose used (150mg) was chosen because o f  the evidence o f  positive
effect (Lieberman 1987) and because it was below the doses which have been reported
to have deleterious effects on some aspects o f  performance. It also meant that the on the
subjective measure o f caffeine intake, subjects would not be taking a daily dose in
excess o f  600mg. The two performance tests used provided a measure not only o f the
speed related aspect o f psychomotor performance but also the overall measures o f
central nervous system (CNS) arousal, and the EEG was recorded from 20 standardised
sites in order to provide a comprehensive assessment o f brain electrical activity across
the entire scalp. There are many different measures o f  mood state and anxiety which
have been used to assess caffeine as a mood altering substance. As it is very important
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The experiment
to assess as many aspects o f  a drug’s action as possible i.e. physiological, psychological 
and performance effects the present study used visual analogue rating scales (a bi-polar 
questionnaire o f mood state measuring both negative and positive mood). It was 
hypothesised that caffeine would improve the MRT component o f the CRT task and 
also the CFF threshold.
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Subjects
12 healthy volunteers (7 male, 5 female), mean age 26.4 (sd 3.5) years 
participated in the experiment. Subjects were non-smokers and regular users o f  above 
50mg, but no more than 400mg o f caffeine a day. Ethical approval was given by the 
DERA CHS Ethical Committee and informed, written consent was obtained from all 
subjects. Mean daily caffeine intake was estimated from a subject reported log, 
completed in the 7 days prior to testing (206mg, sdllSmg). Normal caffeine 
consumption was maintained throughout the experimental period, including test days. 
Subjects were asked to keep to their normal daily routine during experimentation.
Protocol
The study was a double-blind, placebo controlled, crossover. A  150 mg dose o f 
caffeine and a cornflour placebo were administered in identical gelatine capsules using 
balanced administration. Two practice sessions o f  the performance tasks were carried 
out prior to testing to preclude learning. Testing was carried out in an environmentally- 
controlled, sound-attenuated laboratory, on two separate days, one week apart. 
Experiments commenced at 09.40h and the caffeine or placebo capsule was ingested at 
lO.OOh.. After a baseline assessment subjects were tested every 30 minutes for 2 hours.
Materials and Methods
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Each psychometric battery comprised:
2 minutes Eyes Open EEG 
2 minutes Eyes Closed EEG 
Critical Flicker Fusion Threshold (CFF)
Choice Reaction Time (CRT)
Profile o f  Mood State - Bipolar (POMS - BI) questionnaire
Data Analysis 
EEG
Artefacts caused by eye or neck movement were removed from the raw EEG 
data using the Nicolet BEAM II system. Spectral analysis was carried out on 2 second 
artefact-free epochs o f  the data, using the Fast Fourier Transform technique. The system 
allows the signal to be frequency partitioned into 0.5Hz 'bins', ranging from 0.5Hz to 
23.5Hz giving a mean power value in each. The power (pv) in each bin was calculated 
for each channel and the bins were grouped into six wavebands, delta (0.5 - 3.5Hz), 
theta (4.0 - 7.5Hz), alpha (8.0 - 11.5Hz), betal (12.0 - 15.5Hz), beta2 (16.0 - 19.5Hz), 
and beta3 (20.0 - 23.5Hz) with a mean power value being calculated for each band. The 
peak frequency (PF) was also calculated for each waveband using the mid-point o f  the 
frequency bin with the greatest amplitude in each channel, o f each subject for both 
conditions.
Power values were log-transformed and PF was reciprocal-transformed for 
variance stabilisation. Analysis o f  variance was first carried out for mean power values 
for each waveband. Condition (placebo versus caffeine), time (Omins, 30mins, 60 mins,
120
90 mins and 120 mins) subject (12), channel (20), and eyes open/closed, were labelled 
as the main effects while subject was treated as the random effect. Similar ANOVA 
were also carried out for mean PF and mean power in each PF (PFP). The differences in 
mean power values in the alpha waveband at each time point o f  the experiment were 
assessed to investigate the possibility o f  a pharmacological action. Also, a post-hoc 
Bonferroni t-test was carried out to assess the individual channel differences in PF and 
PFP, between drug and placebo conditions.
Performance Tests and Mood State
Analysis o f variance was carried out on the data o f both performance tests, all 
separate components o f the CRT and POMS-BI mood state scores. CRT data were log 
transformed for variance stabilisation. In each case condition and time were labelled as 
the main effects with subject treated as the random effect. A  simple paired t-test was 
also conducted to compare the post-baseline peak effects o f both conditions for CFF and 
CRT.
Full ANOVA results for caffeine versus placebo can be seen in Table A. 1 in 
Appendix A.
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Performance Tests
No significant differences were observed between the placebo and caffeine 
conditions in the CFF threshold (F=1.27, d f= l,ll, p<0.284) although a time 
effect was observed (F=11.37, dfr=4,44, p<0.000) with values reducing over the 
time o f  the experiment as are shown by the means in Table 3.1. The simple paired 
t-test showed that there was no significant difference between the post-baseline 
peak effect in the two conditions (t=1.0663, df=l 1, p<0.3090)
The same was true for the recognition (F=0.377, d f= l,ll, p<0.552), motor 
(F=1.14, d f= l,ll, p<0.309) total (F=0.012, df=T,ll, p<0.914) components o f  
choice reaction time although no time effects were seen in these measures. The 
simple paired t-test showed that there were no significant differences between the 
post-baseline peak effects for RRT (t=0.773, d f= ll, p<0.4846), MRT (t=1.070, 
dfi=ll, p<0.3075) or TRT (t=0.719, df=Tl, p<0.4869) Means for CRT, back 
transformed and corrected for bias, are shown in Table 3.2.
Mood State
There were main effects o f  caffeine compared to placebo in the Energetic- 
Tired factor o f  the mood scores (F=6.37, df = 1,11, p<0.028) and in the 
Confident-Unsure factor (F=8.14, d f= l,ll, p<0.016). Subjects felt more energetic 
and confident in the caffeine condition, although there were no drug/time 
interactions which would have been expected if  the cause o f the difference had 
been drug activity. However, at all time points after the baseline measure both
Results
sets o f  scores were significantly higher with caffeine than with placebo. Time 
effects were also observed in both- factors (Confident-Unsure (F=2.73, d£=4,44, 
p<0.041), Energetic-Tired (F=6.37, d f= l,ll, p<0.028)) This suggested there may 
have been an experimental artefact in the baseline measure itself, masking a 
possible interaction. No significant effects were seen in the Composed-Anxious 
(F=0.85, d f= l,ll, p<0.376), Agreeable-Hostile (F=2.41, dfi=l,ll, p<0.149), 
Elated-Depressed (F=1.28, d f= l,ll, p<0.282) or Clearheaded-Confused mood 
factors (F=1.44, d f= l,ll, p<0.255). The fiill recorded mean scores are shown in 
Table 3.5.
EEG Power
When mean power was calculated for all subjects across all 20 channels, Alpha 
was the only waveband to show any power difference due to drug effect (F=38.91, 
d£=l,ll, pcO.OOOl). A  time difference was also seen (F=16.87, df=4,44, p<0.0000) 
along with a drug x time interaction (F=3.526, df=4,44, p<0.0139). A  post-hoc 
Neuman-Keuls analysis also showed that the difference between the conditions changed 
over the time points o f  the experiment and this is illustrated graphically in Fig 3.1. At 
the baseline, no difference was seen, but at 30 minutes post ingestion there was an 
attenuation o f power with caffeine (p<0.05) which was maintained at 60 (p<0.001), 90 
(p<0.01) and 120 minutes (p<0.05) post ingestion. The means, back transformed and 
corrected for bias are shown in Table 3.4.
An absolute effect o f drug occurred in the beta 1 waveband (F=16.92, d f= l,ll ,
p<0.0017) as well as a time effect (F=3.95, df=l,l 1, p<0.0079) with mean power values
in the drug condition significantly lower than placebo. However, there was no drug x
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time interaction. There was also an absolute effect o f caffeine with lower mean power in 
the delta (F=14.23, d f= l,ll, p<0.0031) and in beta2 (F=8.839, d f= l,ll, p<0.0127). 
Time effects were not seen in the delta waveband results but were in the beta2 
(F=4.701, df=4,44, p<0.0030) and theta wavebands (F=10.89, df=4,44, p<0.0000). 
Again, however, no drug by time interactions were seen in any o f  these wavebands.
EEG Peak Frequency (PF)
Mean PF across all 20 channels and all post ingestion times, for all subjects, 
showed an increase in Beta3, with caffeine compared to placebo (F=9.59, d f= l,ll, 
p<0.010) whilst in Theta it decreased (F=8.65, d f= l,ll , p<0.014). However, delta 
(F=0.83, d f= l,ll, p<0.383), alpha (F=1.09, d f= l,ll, p<0.319), betal (F=2.02, d f= l,ll, 
p<0.183) and beta2 (F=0.98, d f= l,ll, p<0.344) did not show any significant difference 
between conditions. This is more clearly illustrated in Fig. 3.2 and means, back 
transformed and corrected for bias are shown in Table 3.5.
The Post-hoc Bonferroni t test did show significant differences in a number o f 
channels, in all but alpha and betal wavebands. In delta there was a decrease with 
caffeine in P3, PZ (p<0.05), 02  and 01 (p<0.01), but FP2, F8 (p<0.05) and T6 (p<0.01) 
showed an increase. Theta waveband PF decreased in C4, P4, P3 and 01 (p<0.05), 
whilst beta2 showed a similar pattern to delta with a decrease with caffeine in CZ and 
PZ and an increase in the frontal and temporal regions; FP1, F8 (p<0.01), FP2, F7, T5 
and C3 (p<0.05). In P3, however, virtually every channel showed an increase in PF, 
with Frontal and Temporal regions reaching significance; FP2, F8, F7, T5 (p<0.01), T6 
and C3 (p<0.05). These results are presented more clearly in Table 3.6
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EEG Peak Frequency Power (.PFP)
The mean power o f the PF in each waveband, for all channels, all time points 
and in all subjects was decreased in betal (F=6.46, df=l,l 1, p<0.0275), alpha (F=38.91, 
d f= l,ll , p<0.0001), delta (F=31.76, d f= l,ll, p<0.0002) and theta (F=12.50, d f= l,ll ,  
p<0.0047) in the caffeine condition. Beta 2 just failed to reach significance (F=3.57, 
d f= l,ll, p<0.085) whilst beta3 showed no change at all (F=0.01, d f= l,ll, p<0.938). 
The overall means are illustrated graphically in Figure 3.3.
An interesting interaction that did occur was that o f drug by channel for the delta 
values (F=7.43, df+4,44, p<0.0000).This may have been an indicator o f the changes 
which were seen in the individual channels, which were highlighted by the Bonferroni t- 
Test. These are again shown in Table 3.6. Indeed the post-hoc Bonferroni t-test showed 
that all wavebands had significant changes in PFP in individual channels, with the 
Parietal, Occipital and Midline regions specifically affected. Alpha showed a decrease 
o f PFP in P4, 01, FZ, PZ, CZ, OZ , FP2, FP1, F8 and T6 (p<0.01), F7 and P3 (p<0.05) 
with caffeine. Theta decreased in P4, P3, CZ, OZ (p<0.01), 02, 01, and PZ (p<0.05). 
Alpha had some additional attenuation o f PFP in the frontal region FP2, FP1, T4 
(p<0.01), F7 and F3 (p<0.05) with caffeine, but also decreased in P4, P3, 02, O l, FZ, 
CZ, PZ and OZ. The beta wavebands, however, showed a slightly different pattern, with 
the caffeine condition having a tendency for reduction in PFP in the Parietal, Occipital 
and Midline regions, but also some increases in the Frontal and Temporal regions.
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The aim o f the present study was to assess the effects o f caffeine taken over and 
above subjects’ normal daily intake to see if caffeine could be regarded as a true 
psychomotor enhancer or alerter above normal levels. Subjects were asked to maintain 
usual daily intake o f caffeine containing beverages. Subjects’ diary records o f their use 
o f caffeine containing foodstuffs prior to the experiment were used to confirm regular* 
caffeine using status. This reduced possible effects or oversensitivity to the substance, 
which were reported to be correlated with adverse effects on performance (Loke 1990) 
and also ensured that the dose o f caffeine given was indeed additional to subjects’ usual 
daily intake. The possibility o f results being due to a reinstatement o f caffeine in 
subjects suffering withdrawal, which has been suggested as the basis for a large number 
o f  positive results in this type o f research (James 1994), was thus controlled. It was 
recognised, though, that subjects would differ in the pattern o f their normal caffeine 
intake. In the placebo condition it was conceivable that subjects did not receive caffeine 
at a time when they would otherwise have expected a normal dose. There is a 
possibility, therefore that some subjects were in caffeine decline during 
experimentation. However, it was assessed that subjects all normally had some form o f 
caffeine intake prior to the experimentation start time. Thus any missed expectation 
effects were minimised. Also, the length o f the experiment, 2.5 hours meant that 
withdrawal effects were extremely unlikely in the placebo condition.
The performance tests were broadly not significantly affected by caffeine. 
Previous experiments which have demonstrated improvements in performance tests 
with caffeine have required the subjects to abstain from caffeine for up to 24 hours 
before testing (Lieberman et al. 1987, Battig et al. 1984, Zwyghuizen & Doorenbos
Discussion
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1990, Mitchell & Redman 1992, Smith et al. 1994, Fine et al. 1994). It has been 
demonstrated that withdrawal from caffeine occurs between 12 and 30 horns abstinence 
with symptoms including impaired psychomotor performance (Bruce et al. 1991, 
Griffiths et al. 1986). As the design o f the experiment precluded subjects from being in 
a state o f  withdrawal, it would appear that caffeine, given over and above the usual daily 
intake does not improve psychomotor performance. This adds support to the suggestion 
that previous performance studies have simply demonstrated a reinstatement o f  
performance levels following a period o f caffeine withdrawal rather than an 
improvement o f  psychomotor function brought about by caffeine per se.
It has been shown, however, that caffeine can combat performance decrements 
in sleep deprived subjects (Nicholson et al. 1984, Bonnet & Arand 1994, Penetar et al.
1993). This along with a rather overwhelming amount o f anecdotal evidence suggests 
that caffeine is useful in maintaining overnight performance, for a time, in sleep 
deprived individuals or shift workers. In Nicholson et al. (1984) subjects were caffeine 
deprived for 12 hours before the experiment and this may have amplified the 
performance decrements and the results may well reflect some o f the reinstatement 
effects o f  caffeine.
Despite the lack o f effect on the performance tests in this experiment there were 
measurable effects on the other two measures used. The results o f the POMS-BI 
questionnaire do not enable a firm conclusion to be made, but suggest that caffeine may 
ameliorate feelings o f tiredness and improve feelings o f confidence. That the subjects 
were not caffeine deprived suggests that caffeine could possibly be used to give short 
term increase in subjective feelings o f energy and confidence in real situations. Indeed it 
could be implied from this sort o f evidence and a large body o f evidence supporting the
135
idea o f  caffeine promoting the feeling o f well-being (Dews 1982, Sawyer 1982, 
Griffiths et al. 1990, Smith et al 1992, Lieberman et al. 1987) that drinking coffee, tea 
and taking other forms o f caffeine regularly could be motivated more by its 
psychological effects on mood (feeling better, more energetic etc.), than by its 
psychomotor or cognitive activity.
The results o f the EEG brain mapping show that caffeine had what is generally 
regarded to be a “psychostimulant” effect on the brain. Decreased alpha power, with 
caffeine, is similar to that seen in other studies (Nicholson et al 1984, Bruce et al. 1986, 
Pollock et al 1981) and indicates a possible alerting effect (Fink 1968). Indeed the time 
profile o f  this change in electrical activity (Fig. 3.1) showed a distinctive peaking o f  
effect after about 90 minutes which could reflect the pharmacokinetic profile o f  caffeine 
with peak plasma concentrations between 33 and 52 minutes following ingestion 
(Blanchard and Sawers 1983, Bonati et al. 1982). Other studies, however, have also 
seen changes in the power o f other wavebands (Nicholson et al. 1984, Hasenfratz & 
Battig, Bruce et al. 1986) which were not found in this experiment, although there were 
absolute effects decreased power in delta, betal and beta 2 in the caffeine condition o f 
the present study. These results, however, were not supported by drug by time 
interactions. This overall reduction in power has not been reported before. Such a 
difference in effects could again be due to the earlier studies’ lack o f  control o f the 
effects o f withdrawal from caffeine prior to experimentation, although little work seems 
to have been carried out on the EEG aspects o f  this. The current study is more 
representative o f the effect o f caffeine on the EEG o f non-caffeine deprived subjects.
Psychostimulants have been shown to increase alpha and betal power and 
decrease power in other wavebands when compared to a placebo (Saletu 1987). As
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caffeine can be regarded as a “psychostimulant” (Nehlig et al. 1992) the results seen 
here are different to the ‘phannaco-EEG’ findings. However, ‘pharmaco-EEG’ studies 
produce conflicting results within themselves and sometimes various doses o f the same 
drug have produced differing drug profiles, whilst 011 the other hand different drugs can 
show identical profiles (Saletu 1987). To investigate these differences further a more 
detailed analysis was conducted on the Peak Frequency (PF) changes and also, 
somewhat unusually, the changes which occurred in the power o f  the dominant 
frequency (PFP) in each waveband.
The mean PF across all channels, increased in beta3 and decreased in theta. 
Increases in beta PF have been previously reported with caffeine (Hasenfratz & Battig 
1994, Hasenfratz & Battig 1992) although a concomitant increase in alpha PF was also 
observed in both those studies, along with changes in the power o f  other wavebands. 
The decrease in theta PF does not seem to have been reported elsewhere but may also 
be indicative o f psychostimulant action. The mean individual channel data further 
suggests that with caffeine the slower waveband activity had decreased PF specifically 
in the Parietal and Occipital regions, with caffeine, whilst the faster wavebands had 
increased PF mainly in the frontal regions.
The general decrease o f  PFP in all wavebands up to betal, is another indicator 
o f Hie alerting effect o f  caffeine due to the reduction in the power o f  die dominant 
frequency o f the slower wavebands. In the individual channel analysis the slower 
wavebands appeal* to have a different pattern compared with die beta bands, with the 
faster activity showing a decrease in PFP in die Parietal, Occipital and Midline regions 
and the slower activity showing decreases especially to the Frontal regions. This pattern 
o f  activity has not been reported elsewhere and requires further investigation.
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Whilst some o f  the present results reflect some findings from other studies, it is 
considered interesting that none o f the studies have reported identical EEG patterns. The 
present EEG changes are in the context o f the lack o f changes on the psychometric tests 
used, demonstrating more o f a psychological effect o f caffeine, rather than a 
psychophysiological effect on performance. Other studies with different protocols, or 
those where caffeine was withdrawn prior to experimentation will produce results which 
reflect the context and set o f experimental set o f circumstances under which they were 
conducted. It is undoubtedly experimental-methodological differences which account 
for variability between current and previous results, rather than any drug/dose regimen 
variability. Contradictory evidence from different sources is also seen in other aspects o f  
psychopharmacological assessment o f caffeine effects. It could be that experimental 
protocols are eliciting different effects, different subject populations reacting differently, 
or simply that effects o f caffeine on the human are so diverse and complex that each 
study only elucidates one particular facet.
Although this study does not confirm the reliability o f caffeine as a psychomotor 
enhancer it does demonstrate some EEG activity, which cannot be due simply to the 
restoration o f  caffeine in previously deprived subjects. This activity is indicative o f a 
general alerting or ‘ stimulating’ action which other studies (Nicholson et al. 1984, 
Penetar
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Chapter 4
Nicotine As A Putative Psychomotor Enhancer In 
Normal, Healthy Non-smoking Individuals
1 3 9
Introduction
Smoking and chewing tobacco have long been the pastime o f  many cultures 
around the world, and nicotine per se, may have some use as a psychomotor enhancing 
substance in both smoking and non-smoking subjects (Sheiwood 1993, Foulds et al. 
1996, Heimstra et al. 1967, Hindmarch et al. 1990)
Studies investigating the effects o f  nicotine on psychomotor performance have 
concentrated, mainly, on effects seen in regular smokers. The tests used to assess 
performance have ranged from laboratory assessments o f  particular aspects o f  cognitive 
activity to complex simulations o f  the real-world such as car driving. These have shown 
varied results although nicotine has been reported to improve rapid information 
processing (Warburton & Amall 1994, Wesnes & Warburton 1983), memory and 
learning (Mangan & Golding 1983), attention (Wesnes & Warburton 1983), and 
reaction times o f smokers, but not non-smokers, in a search task (Hindmarch et al 1990).
Studies using physiological measures o f  the effects o f nicotine have shown that 
the electroencephalographic (EEG) activity o f  subjects smoking tobacco is modified 
(Comer et al.1979, Knott 1988, Knott 1989, Pritchard 1991). However, such EEG 
measures have provided varied results o f  both increased and decreased Alpha (a) 
waveband activity, differences in the changes o f  dominant frequencies as well as 
changes in other wavebands. Overall results do suggest that nicotine alters the EEG 
profile in a way which reflects an increased level o f alertness, and although this is not 
conclusive it does partly tie in with the subjective opinions o f  smokers (Gilbert 1979, 
Ashton & Golding 1989, Soria et al. 1996).
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The mood o f  a smoker is also affected by nicotine which, although somewhat 
paradoxical, can have both arousing and tranquillising effects, (Gilbert 1979, Golding & 
Mangan 1982). Such properties o f  nicotine are a consequence o f  its pharmacological 
action, low doses causing stimulation o f autonomic ganglia and high doses, following 
initial stimulation, causing inhibition (Golding & Mangan 1982, Goodman & Gilman 
1985). The changes in arousal and emotion produced by nicotine mean that certain 
people will experience different effects depending on the state o f mind at the time o f  
intake (Gilbert & Meliska 1992).
However, one common feature o f the majority o f these studies was that subjects 
abstained from smoking, for between 1 and 10 hours, before testing. The half life o f  
nicotine is around 2 hours (Benowitz 1987), and since a drop to one third the normal 
blood level o f nicotine can evoke a deprivation reaction in smokers (Russell 1987) the 
EEG changes and performance changes could well be due to the reinstatement o f  
nicotine levels rather than an absolute improvement o f function. This was demonstrated 
by Frankenhauser et al.(1971) who reported that smoking a cigarette eveiy 20 minutes 
across an 80 minute session maintained reaction time performance whilst reaction times 
were impaired when subjects were not allowed to smoke. In other words subjects who 
were nicotine deprived would consequently have reduced performance (Lindgren et al. 
1996, Warburton et al. 1988). Notwithstanding this problem, there is enough evidence to 
suggest that nicotine may enhance the performance o f non-smokers.
The effect o f  smoking tobacco on psychomotor performance has been the 
commonest method o f  investigating the effects o f  nicotine, but is unsuitable when using 
non-smoking subjects from both the ethical and quantitative control aspects. However, 
forms o f  administration other than smoking have also been used to investigate the
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effects o f  nicotine on performance: nicotine tablets (Wesnes & Warburton 1978); nasal 
nicotine solution West & Jarvis 1986); nicotine gum (Hindmarch et al. 1990); and sub­
cutaneous injection (Foulds et al. 1996). Whilst oral nicotine is a poor means o f 
delivery, as most o f it is metabolised in the first pass o f  the liver, nicotine gum has been 
shown to provide systemic levels o f between 0.38 and 1.40mg when 2mg gum has been 
chewed slowly and steadily for 20 minutes (Benowitz et al 1987). Doses o f  2 mg have 
been used in non smokers without the nauseous side effects associated with higher doses 
(Hindmarch 1990 personal communication).
The present study, therefore, investigated the effects o f nicotine, delivered by 
chewing 2mg nicotine gum, on the EEG brain map, psychomotor performance and 
mood state o f non-smoking subjects, so ensuring that the effects o f  nicotine per se were 
investigated as opposed to any effects o f  smoking. Withdrawal effects were avoided by 
the use o f  non-smoking subjects. EEG brain mapping provided quantitative EEG data 
over a large number o f scalp sites. The performance tests used had previously been 
shown to detect effects o f nicotine (Sherwood 1993, Foulds et al. 1996, Hindmarch et al. 
1990) and mood state was assessed using the Profile o f  Mood State questionnaire (Lorr 
& McNair 1984).
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Methods and Materials
Subjects
12 healthy volunteers (11 male, 1 female), mean age 25.7 years (sd4.6) 
participated in the experiment. They were all non-smokers and in good physical health 
without a significant clinical or psychological history. Ethical approval was given by the 
DERA CHS Ethical Committee and all subjects provided written informed consent to 
participate in the study. Normal caffeine consumption was maintained throughout the 
experimental period, including test days. Subjects were asked to keep to their normal 
daily routine during experimentation, but to avoid excessive alcohol consumption the 
evening before testing.
Protocol
A  double-blind, placebo controlled, crossover design was used. Nicotine was 
administered in the form o f a 2mg nicotine dose o f polacrilex chewing gum which was 
given in a balanced manner with a placebo gum. The nicotine and placebo gum were 
both disguised inside normal mint flavoured chewing gum, with one drop o f pepper 
sauce added to prevent subjects gaining any flavour cues. Subjects chewed the gum for 
20 minutes in a regular manner to ensure similar dose uptake.
Testing was earned out in an environmentally-controlled, sound-attenuated 
laboratory, on two days, one week apart. Experiments commenced at 09.40h with 
chewing o f  the nicotine or placebo gum at lO.OOh. Two practice sessions on the 
performance tasks were carried out prior to testing. Subjects completed a baseline run o f 
the test battery prior to chewing the gum, and then every 30 minutes after termination o f
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chewing for 2 hours. The test battery took approximately 20 minutes and consisted o f :
2 minutes Eyes Open EEG 
2 minutes Eyes Closed EEG 
Critical Flicker Fusion Threshold (CFF)
Choice Reaction Time (CRT)
Profile o f Mood State - Bipolar (POMS - BI) questionnaire.
Data Analysis
C F F
Threshold values were calculated as the mean o f  three ascending and three 
descending scores. An analysis o f  variance was conducted on the data. Condition and 
time were labelled as the main effects and subject as the random effect. A  simple paired 
t-test was conducted to compare the peak post-baseline effects o f the placebo and 
nicotine conditions.
CRT
A histogram o f distribution within the CRT data identified some values which 
were deemed to be false starts (<200msecs) and those which were plain misses 
(>1500msecs). These were excluded and a subsequent analysis o f  variance was carried 
out on the separate components o f the CRT: Recognition Reaction Time (RRT); Motor 
Reaction Time (MRT and Total Reaction Time (TRT). Condition, time, order and 
number o f presentations were labelled as the main effects and subject treated as the
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random effect. Data were log transformed for variance stabilisation. A  simple paired t- 
test was also used to compare the peak post-baseline effects o f  placebo and nicotine.
M ood State
Data were obtained in the six categories o f  mood state for each condition. An 
analysis o f  variance was conducted on the scores o f  each factor with condition, and time 
labelled as the main effects and subject as the random effect. Values were log 
transformed for variance stabilisation.
EEG
Artefacts caused by eye or neck movement were removed from the raw EEG 
data using the Nicolet BEAM II system. Spectral analysis was carried out on 2 second 
artefact-free epochs o f  the data, using the Fast Fourier Transform technique. The system 
allows the signal to be frequency partitioned into 0.5Hz 'bins', ranging from 0.5Hz to 
23.5Hz giving a mean power value in each. The power (pv) in each bin was calculated 
for each channel and the bins were grouped into six wavebands, 8 (0.5 - 3.5Hz), r\ (4.0 - 
7.5Hz), a  (8.0 - 11.5Hz), (3 1 (12.0 - 15.5Hz), (3 2 (16.0 - 19.5Hz), and {3 3 (20.0 - 
23.5Hz) with a mean power value being calculated for each band. The peak frequency 
(PF) was also calculated for each waveband using tbe mid-point o f  the frequency bin 
with the greatest amplitude in each channel, o f  each subject for both conditions. Both 
power and PF data were log transformed for variance stabilisation. Analysis o f  Variance 
was conducted on both mean power and PF data. Condition (nicotine versus placebo),
1 4 5
time (0, 30, 60, 90, 120 mins), eyes open/closed, were labelled as main effects with 
subject as the random effect.
Principal Components (PC) analysis was also carried out on the power and PF 
data to identify groups o f electrode sites which had similar activity within each 
waveband. Groups were defined as those sites having a PC score>0.65.
An analysis o f  variance was carried out for the mean power and PF values o f 
each waveband in each PC grouping. Condition (nicotine versus placebo), time (0, 30, 
60, 90 and 120 mins), eyes open, eyes closed, ratio o f  eyes open to eyes closed, 
geometric mean o f  eyes open/eyes closed, and group were labelled as the main effects 
and subject within group was heated as the random effect.
Full results o f  the Analysis o f  Variance are seen ion Table A.2 in Appendix A.
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Results
C F F
No significant effects were seen in the CFF threshold (F=0.23, df=l,10, p<0.641) with 
nicotine compared to placebo, but there was a time effect with a gradual decrease in 
threshold over the 90 minute time period (F=5.07, df=4,40, p<0.002) as can be seen in 
Table 4.1. Neuman-Keuls post-hoc analysis highlighted the differences between time 
points (Time 0 > Time 90 (p<0.001) and Time 0 > Time 60, 120 (p<0.05)), but the 
simple paired t-test did not show any significant difference between peak post baseline 
effects o f the two conditions (t=0.0158, df=10, p<0.9878).
CRT.
Whilst there were no significant effects seen in MRT or TRT, there was 
tendency towards a reduction in the RRT component (F=4.22, df=l,10, p<0.069) o f 
the Choice Reaction Time task with nicotine compared with placebo. However, there 
was no drug by time interaction (F-0.306, df=l,10, p<0.4385) and a simple paired t- 
test analysis did not show any significant difference between the peak post-baseline 
effects o f the two conditions in RRT (t=1.048, df=10, p<0.3194), MRT (t=0.032, 
df=10, 0.9754) or TRT (t=0.926, df=10, p<0.3761). Post-hoc Neuman-Keuls analysis 
also failed to find any particular time points at which significant differences occurred. 
In looking at Figure 4.1 where the RRT data are displayed graphically it would appear 
that there was a marginal difference between the nicotine and placebo conditions 
which was maintained over the period o f the experiment and this could account for the 
trend, rather than a true drug effect.
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There was, however an order effect in the RRT component where subjects 
were slower in the first testing session compared to the second session (F=25.71, 
df=l,9, p<0.001). Motor reaction time (MRT) did not show any improvement with 
nicotine (F=0.45, df= 1,10 p<0.84) but there was a time effect with both placebo and 
drug conditions improving towards the end o f the experiment (F=3.54, df=4,34, 
p<0.016). Total reaction time (TRT) did not show any significant drag effect (F=2.51, 
df=T,10 p<0.15) but did show a similar order effect to the RRT (F=23.22, df=l,9, 
pO.OOl). It was thought that due to the magnitude o f the order effects in both RRT 
and TRT significant effects o f nicotine at particular time points in the experiment may 
have been masked. Figures 4.1 and 4.2 highlight the fact that the actual mean times 
for both were reduced at the 120 minute time point o f the experiment. All mean 
reaction times, back transformed and corrected for bias, are shown in Table 4.2.
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No significant drug effects were observed in the Composed-Anxious (F=2.43, d£=l,10, 
p<0.15, Agreeable-Hostile (F=1.49, df=l,10, p<2.51), Elated-Depressed (F=0.01, 
df=l,10, p<0.935), Confident-Unsure (F=0.50, df=l,10, p<0.497), Energetic-Tired 
(F=1.40, df=l,10, p<0.265) and Clearheaded-Confused (F=0.31, df=l,10, p<0.593) 
mood state factors. However there was a time effect for the Elated-Depressed factor 
(F=3.52, df=4,40, p<0.015). Table 4.3 shows the mean scores for the POMS 
questionnaire.
EEG
No significant drug effects were seen in the mean power o f  delta (F=0.16, df=l,10, 
p<0.702), theta (F=1.04, df=l,10, p<0.331), alpha (F=1.66, dffl,10, p<0.227), betal 
(F=0.91, df=l,10, p<0.362), beta2 (F=1.24, df=l,10, p<0.291) or beta3 (F=0.002, 
df=l,10, p<0.965),
The same was true for the mean peak frequency values o f delta (F=0.21, 
df=l,10, p<0.656), theta (F=0.27, d£=l,10, p<0.617), alpha (F=0.01, df=l,10, p<0.915), 
betal (F=0.09, df=l,10, p<0.774), beta2 (F=0.01, dffil,10, p<0.915) or beta3 (F=3.03, 
df=l,10, p<0.113) wavebands o f  the EEG.
However delta (F=3.06,df =4,40,p<0.05) had significantly greater power than 
baseline at all time points in both conditions and theta (F=14.02,df=4,40,p<0.001) had 
significantly greater power than baseline at the latter three time points in both 
conditions. Mean values for both power and PF are shown in Tables 4.4 and 4.5. Indeed 
it was interesting to note that overall time effects were seen in all wavebands: delta 
(F=3.06, df=4,40, p<)0.027, theta (F=11.32, dfr=4,40, pO.OOO), alpha (F=14.02,
Mood State
1 5 2
df=4,40, p<0.000), betal (F=8.58, df=4,40, pO.OOO), beta2 (F=12.27, df=4,40, 
p<0.000) or beta3 (F=3.30, df==4,40, p<0.02). All mean values for both condition were 
seen to increase over the time o f  the experiment.
Time effects were also seen in delta PF (F=2.72, df=4,40, p<0.043) with 
frequencies increasing to the middle time point and decreasing towards the end in both 
conditions, theta (F=4.32, df=4,40, p<0.005) with PF increasing throughout the 
experiment in both conditions and betal (F=2.77, df=4,40, p<0.04).
However, principal components were found in all wavebands and then 
distribution is described in Table 4.6. When analysis o f variance was conducted on tbe 
principal components scores some significant results were found in particular 
wavebands. There was a decrease in the eyes open to eyes closed Alpha ratio, with 
nicotine compared to placebo, in the Principal Component (PC) group alpha 1 (F=l 1.24, 
df=l,10, p<0.007) seen in table 4.7, and PC group alpha 3 (F=7.27, df=4,40, p<0.022) 
seen in Table 4.8, as well as a tune effect o f  the latter (F=2.70, df=4,40, p<0.05). There 
was also an increase in the eyes open to eyes closed beta 3 ratio in PC group beta 3 
(F5.05,df=1.10, p<0.048) as well as a time effect (F=2.79, df=4,40, p<0.05) seen in 
Table 4.9.
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Discussion
The aim o f the present study was to assess the effects o f  nicotine in non-smokers 
to see if  nicotine could enhance psychomotor performance beyond normal levels and 
hence be regarded as a PE. In order to ensure that any effects observed reflected a true 
effect o f nicotine subjects were selected on the basis o f never having smoked. The 
results observed, therefore, were not compromised by subjects being withdrawn 
artificially from nicotine. Even though care was taken over this point the results were far 
from conclusive about any psychomotor enhancing effects o f nicotine.
The EEG data demonstrated that nicotine administered by chewing gum did 
have a central pharmacological action on non-deprived subjects. Whilst mean power and 
Peak Frequencies were not affected by nicotine, principal components analysis revealed 
a more localised effect. Mean power in the eyes open to eyes closed ratio was decreased 
in two components o f the alpha waveband. An increase in mean power was also 
observed in one component o f the Beta3 waveband.
Generally a decrease in alpha power is indicative o f  an increase in alertness 
(Fink 1967). However, there has been some disagreement over the EEG effects o f  drugs 
in general. In some EEG profiles o f  stimulant drugs, which might be expected to 
increase alertness, it has been found that alpha power is increased along with beta 
power, whilst delta and theta power are decreased (Saletu 1987).
The results shown in the present study, compared to other studies may reflect a 
number o f  differences in methodology, but they do suggest a decrease in the volume o f 
alpha activity and an increase in beta activity. Whilst these effects were only seen in 
particular components o f  the EEG the localisation o f the effect may have been the
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reason that statistically significant results were not seen using the mean o f  all recorded 
activity.
It is interesting to note that aspects o f  both Fink’s results and Saletu’s results 
were seen in these results i.e. decrease in alpha power for the former, increase in beta for 
the latter. They, however, were dealing with stimulants in general. However, such 
dissimilarity in the effects o f  nicotine on EEG is not uncommon [Comer et al. 1979, 
Knott 1988, Knott 1989, Pritchard 1991), especially in the Alpha waveband. Comer 
reported a general decrease o f  EEG power in smokers compared to non-smokers whilst 
Knott (1988 & 1989) and Pritchard showed a decrease only in delta and theta power 
with smoking. Additionally Knott (1989) observed an increase in alpha power and 
frequency, but Pritchard, although observing a similar increase in dominant alpha 
frequency; saw a decrease in alpha power. An explanation for these differences could be 
explained by the fact that nicotine produces different effects depending on the dose 
absorbed by subjects. It has been demonstrated that low doses o f nicotine cause 
ganglionic stimulation whilst high doses, following initial stimulation, cause inhibition 
(Golding & Mangan 1982).
Looking more closely at the previous studies this evidence does suggest an 
explanation. One o f  the differences between the studies was that Knott (1988 & 1989) 
used subjects who were used to medium nicotine and tar cigarettes, whilst Pritchard 
(1991) used ‘ light’ smokers. It has been demonstrated that cigarette smokers not only 
regulate the intake o f nicotine by their smoking behaviour and also modulate the effect 
that they require (Warburton et al 1988). The light smokers, therefore probably absorbed 
a lower dose o f nicotine than the ‘medium’ smokers and hence produced a stimulant 
effect, reflected in reduced alpha activity. The medium smokers probably drew in more
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nicotine through different smoking behaviour and hence there was an increase in alpha 
activity, indicating a sedating effect. The similarity o f the effect o f  nicotine on the alpha 
PF adds to the complexity o f the discussion. It could be reflective more o f mood state, 
as smokers o f differing intake tend to use smoking to regulate their mood. An increase 
in alpha frequency may be due to a return to the desired state.
Other aspects o f performance have also been related to EEG activity. Increased 
alpha frequency when smoking has been demonstrated alongside an increase in finger 
tapping rate (Roth & Battig 1991) suggesting that this particular change in electrical 
activity has concomitant effects on simple motor activity. However, in the present study 
this effect was not seen in the EEG or in the motor component o f the performance tasks. 
This may have been due to the different nicotine administration methods used in each 
study, which could affect the pharmacodynamic profile o f nicotine as delivered to its 
site o f action.
There was no main effect o f nicotine on the performance tests, but there was a 
trend towards a decrease in RRT with nicotine, suggesting a possible improvement in 
attentional aspects o f performance. The failure to attain significance may have been due 
to an order effect masking an even greater underlying improvement, as the first testing 
session produced significantly slower RRT than the second. It was deemed to have been 
a spurious effect and had tended to significance due to a difference between the 
conditions which had been maintained at all time points o f the experiment.
All subjects were practised in the psychomotor tasks prior to testing, but there 
still appeal's to have been a learning effect. There was also a significant time effect 
improvement in MRT for both caffeine and placebo conditions. This again tends to
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suggest a learning effect, reinforced by the order effect also seen in this measure. No 
such effect was seen in CFF threshold or in TRT.
Previous studies have reported that smoking improves rapid information 
processing (Warburton & Amall 1994, Wesnes & Warburton 1983) memory and 
learning (Mangan & Golding 1983) and attention (Warburton & Arnall 1994). A  review 
also concluded that nicotine raised Critical Flicker Fusion (CFF) threshold and 
improved reaction times (Sherwood et al 1983). However, the majority o f such studies 
used subjects who were regular smokers who had been withdrawn from regular nicotine 
usage before testing. Such subjects would almost certainly have a reduced level o f 
psychomotor performance prior to nicotine intake in their respective experiments. 
Indeed some studies have actually demonstrated this effect [Heimstra et al. 1967, 
Frankenhanser et a l l970, Tsuda et al. 1996). The positive results seen with nicotine in 
such cases may, therefore, have been a reinstatement to normal levels, rather than an 
absolute improvement. Whilst the results are valid in their own right they merely 
illustrate what happens to performance, physiology and mood when deprived smokers 
are allowed to smoke again. This was confirmed by the lack o f clear results in the 
present study.
One reason for the effects seen here may have been the use o f gum as the 
method o f nicotine administration. Other studies have used alternative methods on both 
smokers and non-smokers. The results, however, have also been varied. Nasal nicotine 
solution improved finger tapping speed in non-smokers (West & Jarvis 1986), and 
chewing nicotine gum decreased reaction time and tracking error in smokers, but did not 
improve non-smokers psychomotor performance (Hindmarch et al 1990). Sub­
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cutaneously administered nicotine increased the speed o f correct responses in a logical 
reasoning task, improved speed, sensitivity and accuracy o f  rapid visual information 
processing (RVIP) and improved accuracy in word recognition in abstinent smokers, 
and, although not all the same effects were seen in non-smokers, nicotine did increase 
the speed o f response in the RVIP task and the digit recall task, the latter at the expense 
o f accuracy (Foulds et al. 1996). Altogether the performance results o f the present study 
were not in any way conclusive, but when taken in context with such previous results 
they do support the idea that nicotine may have a role as a psychomotor enhancer. 
Although it may be that a particular pharmacodynamic profile or absoiption site is 
preferable for such purposes.
Nicotine had no seemingly adverse or positive effects on the mood state o f 
subjects which is strange when one o f the main quoted uses for tobacco by smokers is to 
manipulate their own mood state. It could be expected, from anecdotal evidence, that 
non-smokers would have negative mood effects from nicotine, or it could be assumed 
that if the same pharmacological action is at work then similar results would be 
observed. This difference may be explained by the fact that nicotine action is influenced 
by dose, stress levels, personality and gender (Gilbert & Meliska 1992). If non-smokers 
are self-selecting then it could be assumed that either nicotine affected them adversely or 
that the positive re-inforcing properties were not active in that particular person. As the 
former was not observed in the current experiment the latter would appear to be a more 
appropriate explanation.
Such differences between the results o f studies o f  nicotine effects in smokers and 
non-smokers leads to a variety of explanations. Smokers and non-smokers may react in
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different ways to nicotine. It may be that different administration methods provide 
different doses o f nicotine or have different pharmacodynamic profiles, due to different 
absoiption sites; smoking via the lungs; nicotine gum via the buccal membranes. The 
dose o f nicotine in the current study was not very high, in order to prevent nausea which 
has been seen in some non-smokers (Sherwood 1993). It was also delivered by a means 
which does not lead to rapid uptake, possibly preventing the immediate effect that 
smoking provides which could explain the fact that no significant performance effects 
were seen here.
Time effects seen in this study did suggest some small adjustments to 
methodology would be required to further assess the possibilities o f  nicotine as a PE. 
The order effect in the recognition component o f  the CRT test did suggest a learning 
effect, which means subjects may need to be better trained in the tests involved in such 
work.
This was countered by the gradual decrease of CFF threshold over the time 
course of the experiment, indicating a loss o f arousal most likely due to the tiresome or 
boring nature o f conducting experiments in laboratory conditions. This was probably 
reflected in the similar effect seen in the increase o f the mean power values in all 
wavebands of the EEG. Such an effect is always difficult to eliminate when 
investigating drug effects in this way, but care should be taken to maintain as much 
control over it as possible.
Overall the results did confirm that nicotine produces a measurable effect on the 
EEG when taken in an acute dose by non-smokers although hints at a possible 
improvement in attentional aspects o f performance proved false. In looking for a
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substance capable o f enhancing psychomotor performance nicotine could, because o f  its 
EEG effects be considered a good candidate. Unfortunately the present study did not 
provide conclusive evidence o f this and further work would need to be conducted to 
elucidate the effects. The methodology would have to be slightly adjusted to remove as 
much o f  the tiresome effect o f experimentation as possible. Larger subject groups may 
also be required to increase the precision o f the performance tests.
However, the addictive properties and side-effects o f nicotine in its present form 
would make its regular use unsuitable in all but the most extreme circumstances. 
Another problem would be the dosage required to produce a desired effect. With great 
inter-individual variation and also the paradoxical effect o f high and low doses it would 
be veiy complex to design a regimen for nicotine use in working situations. If the 
addictive element of nicotine could be removed and the nature o f  its mechanism 
stabilised then it may be possible to produce a marketable product for the enhancement 
o f psychomotor performance beyond normal levels.
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Chapter 5
Gingko biloba, a herbal therapeutic, as a putative 
psychomotor enhancer
Introduction
Ginkgo biloba extract (GBE) is a standardised extract o f  from the leaves o f  Ginkgo 
biloba or the ‘Maidenhair’ tree. It is an ancient herbal remedy which has appeared in 
Chinese medical books since 2800 BC (Braquet 1987) and its pharmacology and 
activity have been extensively examined in some publications (Braquet 1987, 
Funfgeld 1988).
GBE has a wide range o f  pharmacological effects due to the number o f  active 
constituents, but it is regarded to be a vasodilator (Peter et al 1966), which has 
positive effects on blood flow (Mufinug and Alemany 1968, Tronnier 1968) and has 
generally beneficial rheological effects. In GBE the active substances are considered 
to be flavone glycosides and terpenes. The former are effective as free radical 
scavengers (Pincemail and Deby 1988) which suggests they may have neuroprotective 
qualities and fit in with current thinking on the use o f antioxidants as possible anti­
ageing agents [REF]. The latter are highly specific platelet activating factor (PAF) 
inhibitors (Braquet et al 1985) which means they are useful for preventing thrombosis 
and is one o f  the reasons GBE is sold as a cardiovascular protector. GBE has also 
been shown to have a number o f  specific effects which are indirectly related to PAF 
inhibition; improvement in postural and oculomotor deficits in a vestibular sectioned 
cat model (Ez-Zaher & Lacour 1989); increased retinal function in a diabetic rat 
model (Doley et al. 1987) and to generally improve peripheral micro circulation and 
blood fluidity in humans.
These effects have meant that GBE has been investigated as a treatment for a 
large number o f elderly people with cognitive dysfunction due to insufficient cerebral
168
blood flow. Indeed a summary o f  results o f  11 clinical trials, involving patients 
suffering from Chronic Cerebral Insufficiency or Cerebral Vascular Accidents, 
reported an average overall efficacy o f  GBE o f  66.3% (Warburton 1988). In this 
general review o f the beneficial effects o f  Ginkgo biloba extract (GBE) up to and 
including 1985, it was concluded that it should benefit a large number o f  elderly 
patients in a wide variety o f clinical categories. Additionally GBE has also been 
shown to improve psychomotor functioning in elderly patients with memory 
impairment or the beginnings o f mild dementia, specifically vigilance (Gessner et al. 
1985), alertness (Pidoux 1988), as well as speed and accuracy (Wesnes et al. 1987)
Currently, therefore, GBE is prescribed in many countries as a protector 
against cerebral deficiency, caused by ageing. It is also prescribed for the somewhat 
milder condition o f  age associated impairment o f  memory (AAIM), regarded as a 
general forgetfulness and sometimes associated with an inability to concentrate for 
long periods, which has a tendency to affect people above the age o f  fifty. Indeed in 
1988 it was the most prescribed drug in Germany (Lancet Dec 23/30 1989). It is now 
also available ‘ over-the-counter’ in pharmacies and health food shops in the UK 
where it is marketed as a protector o f the cardiovascular system. Whilst this is aimed 
squarely at the older market, the very properties which may improve cerebral 
insufficiency i.e. improved cerebral blood flow and hence increased oxygen and 
glucose availability may also improve mental performance in normal, young, healthy 
people. Indeed a few studies have also shown some positive effects o f  GBE on the 
psychomotor function o f  normal healthy subjects mainly in short term memory and 
vigilance tasks (Pidoux 1988, Krauskopf et al. 1983, Subhan & Hindmarch 1984). 
However, these have not proved totally conclusive. The studies have limited
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themselves to acute dosing regimes, above the normal recommended therapeutic 
doses. Indeed effects have not been seen much below a single 600mg dose. Whilst 
GBE is not thought to be very toxic and has had very few reported side effects 
(REFS), doses so high above those which have been demonstrated to be 
pharmacologically effective would not necessarily be desirable for a psychomotor 
enhancer in normal humans which may be taken repeatedly. Current clinical 
knowledge suggests that the positive effects o f  GBE, taken in normal doses, are not 
observed until at least 4 - 6  weeks o f  treatment in therapeutic cases (Kleijnen & 
Knipschild 1992). Also an unpublished study (Hindmarch 1996 personal 
communication) has shown positive effects o f 200mg o f GBE after two weeks daily 
administration albeit in healthy, elderly subjects. Therefore in order to assess the 
efficacy o f  GBE as a possible psychomotor enhancer the effects o f  chronic 
administration o f  GBE, over a six week period, on EEG brain mapping, psychomotor 
function, vigilance, short term memory and mood state in normal subjects were 
investigated.
1 7 0
Subjects
11 healthy volunteers (8 males, 3 females), mean age 25.0 yr. (sd 3.9), from 
the DERA Centre for Human Sciences staff pool participated in the experiment. They 
were all non-smokers and in good physical health without a significant clinical or 
psychological history. Ethical approval was given by the CHS Ethical Committee and 
all subjects provided written informed consent to participate in the study. Normal 
caffeine consumption was maintained throughout the experimental period, including test 
days. Subjects were asked to keep to their normal daily routine during experimentation, 
but to avoid excessive alcohol consumption the evening before testing.
Protocol
The study was conducted in a double-blind, placebo controlled, crossover 
design. The drug condition required subjects to take 120mg o f  Ginkgo biloba extract 
in two tablets each day for six weeks. In the placebo condition subjects also took two 
placebo tablets, identical to the active drug condition, every day for six weeks. Drug 
and placebo were administered in a balanced fashion and a washout period o f  six 
weeks was allowed between conditions.
Testing was carried out in an environmentally-controlled, sound-attenuated 
laboratory. Subjects were required to attend two practice and six testing sessions 
(three for a drag and three for a placebo condition) over a period o f  four months. All 
runs were carried out on the same day o f  the week and at the same time o f  day for 
each subject.
Methods and Materials
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The first test session o f each condition was immediately prior to the first 
drug/placebo administration and formed the baseline measurement. An additional run 
o f the test battery was made 1 hour after drug administration to assess immediate 
effects (Day 1). Follow up testing sessions took place at three weeks (Day 21) and six 
weeks (Day 42) respectively.
In each testing session (except Day 1, when test battery was conducted first as 
a baseline and then repeated 1 hour after initial drug administration) the following test 
battery was carried out once which took approximately 20 minutes and consisted o f :
2 minutes Eyes Open EEG 
2 minutes Eyes Closed EEG 
Critical Flicker Fusion Threshold (CFF)
Choice Reaction Time (CRT)
Sternberg STM Scanning Test 
Compensatory Tracking Task
Profile o f  Mood State - Bipolar (POMS - BI) questionnaire
Data Analysis
Performance Tests
Analysis o f  variance was conducted on each o f  the measures o f  all the performance 
tests for each o f  the four repeated measures. CFF, CRT and CTT had time and 
condition labelled as main effects and subject as the random effect A log transform 
was required to stabilise variance in the CRT data and the reaction time data from the
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Sternberg STM test. Time, condition and number o f figures in test group were 
labelled as main effect with subject as the random effect in the analysis o f  the 
Sternberg data.
A simple paired t-test was also conducted to compare the post-baseline peak 
effects o f  the two conditions in the CFF and the CRT.
Mood State
Analysis o f  variance was conducted on the mean scores o f  each o f  the six mood 
factors assessed by the POMS questionnaire for each o f  the four repeated measures. 
Time and condition were labelled as main effect and subject was treated as the 
random effect.
EEG
Head, neck and eye movement artefacts, as detected by the neck and face 
electrodes, were removed from the EEG data using the BEAM II system. They were 
then spectrally analysed in 2 second epochs using the Fast Fourier Transform 
technique. Approximately 40 epochs were used to gain mean power values for each o f  
the 20 channels in 0.5Hz ‘bins’ which allowed frequencies to be grouped into six 
wavebands: Delta (d), Theta (q), Alpha (a), Beta (b) 1,2 and 3 ., from 0.5 - 32 Hz. The 
peak frequency (PF) was also calculated for each waveband using the mid-point o f  the 
frequency bin with the greatest amplitude in each channel, o f  each subject for both 
conditions.
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Analysis o f  variance was then conducted on the mean power and PF values for 
each waveband, with time, condition and ratio o f  eyes open/eyes closed labelled as the 
main effects with subject treated as the random effect.
Principal components analysis was conducted on the mean power for each 
channel, in each waveband, to assess for topographically related activity changes. 
Analysis o f variance was then carried out on the principal component values for each 
waveband between drug and placebo conditions in each o f  the identified principal 
components. Again time, eyes open/closed and condition were labelled as main effect 
and subject as random.
Complete analysis o f  variance results are shown in Table A.3 in Appendix A
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Performance Tests
CFF
No significant drug effects were observed in the CFF threshold (F=0.015, df=l,10, 
p<0.905) Mean values for CFF, as seen in Table 5.1, were at a level which was 
deemed to be normal for the conditions under which the experiment was conducted. 
The simple paired t-test also showed no significant differences between the post­
baseline peak effects o f the two conditions (t=0. 5527, df=10, p<0. 5926).
CRT
No significant drug effects were observed in any component o f  the CRT task. Table 
5.2 shows the means, back transformed and corrected for bias. The RRT component 
(F=1.66, df=l,10, p<0.229) returned differences o f no more than 6ms between baseline 
and endpoint measurements. Although the mean values suggested that MRT did 
improve towards the third week measurement with GBE the analysis showed that they 
did not fall sufficiently inside the 10% probability area to warrant being termed a 
trend (F=3.59, d£=l,9, p<0.090). This could have been due to familiarisation with the 
task not having been as successful as thought, or adaptive techniques being adopted 
by the subjects. TRT did not show any drug effects either (F=0.03, df=l,9, p<0.878)
There was a large variation between subjects, which is reflected in the standard 
deviations (sd in Table 5,2). This could be expected in such a test and suggests that 
effective PEs would need to have a strong effect to be detected. Time effects were also 
seen in MRT (F=5.21, df=3,27 p<0.006) and TRT (F=5.80s df=3,27, p<0.003) with a 
general decrease in reaction times over the time-course o f the experiment.
R esults
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The simple paired t-test comparison o f post-baseline peak effects in both 
conditions showed no significant differences for MRT (t=0.360, df=9, p<0.7267) or 
TRT (t=1.394, df=9, p<0.1967). RRT did show a trend towards a difference (t=2.128, 
df=9, p<0.0622), but was not deemed to be a true effect.
Compensatory Tracking Task (CTT)
No significant differences were seen in either the tracking RMS error scores (F=0.01, 
df+1,10, p<0.915) or the reaction times (F=3.38, df=l,10, p<0.096), although the latter 
cam close to the level o f  being a trend just as with the MRT component o f the CRT. The 
mean values for each aspect o f  the tracking task are seen in Tables 5.3 & 5.4. The 
results suggested no enhancement in vigilance. There was, however, a tendency for 
both RMS Error (F=4.72, df=3,30, p<0.008) and reaction time (F=3.33, df=3,30, 
p<0.032) to decrease over the time o f  the experiment which have been the result o f  a 
learning effect, despite the practice sessions prior to the study.
Sternberg STM Task
No differences between drug and placebo conditions were observed in the present 
correct reaction time (F=0.05, df=l,9, p<0.828), absent correct reaction time (F=1.17, 
df=l,10, p<0.305), or number o f absent correct detections (F=1.00, df=l,10, p<0.340) o f 
the STM task. An absolute effect o f  drug was seen in the number o f  present correct 
detections (F=6.71, df=l,10, p<0.027) where the results were worse in the GBE 
condition. However, as this was one isolated result due to drug amongst a number o f 
other measures it was thought to be a spurious result. This was supported by the fact 
there were no drug/time or other interactions.
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Some o f the measures did increase or decrease, as can be seen in the means shown in 
Tables 5.5, 5.6, 5.7 and 5.8, but these again failed to achieve significance, or even to 
reach a trend level.
Mood State
Whilst the analysis o f  variance confirmed the six different factors were distinctly 
different (F=14.04, df=5,50, p<0.000), no differences were identified in Composed- 
Anxious (F=0.02, df=l,10, p<0.890), Agreeable-Hostile (F=0.171, df=l,10, p<0.688), 
Elated-Depressed (F=0.184, df=l,10, p<0.677), Confident-Unsure (F=0.003, df=l,10, 
p<0.957), Energetic-Tired (F=0.01, df=l,10, p<0.922), or Clearheaded-Confused 
(F=0.04, df=l,10, p<0.851) factors due to experimental effects. Indeed all results o f  
both conditions were decidedly similar suggesting absolutely no effect o f  GBE on the 
mood state factors measured. However there were time effects for Agreeable-Hostile 
(F=3.92, df=3,30, p<0.018), Elated-Depressed (F=3.89, df=3,30, p<0.018), Confident- 
Unsure (F=4.97, df=3,30, p<0.006), Energetic-Tired (F=3.57, df=3,30, p<0.025), and 
Clearheaded-Confused (F=4.89, df=3,30, p<0.007). All scores increased over the time 
o f  the experiment i.e. moved towards the positive pole o f the mood factors possibly as 
a result o f  subjects becoming more familiar with the experimental surroundings. 
Means are shown in Table 5.9
EEG
No significant effects o f  GBE were seen in the mean power o f delta (F=1.12, df=l,10, 
p<0.314), theta (F=0.40, df=l,10, p<0.541), alpha (F=0.51, df=l,10, p<0.493), betal 
(F=0.918, dfi=l,10, p<0.361), beta2 (F=0.09, dffl,10, p<0.769) or beta3 (F=0.02,
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df=l,10, p<0.902), tlie means for which, back transformed and corrected for bias are 
shown in Table 5.10. The lack o f  changes seen in the mean peak frequencies in delta 
(F=0.50, df=l,10, p<0.497), theta (F-1.02, dfr=l,10, p<0.336), alpha (F=0.10, df=l,10, 
p<0.764), betal (F=0.15, dffil,10, p<0.707), beta2 (F=0.01, dffl,10, p<0.922) or beta3 
(F=0.01, df=l,10, p<0.911), and which are shown in back transformed and corrected 
for bias form in Table 5.10, confirmed that GBE had no effect on the EEG o f  normal 
subjects.
However, large time effects were seen in the mean power o f  all wavebands: 
delta (F=10.79, dff3,30, p<0.000), theta (F=24.38, df=3,30, p<0.000), alpha (F=140.10, 
df=3,30, p<0.000), betal (F=18.10, df=3,30, p<0.000), beta2 (F-29.34, df-3,30, 
p<0.000) and beta3 (F=4.85, df=3,30, p<0.007). All values increased over the time 
course o f  the experiment in both conditions, suggesting that subjects made some 
adjustment to the experimental surroundings. This may have been reflected in the time 
based changes seen in Mood State scores. Of the PF means only theta showed any time 
effect (F=4.46, df=3,30, p<0.010). Means, back transformed and corrected for bias are 
seen Table 5.11.
Principal Components analysis identified a number o f  components within the 
mean power values o f  each waveband. The distribution o f  these is seen in Table 5.12. 
Again, however, no differences were seen in any o f  the components between drug and 
placebo conditions. Values for both mean power and mean peak frequency were very 
steady and a low Standard Deviation (sd in tables 5.10 and 5.11) reflected this.
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The results showed no effect o f  GBE in any o f  the performance tests or any o f  the 
measurements made. As such the lack o f  effect seen here suggests that GBE does not 
improve psychomotor performance o f  normal healthy people when taken chronically, 
at the recommended dose for cardiovascular protection or cerebrovascular 
therapeutics.
In order to assess the reasons for this complete lack o f  effect it is necessary to 
look at the background that was used to support the hypothesis that GBE could be o f  
use as a PE and specifically at the wide range o f  pharmacological effects which have 
been reported.
The pharmacological effect o f  GBE may not have been the correct approach to 
improving psychomotor performance above normal levels. From the earliest 
experiments GBE was found to be a vasodilator (Peter et al 1966, MuBnug and 
Alemany 1968, Tronnier 1968) and latterly it has been concluded that GBE can 
improve blood flow to the brain and the periphery (Hitzenberger 1992, Kiesewetter et 
al. 1992, Jung et al. 1990). The dose used in the current experiment was similar to 
those used previously and as such would have been expected to improve the blood 
supply to the brain. Indeed GBE has been demonstrated to be a practical therapeutic 
for conditions where psychomotor performance has declined due to cerebral blood 
flow insufficiency, or other conditions which have led to the reduction o f brain 
function through psychopathological effects (Heiss 1987, Pidoux 1983, 
Warburtonl988).
However, the lack o f  EEG results in the present study, either in power or 
frequency change, suggest that GBE did not have the central pharmacological effect
Discussion
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proposed. It has previously been shown that centrally active drugs are able to be 
profiled by their effects on the EEG (Saletu 1987), and previous EEG studies have 
supported the fact that GBE does have central effects when improving central blood 
supply (Funfgeld & Stalleicken 1988, Gessner et al 1985, Pidoux et al. 1984). A  study 
o f  the effect o f  GBE on the EEG o f healthy subjects has also reported that it affects 
the power in all wavebands and indeed the peak frequencies as well (Ktinkel 1993). 
However, in this study subjects were withdrawn from caffeine overnight before 
experimentation. As has been mentioned in Chapter 1 withdrawal effects o f  caffeine 
can affect such measures and may have confounded the results o f  that particular study.
The present study did not withdraw subjects from their normal caffeine intake 
during experimentation and the results suggested that GBE did not have an effect on 
neural activity. This adds weight to the argument that Kiinkel’ s subjects were affected 
by their caffeine withdrawal. Therefore, the present results do not support the idea that 
psychomotor performance can be improved, by GBE, through improvement o f  the 
blood supply to a brain which already has a normal supply. This, in turn, suggests that 
simply increasing the general resource supply to a normal, healthy brain does not 
increase neural functioning when undertaking the tasks presented in this experiment.
This is worth noting, because the psychomotor effort required for the tests 
used here may not be high enough to deplete the metabolic resources o f  a healthy, 
young subject beyond a normal working level. It is also probable that if there is no 
resource depletion then the equilibrium o f blood, oxygen and glucose in the brain will 
dictate that overcompensation o f  supply does not occur. Therefore substances such as 
GBE would not be able to improve psychomotor performance in this situation as 
resources would not be the problem. In cases o f  cerebral insufficiency, however, GBE
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would ensure that the blood supply improved and return, at least partially, some o f  the 
cognitive deficit seen in such cases, i.e. it would be a cognitive replacer.
GBE, though, has a variety o f  other pharmacological actions. Various 
molecules o f  the terpenoids and ginkgolides which form part o f  the extract have 
proven to be Platelet Aggregating Factor (PAF)- Acether inhibitors which reduce the 
ability o f  platelets to aggregate in the blood clotting process, can improve broncho- 
constriction in asthma and can also have beneficial effects on the immune system 
(Pidoux 1987). GBE has also been shown to be a potent free radical scavenger 
suggesting it has possible neuroprotective capabilities (Pincemail & Deby 1988). 
These effects would probably not cause changes to psychomotor performance in an 
acute dosing study and it is possible, although unlikely, that this function would not 
be detectable by EEG. If these properties were to show any effects on psychomotor 
performance they would only be seen in a chronic administration study as was carried 
out here. However the lack o f  results in the performance tests and mood state 
assessment suggest that such neuroprotective properties have no effect on 
physiological brain function in young, healthy, normal, subjects.
Looking at previous studies and comparing them to the present results the 
overall picture supports the hypothesis that GBE may be effective as a cognitive 
replacer in clinical deficit conditions but not o f  any use in improving psychomotor 
performance above normal levels. However, the lack o f  effect on the EEG in the 
present study is particularly perplexing. With such a reliable indicator o f  physiological 
effect and with such an active substance as GBE, even if  there is no detectable effect 
on performance tests it could have been expected to affect brain electrical activity. 
Previous studies have shown improvements in the quantitative spontaneous EEG o f
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demented and healthy individuals with GBE (Funfgeld 1989, Funfgeld & Stalleicken 
1988, Pidoux 1986, Gessner 1985) and in age-associated memory impairment subjects 
chronic GBE treatment resulted in decreased P300 latencies (Semlitsch et al. 1995). In 
the latter experiment no accompanying changes were seen in subjective well being so 
it was concluded that the changes were not mediated by thymopsychic alterations.
It may be that the efficacy o f  GBE in clinical conditions could be due to 
another particular pharmacological activity o f  GBE rather than the ones which have 
been used as indicators o f  improvement (although these should not be discounted). An 
illustration o f  this possibility can be seen in two studies.
In the first, the possibility that a decrease in cell membrane fluidity, due to the 
presence free radicals, may be one o f  the major causes o f age related cognitive 
function decline was investigated (Stoll et al. 1996). GBE improved the short term 
memory o f  aged mice in a passive avoidance task and it was shown that neuronal 
membrane fluidity was also improved. Whilst the two were not statistically correlated 
the possibility o f  connection should not be discounted.
In the second, three strains o f  mice were given long term treatment with GBE 
for 7 months, which took them into old-age (Barkats et al. 1995). There were inter­
strain differences in various areas o f  the brain, but the chronically treated group 
showed increased projection o f  the inter/infra pyramidal mossy fibres into the CA3 
region o f  the hippocampus. It was concluded that this demonstrated neuroprotective 
and neurotrophic effects o f  GBE probably due to its antioxidant effect. These results 
taken as a whole do not unequivocally suggest that GBE improves psychomotor 
functioning per se, but does suggest an extremely wide range o f  actions o f GBE, most
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o f  which are deemed beneficial to psychomotor functioning, and which will no doubt 
be elucidated as investigations continue.
The lack o f  effect seen in the present study, therefore, reflects the inability o f  
GBE to alter the aspects o f psychomotor performance that the test battery used here 
assessed, namely vigilance, reaction time and short term memory, as well as making 
no change in the general level o f  central nervous system arousal. One possibility is 
that the present experimental design may have been at fault. The lack o f  positive 
results could partly be explained by the fact that the present study used different tests 
which may not have been sensitive to the particular effects o f  GBE exhibited 
previously. Whilst all the tests used in the present study have been used widely for the 
assessment o f  psychomotor performance in normal humans and have good face 
validity and reliability (Kerr & Sherwood), the majority o f  clinical studies have 
tended to use global clinical observer type scales in order to assess the behavioural 
efficacy o f  GBE (Warburtonl988). Such tests would not have been appropriate for 
assessing normal subjects as they are too general and are mainly designed to detect 
deterioration o f  performance. In one study, however, patients with pre-senile and 
senile primary degenerative Alzheimer’s dementia were given 240mg GBE per day 
and were assessed on psychopathologicai, attention and memory, and daily activity 
behavioural assessment tests (Kanowski 1996). GBE was deemed to be efficacious if 
it improved 2 o f the 3 variables and the treatment group had significantly more 
responders than placebo.
A  few other investigations o f  the effects o f  GBE in deficit conditions, have 
also used similar tests to the present study and shown positive effects, in vigilance 
(Funfgeld & Stalleicken 1988), alertness (Pidoux 1986), and general cognitive skills
19 3
(Wesnes et al. 1987). Therefore, tests o f  specific aspects o f  psychomotor performance, 
more sensitive than clinical observer scales have been shown to detect beneficial 
effects o f  GBE, albeit in cognitive deficit patients. This does not support the idea that 
an incorrect test battery was employed in the present study.
However, the time effects seen in the results do suggest that there was some 
adjustment by subjects to the experimental methodology. For instance the fact that the 
motor and total reaction times reduced significantly over the time o f  the experiment in 
both drug and placebo conditions suggests a learning or familiarisation effect. Similar 
effects were also seen in the tracking task, but not in the STM test or the CFF 
threshold. The lack o f  time effect in the latter two tests reinforces this suggestion 
because effects due to factors outside the experiment would have been expected to 
occur in all tasks. Additionally the general improvement o f  mood and increase o f 
power generally in the EEG in both conditions over the six weeks o f  each condition 
did suggest that subjects became more familiar and comfortable in the laboratory 
surroundings as time went on.
The dosing regimen used in the current study was a chronic administration o f  
120mg GBE per day for six weeks in the drug condition. The previously mentioned 
studies in cognitive deficit patients have all used similar regimen and have shown 
some positive results. The lack o f  effect in the cmrent study may have been due to 
GBE not being effective in young normal healthy subjects at that dose, or indeed if 
used chronically. Although, previous evidence o f  GBE being effective in improving 
the psychomotor performance o f  normal, healthy individuals has been reported. A 
review o f  the literature (Pidoux 1988) mentioned one such study by Krauskopf et al 
(1983) which reported that EEG changes indicated a stabilisation o f  spontaneous
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vigilance at a dose o f  240mg and some evidence o f  hypervigilance at 600mg. It could 
be argued that those results were only seen in a physiological variable which could be 
related to performance, but there is further evidence o f  psychomotor enhancement 
with GBE reported in a study using performance measures. The same higher dose o f  
GBE, as used in Krauskopf s study, had no effect on Critical Flicker Fusion, Choice 
Reaction Time or subjective drug ratings, but did improve the performance o f  the 
Sternberg memory scanning task (Subhan and Hindmarch 1984). It was concluded 
from this that the GBE effects in the memory task were localised to the serial 
comparison stage o f  the reaction process. This aspect o f  performance is closely related 
to vigilance. In another study, GBE prevented the decline in results seen in a free 
recall score with placebo. This maintenance o f  performance over a period o f  time 
again adds to the argument that GBE may improve vigilance (Warot et al 1991). 
Additionally a recent unpublished sub-chronic study, using healthy, although aged, 
subjects, showed beneficial effects on vigilance performance after two weeks daily 
administration o f 200mg GBE (Hindmarch personal communication 1997).
However, there were two main differences between previous studies and the 
present one, the dose and the administration regimen. To fill a gap in the knowledge 
that existed in the use o f  GBE the current study concentrated on looking at chronic 
effects in normal healthy subjects. From the results it appears that GBE does not 
improve psychomotor performance in healthy individuals when taken chronically at 
120mg per day, but may be able to when taken in large acute doses o f  around 600mg. 
This suggests that the mechanism o f GBE effect in healthy normal subjects does not 
occur at 120mg, as measures similar to the previous studies, such as EEG and
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Sternberg STM Scanning Task, were used and would have picked up the effect had it 
been present.
In conclusion, the purported ability to enhance vigilance in normal healthy 
subjects is an attractive suggestion. Vigilance plays a vital role in the multi-tasking 
attributes required in today’ s high mental workload situations related to the operation 
o f information technology systems. Any ability to improve vigilance could prevent 
some human errors in safety critical situations such as airline pilots, air traffic control 
operators or industrial plant operators. However, it is clear from the results found here 
that taking a daily 120mg dose o f  GBE will not provide this increase and, in this, 
context is not a psychomotor enhancer.
Further work should concentrate on looking at the effects o f  a variety o f  doses 
o f GBE in normal healthy subjects in order to understand the possibility o f  two 
different mechanisms which may occur at different dose levels and in different mental 
conditions.
1 9 6
Chapter 6
Does citalopram hydrobromide, a new selective anti­
depressant SSRI, have psychomotor enhancing 
properties in normal healthy subjects?
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Selective Serotonin Re-uptake Inhibitors (SSRIs) are a group o f  drugs which 
act by preventing the re-uptake o f  5HT (Serotonin) into pre-synaptic neurones. The 
resultant facilitation o f  5HT transmission leads to an elevation o f  mood (Montgomery 
& Johnson 1995) Their current use is as a treatment in the initial stages o f  depressive 
illnesses and also to prevent relapses following initial treatment. It was identified in 
the literature search in Chapter 1 that there was some evidence that some o f  the SSRI 
group may have an additional alerting effect which suggested that some SSRIs may be 
devoid o f  the sedative side effects o f  the older tri-cyclic antidepressants such as 
amitryptiline (Kasper et al 1994). This led to the suggestion that SSRIs may have 
psychomotor enhancing properties in normal, healthy subjects (Ken* et al 1991). 
Previous studies o f  the 5HT3 antagonists such as ondansetron and granisetron had 
promised much in improving animal models o f memory and learning (Chugh et al. 
1991, Broocks 1990, Barnes et al. 1991) thought to be mediated by the serotonergic 
system, but delivered little in the way o f  results when the experiments were 
transferred to human studies (Leigh et al. 1992, Link et al. 1991, Hall & Cueppens 
1991).
Despite their undoubted efficacy some o f the SSRIs, however, have effects 
on neurotransmitter systems other than 5HT, mainly cholinergic and adrenergic, and 
have been associated with some peripheral side-effects and a decrease in psychomotor 
performance o f patients (Lader et al 1986). The more recently developed compounds, 
however, are more selective and the latest member o f  the group, citalopram 
hydrobromide (CH), has very few anticholinergic or adrenergic effects as well as a
Introduction
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low potential for interaction with other drugs. This improved selectivity is probably 
due to it binding with only the 5HT specific site o f the 5HT transporter (Hyttel et al 
1995). Indeed it has been prescribed to >600,000 patients with only a few reported 
side effects (Baldwin & Johnson 1995). It has also been suggested that some o f  these 
latest compounds, may actually increase psychomotor performance.
Effects on psychomotor performance due to the use o f  antidepressant 
medication have been widely reported, especially the adverse effects o f  the tri-cyclic 
antidepressants (TCAs) (Hindmarch 1982, 1987, 1988, Sherwood and Hindmarch 
1993) The SSRIs have consistently been found to have less ‘behavioural toxicity’ 
than TCAs and, in some situations have been reported to increase certain psychomotor 
performance measures in normal healthy subjects (Kerr 1991).
Some o f  the older SSRIs, however, have shown both improvements and 
decrements o f  different aspects o f  performance, probably due to lower selectivity for 
5HT re-uptake. Sertraline, zimeldine and paroxetine all raised Critical Flicker Fusion 
(CFF) threshold compared to placebo, an indication o f  an increase in CNS activity 
(Hindmarch et al 1990, Hindmarch and Bhatti 1988). Paroxetine not only raised CFF 
threshold, but also improved the recognition component o f a Choice Reaction Time 
test (CRT). (Hindmarch and Harrison 1988).
Additionally, a comparison o f  five antidepressants concluded that paroxetine 
and fluoxetine both improved CFF threshold. Paroxetine, also increased perceived 
alertness and reduced choice reaction time whereas fluoxetine increased tracking error 
score, choice reaction time and subjective sedation. (Sherwood and Hindmarch 1993).
The pharmacokinetics, side effects and tolerability o f  CH have all been 
extensively assessed (Baldwin & Johnson 1995, Baumann & Larsen 1995, Hyttel et
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al. 1995). Maximum plasma levels are reached two to four hours after dosing. 
Terminal elimination half life is approximately 1.5 days and excretion is via urine and 
faeces. It has also been reported that it does not interact with alcohol (Baumann and 
Larsen 1995).
In summary, the newer and more selective SSRIs seem to be able to improve 
some aspects o f  psychomotor performance, whilst some o f  die less selective o f  the 
group have detrimental effects on performance. The effects o f  CH have not yet been 
fully defined, but it is likely to be more efficacious at improving psychomotor 
performance due to its greater selectivity. Therefore, the effects o f  CH on brain 
electrical activity, psychomotor performance and mood state were assessed. This 
assessed the effects o f CH on tests which have been shown to be sensitive to the 
effects o f  other SSRIs as well as any electrophysiological or mood change correlates 
which may occur in normal healthy subjects.
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Methods and Materials
Subjects
12 healthy, non-smoking male subjects, mean age 25.3 yrs (sd 4.1), were 
recruited from the staff pool at the DERA Centre for Human Sciences. Procedures 
were subject to ethical approval, and informed, written consent was obtained from all 
subjects. Medical screening consisted o f  a medical health questionnaire and a liver 
function test, to ensure subjects were not contra-indicated for CH.
Protocol
The study was conducted using a double-blind crossover placebo controlled 
design.. Subjects were required to attend two practice and two test sessions (one drug 
and one placebo condition), the latter being on the same day o f the week, one week 
apart, with runs all commencing at the same time o f day. Subjects also attended two 
practice sessions to ensure consistent performance in Critical Flicker Fusion (CFF) 
Threshold, Choice Reaction Time (CRT), Vigilance and Short Term Memory (STM) 
performance tests.
20mg o f CH or placebo was administered, in tablet form, during each test 
session. One subject was tested in the morning o f each test day over a period o f  4 hours. 
Each was tested in the same order on every test day that they attended, to ensure 
consistency with respect to time o f day effects.
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Subjects first completed a baseline run o f the test battery which took
approximately 20 minutes and consisted o f :
i. 2 minutes Eyes Open EEG
ii. 2 minutes Eyes Closed EEG
iii. Critical Flicker Fusion Threshold (CFF)
iv. Choice Reaction Time (CRT)
V. Sternberg STM Scanning Test
vi. Compensatoiy Tracking Task
vii. Profile o f  Mood State - Bipolar (POMS - BI) questionnaire.
Following the baseline test run, subjects were administered either 20mg o f CH 
or placebo in tablet form. The test battery was then repeated in the same order at two 
and four hour intervals after administration.
Data Analysis
CFF
Threshold values were calculated as the mean o f three ascending and three descending 
scores. An analysis o f  variance was conducted on the data. Condition, time, subject and 
group were labelled as the main effects and subject as the random effect. A  simple 
paired t-test was also used to compare the post-baseline peak effects o f  both placebo and 
CH conditions
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CRT
A  histogram o f distribution within the CRT data identified some values which were 
deemed to be false starts (<200msecs) and those which were plain misses (>1500msecs). 
These were excluded and a subsequent analysis o f  variance was carried out on the 
separate components o f  the CRT: Recognition Reaction Time (RRT); Motor Reaction 
Time (MRT and Total Reaction Time (TRT). Data were log transformed for variance 
stabilisation. Condition, time and run order were labelled as the main effects and subject 
as the random effect. A simple paired t-test was also used to compare the post-baseline 
peak effects o f  the two conditions.
CTT
An analysis o f  variance was conducted on both the tracking score and reaction time data 
from the CTT. Condition and time, were labelled as the main effects and subject as the 
random effect.
Sternberg STM
Again, analysis o f  variance was conducted on both the reaction time and number correct 
data from the STM test. Data were log transformed for variance stabilisation. Condition, 
time, group and number o f  presentations were labelled as the main effects and subject as 
the random effect.
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Data were obtained in the six categories o f  mood state for each condition. An 
analysis o f variance was conducted on the scores with condition and time, labelled as 
the main effects and subject as the random effect.
EEG
Artefacts caused by eye or neck movement were removed from the raw EEG 
data using the Nicolet BEAM II system. Spectral analysis was carried out on 2 second 
artefact-free epochs o f the data, using the Fast Fourier Transform technique. The system 
allows the signal to be frequency partitioned into 0.5Hz 'bins', ranging from 0.5Hz to 
23.5Hz giving a mean power value in each. The power (|_iv) in each bin was calculated 
for each channel and the bins were grouped into six wavebands, 6 (0.5 - 3.5Hz), rj (4.0 - 
7.5Hz), a  (8.0 - 11.5Hz), (3 1 (12.0 - 15.5Hz), p 2 (16.0 - 19.5Hz), and p 3 (20.0 - 
23.5Hz) with a mean power value being calculated for each band. The peak frequency 
(PF) was also calculated for each waveband using the mid-point o f  the frequency bin 
with the greatest amplitude in each channel, o f each subject for both conditions. 
Analysis o f variance was conducted on both mean power and PF data. Condition, time, 
channel and eyes open/closed were labelled as main effect and subject as random effect.
Principal Components (PC) analysis was carried out on the power data to 
identify groups o f sites which had similar activity within each waveband. Groups were 
defined as those sites having a PC score >0.65.
Mood State
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An analysis o f variance was carried out for the mean power o f each waveband in 
each PC grouping. Condition, time and eyes open/eyes closed, were labelled as the main 
effects and subject was treated as the random effect. This was also carried out for mean 
PF in each PC group.
Complete analysis o f  variance results can be seen in Table A.4 in Appendix A.
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P erform an ce Tests
CFF
CH did not significantly affect the CFF threshold (F=1.21, d£=l,ll, p<0.296). 
However when illustrated graphically, as in Figure 6.1 it appeared that CFF increased 
in threshold value between the baseline and the 2 hour point with the drug as 
compared to the placebo. The threshold then appeared to decline in the subsequent 2 
hours until at the 4 hour point the level had returned to marginally below the level 
seen in the baseline.
This was further investigated by looking at the individual subjects’ results for 
any sub-groups in which drug effects may have been masked by subjects who did not 
react to the drug. However the non-significance o f the results was thought to be due 
entirely to a large variance between subjects. However, the simple paired t-test did not 
reveal any significant differences between the post-baseline peak effects o f  the two 
conditions (t=1.4700, d f= ll, p<0.1696). Means are shown in Table 6.1.
Choice Reaction Time
When the results were portrayed graphically it appeared there was a tendency 
for the mean reaction times in both the recognition component and the total time 
component to have reduced levels at the four hour point. However no significant 
changes were seen in the RRT (F=1.89, d f= l,ll, p<0.198), MRT (F=0.509, d f= l,ll, 
p<0.490) or TRT (F-0.322, d f= l,ll, p<0.582) components o f  the CRT test and the 
probabilities produced by the analysis did not even support a tendency to
Results
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improvement. Figures 6.2 and 6.3 illustrate the actual difference in mean times 
between the RRT and MRT aspects o f the CRT and suggests the significance may 
have been masked by the large variances in results between the individuals. However, 
when further analysed there were no significant post-baseline peak effect t-test 
comparisons in the RRT (t=0.933, df=l 1, p<0.3705) MRT (t=1.704, df=l 1, p<0.1165) 
or TRT (t=1.062, d f= ll, p<0.3108). Means, back transformed and corrected for bias 
are shown in Table 6.2.
Compensatory Tracking
No significant changes in either the reaction times (F=0.11, df=l,l 1, p<0.745) 
or tracking score (F=T.13, d f= l,ll, p<0.311) in the CT task were seen with CH 
although there was a time effect (F=4.18, df=2,22, p<0.028) with both the placebo and 
the CH conditions seeing a trend to increased reaction times over the time period o f  
the experiment. As performance in this particular task assesses the vigilance 
component o f psychomotor performance this could possibly be a reflection on a lack 
o f  concentration by subjects due to the slightly tedious nature o f  the experiment. All 
efforts were made, however, to prevent tedium becoming a factor. Means are shown 
in Tables 6.3 (tracking score) and 6.4 (RT).
Sternberg Short Term Memory Scanning Task
There were no significant effects due to CH seen in the present correct 
reaction time (F=0.51, d f= l,ll, p<0.488), absent correct reaction time (F=0.01, 
df=T,ll, p<0.945), number o f present correct detections (F-0.06, d f= l,ll, p<0.809) or 
number o f  absent correct detections (F=0.08, d f= l,ll , p<0.785) in the STM task.
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Again large variances between subjects may have resulted in some masking o f  effects. 
When looking at the actual recorded means for both the present and absent correct 
measures the mean reaction time, to respond to the probe number, reduced over the 
time o f  the experiment to a greater extent in the drug condition compared to placebo 
for the smallest test group, about the same for the mid-size test group and was 
reversed for the largest test group. These possible interactions, however, did not attain 
significance.
There was a time effect, however, where the time taken to respond correctly 
to probe numbers which were present in the test group for both conditions reduced 
over the time course o f  the experiment (F=3.45, df=2,22, p<0.048). This suggested a 
possible learning or familiarisation effect. Although, if this had been the case similar 
effects on the other measures on the Sternberg test would have been expected. These 
were not observed in the current study. Mean reaction times are shown in Tables 6.6 and 
6.7, mean number correct in Tables 6.8 and 6.9. All were back transformed and 
corrected for bias.
M ood State
No significant effects were observed in the Agreeable-Hostile (F=2.63, 
df==l,ll, p<0.133), Elated-Depressed (F=1.38, d f= l,ll, p<0.264), Confident-Unsure 
(F=0.73, d f= l,ll, p<0.411), Energetic-Tired (F=1.22, d f= l,ll , p<0.292), or 
Clearheaded-Confused (F=1.39, df==l,ll, p<0.263) factors o f  the POMS questionnaire. 
However, there was a tendency for subjects to become more anxious with CH, as 
assessed by the Composed-Anxious factor (F=4.20, df=l,l 1, p<0.065). The lack o f  any 
significant drug/time interaction, or even tendency suggested this was a spurious
208
result. Also, as it did not attain significance it was deemed to have occurred by 
chance.
A tendency towards a time effect was also seen in the Energetic-Tired factor 
in both conditions (F-3.28, df=2,22, p<0.055) suggesting an end-effect with the 
subjects feeling more energetic at the last time point o f the experiment. Means are 
shown in Table 6.9.
EEG
No significant drug effects were seen in the mean power o f  the delta (F=0.05, 
d f= l,ll, p<0.826), theta (F=0.70, d f= l,ll, p<0.421), alpha (F=0.40, d f= l,ll, p<0.543), 
betal (F-1.33, d f= l,ll, p<0.273), beta2 (F=1.30, d f= l,ll, p<0.278) or beta3 (F=1.59, 
df=l,l 1, p<0.233) wavebands o f the EEG. Means, back transformed and corrected for 
bias are seen in Table 6.10
The same was true for peak frequencies o f delta (F=1.20, df= 1,11, p<0.297), 
theta (F=0.157, d f= l,ll, p<0.699), alpha (F=1.693, d f= l,ll, p<0.192), betal (F=0.257, 
d f= l,ll, p<0.622), beta2 (F=1.85, d f= l,ll, p<0.201) and beta3 (F=0.36, d f= l,ll, 
p<0.563). The constancy o f the values seen in the overall means in both the power and 
peak frequency data highlighted that this lack o f effect was genuine rather than by 
chance. Means, back transformed and corrected for bias axe seen in Table 6.11.
However there were time effects in the mean power values o f  theta (F=9.58, 
df=2,22, p<0.001), betal (F=7.20, df=2,22, p<0.004), beta2 (F=6.68, df=2,22, p<0.005) 
and beta3 (F=13.12, df=2,22, p<0.002) with an overall increase o f activity in these 
wavebands in both conditions, over the time course o f the experiment. This suggested 
that some change may have occurred due the experiment itself, possibly tedium or
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subjects becoming accustomed to the procedures used. Peak Frequency means only 
showed a similar effect in theta (F=6.25, df=2,22, p<0.007).
Principal Components analysis identified several components in each 
waveband which demonstrated similar topographical activity, the distribution o f  which 
can be seen in Table 6.12. However, subsequent analysis o f variance on both the 
components o f  mean power and PF failed to show any significant differences due to CH. 
Most did show significant time effects which probably reflected the changes occurring 
in the EEG over the time course of the experiment.
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The aim o f this study was to assess if an increase in the availability o f  
serotonin could enhance psychomotor performance beyond normal levels. To do this 
the effects o f  the newest member o f the SSRI group, citalopram hydrobromide (CH), 
were investigated on various aspects o f  performance, EEG and mood. However, no 
significant effects due to CH were found on any test or measurement in this 
experiment when compared to the placebo condition.
The lack o f effect o f  the drug on any aspect o f  the EEG clearly indicated the 
lack o f  a central pharmacological effect. Even if no effect is seen in performance tests 
it is common for drugs to have a profile o f  action on the various frequencies o f brain 
electrical activity (Saletu et al. 1987) and indeed CH and other SSRIs have previously 
been reported to produce such profiles (Saletu & Grunberger 1988, Patat et al. 1994). 
However, most studies o f  the effects o f  SSRIs have been conducted in patient 
populations and effects, therefore, were probably more o f  a reinstatement o f 
psychomotor deficit than overall improvement.
One specific area o f  the results, CRT, was not clear due to the large variances 
between individuals in the data. The means showed a very visible reduction in the 
RRT and TRT, which has also been shown in a previous study o f  the SSRI paroxetine 
(Hindmarch and Harrison 1988), but the effect did not attain statistical significance. It 
was thought that the drag may have affected the performance o f  some subjects but not 
others. However, further statistical evaluation did not elucidate the situation any 
further. The lack o f effect o f  CH on mood could be seen as unexpected as it is
Discussion
224
primarily used as an anti-depressant, although the results do suggest that mood can 
only be elevated to a normal level with this particular drag.
To work out the reasons for this lack o f effect, it is necessary to look at the 
background which suggested CH as a putative PE. There have been a number o f 
studies which have shown some SSRIs to improve Critical Flicker Fusion Threshold 
(Kerr et al 1991, Kerr 1991, Hindmarch 1987) and reaction time (Hindmarch and 
Harrison 1988). Indeed, paroxetine has been reported to increase CFF threshold and 
hence improve information processing ability in the elderly (Ken* et al. 1992) and 
fluoxetine also improved CFF in comparison to the tri-cyclic antidepressant 
amitriptyline (Kerr 1993, Fairweather 1993). However, CH is the one o f  the newest 
SSRIs and its effects on the psychomotor performance o f normal healthy subjects has 
not been investigated fully which was one o f the reasons for the present study. 
Therefore the lack o f  effect could be due to one o f  a number o f reasons.
Some previous studies have shown that the older members o f  the SSRI group 
can decrease performance or at least have no effect (Hindmarch 1987, Sherwood & 
Hindmarch 1993) and the latter appears to be the case in the present study. The histoiy 
o f  the development o f  SSRI drags has dictated that newer compounds are designed to 
be more selective for serotonin uptake receptors, which reduces the likelihood o f  the 
drug affecting other neurotransmitter systems. It is this which could explain the 
difference in effects that some studies have seen with members o f the SSRI group and 
more specifically with CH which is the most selective SSRI available.
The results found here do not support the hypothesis that CH can improve 
psychomotor performance above normal levels. One reason for this could be that the 
pharmacology o f  increasing availability o f  serotonin specifically at the uptake
2 2 5
receptor sites is not the correct approach to enhancing psychomotor performance per 
se. It is possible that the very specificity o f CH for tire re-uptake receptors and its lack 
o f  effect on other neurotransmitter systems are the reasons for no change in the 
performance tests used.
However, previous evidence does suggest that serotonin has a role in cognitive 
processing. Indeed, pathophysiological serotonin deficit has been related to the 
impairment o f memory and learning in humans (Park et al. 1994, Morris et al. 1993). 
The distribution o f serotonergic pathways in the brain also provides anatomical 
evidence for the role o f serotonin in mood and depression as they are closely related to 
that o f  the noradrenergic system within the limbic areas (Leonard 1994). How the 
latter links to psychomotor performance and where the current results lie in this 
system is unclear, but there are a large number o f  receptor subtypes for serotonin 
(Gaddum & Picarelli 1957, Humphrey et al. 1993), most with specific actions. Hence 
the activity o f  serotonin is very complex (Leonard 1994).
One proposal that could be made from the present results is that the 
improvement seen in previous studies with other SSRIs may be a combination o f  
selectivity for the serotonin re-uptake receptor and actions on the noradrenergic or 
cholinergic systems. As CH has very little affinity for other receptors (Hyttel et al. 
1995), this combination o f actions would not have occurred and, therefore no effects 
on the performance tests could have been expected.
It is clear from the results o f  studies investigating the manipulation o f 
cognition through serotonin levels that a general raising of central serotonin decreases 
memory and performance in healthy animals (McEntee & Crook 1991). This is, o f 
course, in direct contradiction o f the Park and Morris studies in deficit humans.
2 2 6
However it has also led to the theory that a reduction in general serotonin levels may 
enhance cognitive performance (Costall 1992). This has resulted in many studies on 
the effect o f 5HT3 antagonists on memory and learning in animals. The results have 
been promising in animal studies (Chugh et al. 1991, Broocks 1990, Barnes et al. 
1991) and in some deficit human studies (Costall & Naylor 1992), but they have 
failed to extrapolate to normal healthy human subjects (Hall & Cueppens 1991, Link 
et al 1993, Leigh et al 1992). Therefore, this suggests that decreasing the availability 
o f  serotonin is probably not the mechanism for absolute improvement o f psychomotor 
performance in normal humans. It also lends support to the argument that the 
improvements seen with some SSRIs may be due to some pharmacological activity 
which is not exclusive to the serotonergic system.
With hindsight it is possible that the tests used in the present study were not 
suitable for assessing the effects o f  CH on normal subjects. Firstly the test may not 
have been particularly sensitive to any action o f  CH, although any central action o f  
the drug should have been picked up by the EEG.
Time effects did not occur in CFF or CRT tests confirming that subjects were 
sufficiently motivated and practised to complete the tests to the best o f their ability. 
However, reaction time in the CTT did increase over time in both conditions 
suggesting an element o f  tedium with this particular test o f  vigilance. Conversely in 
the STM task, the reaction time taken to correctly identify probe numbers present in 
the test group improved over the time o f  the experiment. It may have been that this 
task held the interest through greater cognitive requirement compared to the vigilance 
test. Indeed one o f  the reasons for the lack o f  effect o f  CH could be that the 
performance tests were not taxing enough. It may be that increasing the resources o f
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the brain, especially one neurotransmitter, is not going to improve psychomotor 
function per se unless there is a demand on those resources, through increased 
cognitive effort and normal levels become insufficient. Another point is that the CH 
experiment was the longest o f this series in terms o f subjects spending one period in 
the laboratory, whilst every attempt was made to prevent tedium becoming an issue, it 
may have had some effect.
One major point that the present experiment does highlight is that CH has no 
sedative or alerting side effects. This implies that the drug is truly without detrimental 
side effects on performance. Therefore, in the context o f  using CH as an 
antidepressant this is extremely useful as it does not, when taken in an acute dose, 
adversely affect psychomotor performance as many earlier developed anti-depressants 
do (Hindmarch 1982, 1987, 1988, Sherwood and Hindmarch 1993). This suggests that 
citalopram would be a drug o f choice if  prescribed for clinical reasons to individuals 
who work in a safety critical environment. Previously the prescribing o f  tri-cyclic 
antidepressants has involved careful monitoring o f  patients and has meant that long­
term treatment has had its drawbacks.
In conclusion, it cannot be concluded that citalopram would be useful as a PE, 
as its effects, if any, in normal healthy subjects, were unclear from this experiment. A 
more selectively designed experiment may elucidate the reason for such high 
variances between individuals in the CRT test. However, the very selectivity for 
which CH was chosen as a putative PE for investigation may not have been the action 
which has suggested PE properties in other members o f  the SSRI group. It would also 
seem that concentrating on increasing the supply o f a single neurotransmitter may not 
be the correct pharmacological method for enhancing psychomotor performance
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above normal levels. Nevertheless, as more selective SSRIs are developed it is not 
unfeasible that newer derivatives would be suitable for assessment in the role o f PE in 
the future.
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Chapter 7 
Discussion and Conclusions
Introduction
“Drugs which enhance cognition may benefit the two 
largest groups o f  psychiafric patients who have been  
by-passed  during the psychopharm acolog ical revolution  
o f  the p a st  35 years: those with developm ental 
disabilities and those with brains ravaged  by senile 
dementias. But who am ong us w ould not benefit from  
such a  drug i f  indeed it cou ld  enhance norm al 
perform an ce ” LE  H ollister 1990
The programme o f  experiments described in this dissertation investigated the 
possibility o f  enhancing the psychomotor performance o f healthy humans above the 
levels at which they normally operate. More specifically this was an attempt to 
identify a readily available and usable drug for real situations. The literature review, 
conducted to assess the current status o f  research into pharmacological enhancement 
o f  psychomotor performance highlighted the lack o f  good quality scientific 
assessment o f so-called psychomotor enhancers (PEs) in normal non-deficit humans 
(Table 1.1). Despite a number o f essays on the benefits such drugs would bring to 
society, and the care which should be taken in assessing them as true PEs, very little 
work has been conducted with the express intent o f enhancing psychomotor 
performance over and above normal levels. This is in contrast to the efforts that have 
been made to assess those drugs designed to replace cognitive function in cognitive 
deficit patients (CRs). The present study, therefore, has made a start in fulfilling that
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requirement and has provided some interesting insights into the investigation o f 
putative PEs.
What was found
Overall the results have shown that in carefully controlled laboratory 
assessments o f specific aspects o f  psychomotor performance, some drugs such as 
caffeine and nicotine do have an effect on physiological variables related to cognition. 
This was reflected in changes to the EEG which are concomitant with previous reports 
o f  alerting drags (Fink 1968), although they were slightly different in overall profile 
o f  activity than some previous studies o f the two substances (Knott 1989, Saletu 1991, 
Pritchard 1991, Hasenfratz & Battig 1992). However, effects on the performance tests 
with the same drags were inconclusive. In the present study there was a trend towards 
improvement in recognition reaction time results with nicotine, which had been seen 
previously (Bates et al. 1995, Houlihan et al. 1996). However, this difference was not 
able to be isolated to a specific point in the pharmacodynamic profile and was not 
thought to indicate improvement due to a drug effect, in this situation. Subjective 
assessments o f energy and confidence also suggested some improvement with 
caffeine, but was not conclusive due probably to an experimental effect in the baseline 
measure o f the POMS questionnaire. However the two other drags, GBE and 
citalopram hydrobromide did not affect any o f the measures which were recorded.
Further analysis was conducted, using simple paired t-tests for the CFF and 
CRT measures in all the experiments. This took into account the nature o f variable 
drug effects in human subjects, by comparing the mean post-baseline peak effects o f
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the drag and placebo conditions. However, this did not shed any further light on any 
drag effects that may have been present, but were not picked up due to subject 
variability. Indeed variability in the results o f  the Choice Reaction Time test was 
thought to be high, although not unrealistic. It may have been that this variability 
masked some genuine effect, although the more specific statistical investigation failed 
to elucidate any such differences. It would be prudent in future to develop the 
methodology for such investigations to take account o f this.
In Chapter 1 the use o f one dose o f  each drug for assessment was discussed. It 
was felt, in the light o f previous work, that the doses chosen were relevant and 
appropriate. However due to the lack o f effects overall it may have been better to have 
looked at a low dose and a high dose in each case. Nevertheless the study set out to 
answer a number o f specific questions with the intention o f investigating the 
possibility o f presently available drugs being able to enhance psychomotor 
performance above normal levels. The results add support to the hypothesis that it 
may be possible to do this, but it would seem that there are few reliable or highly 
efficacious drags available at this stage. The experiments conducted here have 
produced some interesting results which can guide the research forward, especially 
with regai’d to the type o f pharmacological activity which will be more useful in the 
field o f  psychomotor enhancement.
The pharmacology of putative psychomotor enhancers
The experiments were conducted with four different drugs, each with a 
particular pharmacological activity which has shown promise as a PE. One reason for
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doing this was to see if there was a particular pharmacological approach to take for 
psychomotor enhancement. Caffeine, nicotine and GBE were chosen as naturally 
occurring compounds with a good history o f social and medical use, as discussed in 
Chapter 1, and were all purported PEs. Although, there has been very little, if  any, 
experimental work to look at their ability to increase psychomotor performance above 
normal levels. Citalopram hydrobromide was investigated because it showed promise 
in the context o f its pharmacological group and had not yet been looked at for the 
purpose o f psychomotor enhancement.
However, all four drugs had distinctly different pharmacological activities. 
When looked at in the context o f the same test battery and with normal healthy 
subjects the results gave a clearer idea o f what pharmacological approach to take to 
affect normally efficient psychomotor processes.
Caffeine has been deemed to be a ‘psychostimulant’ (Nehlig et al. 1992) and 
acts by inhibition o f the adenosinergic neurotransmitter system, mainly at the A l and 
A2 receptors (Robertson & Curatolo 1984, Williams 1987). When caffeine was 
assessed under the present test battery this was confirmed by a definite 
pharmacological effect on the EEG reflected in attenuated alpha power as well as a 
number o f other more localised changes. Although it did not cause significant 
improvement in the performance tests it did have a tendency to improve those aspects 
o f  mood on which caffeine is generally regarded to have an effect. Therefore, whilst 
caffeine was not proven to be PE, its pharmacological activity was shown to have 
promising effects in non-deprived, normal subjects. More specifically this particular 
experiment demonstrated that caffeine has a definite pharmacological' effect in non­
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caffeine deprived individuals, so ruling out a possible caffeine reinstatement effect in 
this experiment.
Nicotine is also a stimulant in the form o f a neurotransmitter mimic for 
specific receptors in the cholinergic system and produced an effect on the EEG in the 
present study. The results were, in some ways, similar to previous studies, but not 
exactly. The difference may have been due to the administration method i.e. nicotine 
gum, but did demonstrate a pharmacological effect o f  nicotine in non-nicotine 
deprived subjects. This confirmed that nicotine does have the capability to affect 
neural functioning in normal non-smoking subjects.
Ginkgo biloba extract (GBE), amongst many other things, is a vasodilator. As 
such it improves the blood and general resource supply to the brain. Under the 
conditions o f this experiment it did not produce any effects either positive or negative. 
Indeed the lack o f an effect on the EEG indicated that no central pharmacological 
effects occurred. This suggested that GBE did not increase the blood supply to the 
brain o f  normal subjects. Hence it could be concluded that this is not a suitable 
method o f increasing psychomotor performance in normal subjects under these 
conditions.
Citalopram hydrobromide is a serotonin re-uptake inhibitor and hence 
increases the amount o f available serotonin in the brain. However, the lack o f  effect 
on any o f the measures in this test battery suggest that it did not have a 
pharmacological effect on normal subjects at all. As with GBE it could be concluded 
that improving the supply o f this particular resource to the brains o f  normal subjects is 
not an appropriate method o f increasing psychomotor performance.
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To make sense o f these results it was important to relate them back to the 
reasons for selecting them for investigation in the first place.
Extrapolating results, from CRs to PEs?
In the introduction it was concluded that most currently available drags used 
for cognitive replacement would not be suitable as PEs. The results here support that 
but do also provide some interesting connections between cognitive replacement and 
psychomotor enhancement
In the literature the term Cognitive Enhancer is confined in many cases to the 
use o f drags to improve cognitive deficit conditions caused by Senile Dementia o f  the 
Alzheimer’ s Type (SDAT), Parkinson’ s disease, stroke, organic brain disease, other 
forms o f cerebral blood supply insufficiency and a number o f other psychiatric 
disorders which cause cognitive decline (Calvani & Carta 1991, Shimizu 1991). As 
discussed in the introduction, the majority o f these have concentrated on supplying or 
releasing greater quantities o f one or other specific neurotransmitter (Sailer 1991, 
Sarter et al. 1992a, 1992b, Frostl & Maitre 1989) . The neurotransmitter in question 
has generally been discovered to be lacking due to the pathophysiological changes 
occurring in the condition being investigated. It has been common, therefore, for 
researchers to latch onto this one system and attempt to find drugs which would 
enhance the availability or activity o f the specific neurotransmitter in order to alleviate 
the deficit condition i.e. CRs.
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Clinical trials o f treatments for such diseases have also been conducted in 
normal, healthy human subjects. However in these situations researchers were actually 
concentrating on the lack o f effects to assess if drugs were clinically safe. It has been 
by chance that some o f these trials have shown some positive results in normal 
subjects (Wilsher et al. 1979, Largergren 1981, Brinkman & Gershon 1983) As the 
deficit conditions are the only targets for pharmaceutical companies to aim at it is 
only from the basis o f these studies that any educated identification o f drugs with 
possible psychomotor enhancing properties could be made. However, the evidence 
seen from reviewing the literature suggested that enhancing performance in normal 
subjects would be more successful if the psychomotor component were targeted.
Therefore, as Gamzu (1990) suggested a specific goal was set in the 
investigation o f possible CEs. The present study did this by investigating drags with 
the purported ability to enhance specifically psychomotor performance i.e. PEs. The 
results have produced the idea that increasing such performance beyond normal levels 
probably requires a slightly different approach to that o f reinstating cognitive deficit 
in clinical patients. Indeed the two substances which are used almost universally for 
their perceived effects, but are not used clinically, produced some beneficial 
psychopharmacological and electrophysiological effects in the present study. The two 
drags which have been used for clinical purposes did not show any effects in the 
normal subjects assessed.
To try and make sense o f this, the actual pathophysiology o f  the deficit 
conditions may give some answers. One major example o f a cognitive deficit 
condition is senile dementia of the Alzheimer’ s type (SDAT), in which sufferers were
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found to have greatly reduced cholinergic function (Crow & Grove-White 1973, 
Drachman & Leavitt 1974). Subsequently the majority o f SDAT treatments have 
concentrated on improving the supply o f acetylcholine in the brain, whether by re­
uptake inhibition at the pre-synaptic terminal, supplying greater quantities o f  pre­
cursor substances such as choline, lecithin or even stimulating the post synaptic 
receptors (Salter et al. 1992a, 1992b, Frostl & Maitre 1989).
Sarter has conducted several exceptionally detailed reviews o f  virtually all 
possible CEs that have been researched for SDAT and also other deficit conditions. In 
the reviews it is clear that the drugs fall into three distinct groups: cholinomimetics; 
nootropics and non-cholinergic based drugs. Looking at the number o f substances in 
question it is without doubt the cholinomimetics which are most prolific in this field, 
due to the relationship o f cholinergic activity to the SDAT condition. Cholinergic 
activity as a consequence has been related to the two most relevant and obvious 
cognitive functions which are affected in SDAT, memory and attention.
This has left two problems when looking for true PEs: the majority o f drugs 
available for assessment are cholinomimetic, and they are mostly aimed at enhancing 
memory and attention. However, other aspects o f cognitive and psychomotor 
performance exist and could either at best be unaffected by these drugs, or, at worst 
adversely affected as with physostigmine (Tandon et al. 1993). Indeed there has been 
little evidence o f presently available cholinomimetic drags improving the cognitive or 
psychomotor performance o f normal subjects as was discussed in Chapter 1. 
However, that is not to say that drugs which affect the cholinergic system will not
238
affect the psychomotor performance o f normal subjects. It may just be that the 
cholinergic system needs to be activated in a certain way.
For instance, as muscarinic receptor numbers remain stable during the course 
o f  SDAT deterioration nicotinic ones decline (Kellar et al. 1987, Rusted and 
Warburton 1991), When agonists have been investigated as treatments it has 
invariably been the muscarinic ones, as they have target receptors which are known to 
be present in reasonable numbers. This target is obviously justified in this type o f  
research. However, the fact that the effects o f  SDAT treatments for cognitive 
replacement do not extrapolate from patients to normal subjects suggests that 
muscarinic receptors are the incorrect target for true CEs or PEs as all receptor types 
are present in normal healthy humans, within a correct range o f  numbers, by 
definition. From the positive results in EEG alpha power attenuation in the present 
study it would seem that the nicotinic receptors may be a more appropriate cholinergic 
target for PEs in normal subjects.
However the results from the nicotine experiment also illustrate another point. 
Despite the idea that stimulating muscarinic receptors is useful in cases o f  dementia 
but not in normals, it has been argued that nicotinic stimulation o f the cholinergic 
system also reduces fluctuations in cortical arousal due to sustained acetylcholine 
release, in clinical deficit patients (Warburton et al 1988). This particular effect was 
not observed with nicotine in the measure o f cortical arousal, CFF, used in the present 
study. This suggests that nicotine does not have the same effects in normal subjects 
compared to deficit patients. In addition previous studies which have shown 
differences in CFF with nicotine have tended to use nicotine using subjects who were
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withdrawn from the substance for up to 12 horns prior to experimentation. This 
therefore could be concluded as still replacing a deficit in psychomotor performance 
rather than a true enhancement and is another example o f a complex neurotransmitter 
stimulation system which is not yet full understood. However, it does suggest that 
nicotine could be used as both a CR and PE and that stimulation o f the cholinergic 
system via nicotinic receptors is probably an appropriate method for enhancing at 
least the attentional aspects o f  psychomotor performance.
Other clinical therapeutics have also shown no extrapolation o f  effect from 
patients to normal subjects. The results from the current CH experiment support this, 
with no evidence o f  a pharmacological effect having taken place in normal subjects. 
However serotonin has been shown to have a role in cognition (Costall et al. 1992). It 
may be that due to complexities which are beyond comprehension at the moment, 
current serotonergic promoting drugs do not affect the system in a manner which can 
improve psychomotor performance. Indeed caffeine and nicotine both actively 
stimulate activity o f their respective neurotransmitter systems. CH only ensures an 
adequate supply o f the already present transmitter.
The results seen with GBE can be taken in a somewhat different way as it is 
the one drag that was investigated which did not directly affect a central 
neurotransmitter system. It’ s main effect, the improvement o f cerebral blood supply 
did not seem to occur in the experimental conditions used here. This was reflected in 
the lack o f EEG and arousal effects. It is possible that GBE is not effective in these 
situations, only in deficit conditions caused by lack o f  blood supply. This does
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suggest that the effects o f the resource increaser type CRs do not extrapolate from 
clinical patients to healthy normal subjects.
One group o f drugs which was not assessed in the current study, the 
nootropics studies have concentrated on their use in improving memory and learning, 
with some good results in animals and some dementia models (Giurgea & Salama 
1977, Leonard 1994, Pepeu & Spignoli 1989). They increase the release o f dopamine 
in the cerebral cortex which is thought to have a role in the acquisition phase o f  the 
learning process (Iversen 1977). They also indirectly potentiate cholinergic function 
(Poschel 1988). Again, however, beneficial results on psychomotor performance from 
clinical and animal studies have not been -replicated in normal human subjects 
(Tacconi & Wurtman 1986). This would add further weight to the idea that clinical 
treatments do not necessarily improve normal psychomotor performance as they are 
targeted incorrectly. It is possible that in this particular case a different approach to 
activating the dopaminergic system, as has been shown in the case o f nicotine and 
caffeine, may also have an effect on normal subjects. This should be an area for future 
research.
Overall the results suggest that drugs which are targeted at producing specific 
actions as CRs are not generally able to be used as PEs in normal subjects. However, 
the neurotransmitter systems they are aimed at are probably the same ones which 
should be targeted for PE development.
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Relative Effect of investigated substances
Looking at the pharmacological effects and the significant results seen in the 
present results overall, they suggest that the most active drugs assessed were caffeine 
and nicotine. Both are stimulants and act on different target receptors than GBE or 
CH. The latter, whilst useful in clinical situations for cognitive replacement do not 
seem to have the right pharmacological action to enhance psychomotor performance 
in normal subjects, who do not have a deficit o f resources. However, due to the 
construction o f the series o f experiments it was possible to look at the relative effect 
o f  each drag in some o f the tests used.
A  variety o f performance tests were used for each o f  the experiments. Each 
test was included in the test battery to assess each individual drag dependent on the 
known effects o f he drug. This meant for caffeine and nicotine CFF and CRT were 
used as they had both previously shown effects on arousal and reaction time. A 
limiting factor in the case o f these two drags was that they both had relatively short 
pharmacodynamic profiles and it was important to use only the most relevant 
performance tests in conjunction with the EEG and Mood State assessment. As GBE 
and CH bad been reported to have possible effects on short term memory and 
vigilance, and there were 110 time constraints due to pharmacodynamic profile the 
Sternberg STM task and the CTT were also included as well as the CFF and CRT.
This meant that there was a consistent and comparable situation in each 
experiment for both CFF and CRT. A meta-analysis was therefore able to be 
conducted using the Cohens-d method (Cohen 1977). This is a measure o f the degree
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to which the treatment and control means differ in terms o f  the standard deviation 
from the parent population. It is calculated from the formula:
Hi- Pa 
d =  ------------
5
where d = relative effect
Pj -  mean o f the active condition (drug)
p2 = mean o f control condition (placebo)
5 = is the standard deviation common to the two conditions
When the values for each experiment are tabulated as in Tables 7.1, 7.2, 7.3 and 7.4 
overleaf, it gives a good idea o f the difference in relative effects o f  the different drugs 
assessed.
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Table 7.1 Cohens-d values for CFF
Caffeine 150 0.129
citalopram hydrobromide 20 0.088
nicotine 2 0.013
GBE 120 0.009
placebo 0.000
Table 7.2 Cohens-d values for RRT
nicotine 2 0.271
GBE 120 0.201
citalopram hydrobromide 20 0.096
placebo 0.000
Caffeine 150 -0.125
Table 7.3 Cohens-d values for MRT
Caffeine 150 0.153
placebo 0.000
citalopram hydrobromide 20 -0.027
GBE 120 -0.137
nicotine 2 -0.141
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Table 7.4 Cohens-d values for TRT
nicotine 2 0.135
GBE 120 0.090
citalopram hydrobromide 20 0.050
placebo 0.000
Caffeine 150 -0.036
It is interesting to note that 011 a relative measure all four drugs assessed 
produced greater arousal than placebo as measured by the CFF. O f course there was 
no significant difference in either the one or two tailed ANOVA in the CFF measure. 
However, relating these results to previously reported effects o f all four drugs shows 
that the selection made from reviewing the literature was done effectively.
More specifically in the CRT comparisons it was shown that caffeine was only 
relatively better than placebo in the motor component. This supports previous reports 
o f caffeine being effective on the speed of psychomotor performance as opposed to 
the processing aspects. Nicotine, GBE and CH, however were relatively more 
effective than placebo overall in the recognition and total components o f CRT. This 
suggests, as previously reported that they are more likely to enhance 
attentional/vigilance aspects o f psychomotor performance, although no significant 
effects due to these drugs were observed in the present study, as discussed previously.
Overall these comparisons do suggest that there are distinctly different 
systems controlling the improvement o f motor and attentional aspects o f psychomotor 
performance. Specifically they suggest that the adenosinergic inhibition shown by
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Fig 7.1 Resource : Activity Ratio theory of psychomotor enhancement
In developing this model it was assumed that there would be an initial 
requirement for psychomotor activity which would draw on the available resources i.e. 
oxygen, glucose, neurotransmitters. In normal subjects this would result in normal 
psychomotor performance which would form the baseline measure. If, however, the 
psychomotor requirement were increased, more resources would be drawn in order to 
fuel the activity. Until such point as resources were exhausted or in short supply 
psychomotor performance would still remain at baseline. The model then illustrates 
the outcomes of the drugs investigated in the present study as examples of resource 
increasers or activity increasers. The results indicated that caffeine and nicotine did
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have some activity in the normal subjects used and indeed under refined conditions 
may have been shown more unequivocally to improve certain aspects o f psychomotor 
performance. The diagram is treated as if this has occurred for the purposes o f 
demonstration o f  the theory.
This suggests that by increasing central neural activity using drugs the output 
performance could be improved. The specific site o f stimulant activity is not clear 
from the results found in the four experiments conducted in this study. A  starting 
suggestion could be made, however, at the inhibition o f the adenosinergic A l and A2 
receptors, as for caffeine, or the stimulation o f the nicotinic receptors o f  the 
cholinergic system. With further work it may be found to be true for other 
neurotransmitter systems.
However, just increasing the amount o f  resources available would not increase 
the activity involved in completing the original psychomotor requirement. This was 
the approach used to suggest that GBE and CH were possible PEs, but was not shown 
to have any effect on the tests used here.
Additionally if  a disease condition caused a decrease in resource availability 
then the output performance would also decrease. This is the point at which CRs 
would be administered and would raise performance back towards normal levels, 
although not beyond.
Extra activity caused by either stimulants or by increased psychomotor 
requirement i.e. more taxing psychomotor task, means that there would probably be 
an increase in the draw on resources. There would be a point at which the resource 
supply would become the performance limiting step. This suggests that resource 
increasers, such as GBE or CH could have a place in improving psychomotor
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performance beyond normal level. This would only occur under the most extreme 
situations. However, it should not be ruled out in future work to include the use of 
combinations o f  stimulants/activators and resource increasers.
Problems with Methodology
Part o f  the aim o f the present study was to provide a comprehensive test 
battery suitable for assessing PEs in normal subjects. In the main it was felt that the 
test battery was adequate for the aim o f the present study. However, the lack o f  effect 
described in Chapters 5 and 6 was somewhat surprising as the drugs and tests used 
were chosen due to their undoubted efficacy in affecting aspects o f  psychomotor 
function. The main problem had been that most previous studies have not been 
conducted for the purpose o f looking at changes in normal psychomotor performance.
There has been a lot o f  active research on the effects o f  various drugs on 
behaviour and mental performance as discussed in Chapter 1. However, one o f  the 
major problems with the field o f psychopharmacology has been a very wide variety o f 
tests used to assess the psychomotor performance. Indeed it would appear that eveiy 
laboratory has its own set o f  specific tasks (the author is not excluded from this) 
which it has retained as a battery and developed over a period o f  some years. Some 
rely on mainly performance tests which have burgeoned in number with the advent o f  
the PC. Others use EEG or the more recent forms o f brain activation imagery as a 
physiological correlate or questionnaires to gain subjects views on the effects. The 
more clinically driven studies use global clinical scales completed by an observer or 
carer. Very few combine more than two o f  these while most only use one type o f  test
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per experiment. This has led to a lot o f available information but which has sadly been 
produced in a non-uniform way.
The present study combined three types o f  test into one battery to provide a 
good overview o f drug activity on physiological, psychological and performance 
measure. The results showed that the EEG was the most sensitive and probably the 
most objective test used. Both caffeine and nicotine had some effects which were 
along the lines o f expectation, i.e. changes in alpha and some beta (Knott 1989, 
Pritchard 1991, Hasenfratz & Battig 1992). However, there were also effects which 
were noticeable in their absence. Decreases in the slower wavebands delta and theta 
(Bruce et al. 1986, Hasenfratz & Battig 1992, 1994) have been reported for both 
substances as well as increases in the higher beta bands, neither o f which were 
observed here. These were probably indicative o f the difference o f  effect between 
subjects deprived o f either substance before experimentation and those who were not. 
Nevertheless EEG was a suitable measure to use in the present investigation
The performance tests used here had previously been reported to detect drug 
effects, especially for those that were chosen for investigation in the current study, as 
described in Chapter 1. However, they did not detect any clear effects o f  any o f  the 
drugs assessed. As previously mentioned the variability o f  the data may have masked 
effects in the nicotine experiment and there may have been a missed expectation effect 
with the caffeine, although this was unlikely due to the timescale involved. The results 
o f  the GBE and CH were less surprising. The similar lack o f effect on the EEG of 
these two drugs indicated that they probably had no pharmacological effect under 
these conditions. This was further supported by the fact that neither GBE or CH had
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any effect on the STM and CTT tests. Therefore, although there were veiy few effects 
seen the test battery probably had the right mix o f tests for the present investigation. 
However, more taxing tasks may have further elucidated the mechanisms o f action o f 
both caffeine and nicotine. This should be taken into account in further work. Using 
the performance tests in conjunction with the EEG was the correct approach to take as 
it highlighted reasons why no effect had been seen in the case o f  GBE and CH, and 
allowed some comparison to be made between different type o f measures for caffeine 
and nicotine.
Mood state assessment is a subjective measure, and as such did not provide 
any clear indications o f the effects o f the drags being assessed. As before, the lack o f 
pharmacological effect o f GBE and CH meant that there would be no mood state 
effects. However, with nicotine and caffeine the story may have been slightly 
different. It has been previously reported that both substances have effects on subjects 
mood (Lieberman 1987, Gilbert 1979, Golding & Mangan 1982, Bruce et al. 1986, 
Smith et al. 1991). Though, as has been said before, most o f the subjects in these 
studies were withdrawn from the substances being investigated prior to assessment. 
This, and the lack o f conclusive effect in the present study on mood state assessment, 
suggests that positive subjective effects are more difficult to produce or to detect 
when looking at the effects o f putative PEs in normal subjects. However, as there 
were no significant negative effects on mood, the use o f the POMS-BI questionnaire 
has justified itself as suitable for inclusion in any future investigation o f this type.
In future research it is concluded that the current test battery would be a 
suitable one to use as it combines the three major aspects o f assessment which need to
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In conclusion, the current study found that psychomotor enhancement is not 
yet achievable in a truly effective manner using drugs or natural substances which are 
currently available. However the results did provide evidence which suggests that 
development o f PEs is possible.
Improvement seen in certain measures o f the test battery with caffeine and 
nicotine highlight the fact that stimulants which actually activate a particular 
neurotransmitter system in a specific way are the most likely candidates to provide 
genuinely usable PEs. Adenosinergic inhibition with caffeine, and cholinergic 
stimulation via the nicotinic receptors appears to enhance alertness, as seen in the 
EEG results. Vasodilation or resources increasers such as GBE or CH will be most 
unlikely to improve those aspects o f  psychomotor performance tested here. However, 
they may have some use in improving the brains ability to deal with more taxing tasks 
which tap into central cognitive processing.
Overall the results do suggest that there is a pharmacologically different 
approach to take for psychomotor enhancement in normal subjects as compared to 
cognitive replacement in clinical deficit patients. In the latter there is deemed by 
definition to be a lack o f one or other resource available to the brain, be it 
neurotransmitter, blood supply or both. This situation requires a drug which is able to 
increase the supply o f the deficit resource. To cause psychomotor enhancement in 
normal subjects, who have normal levels o f resources available, a specific activation 
o f one or other o f the neurotransmitter systems is probably required.
Conclusions
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The test battery which was constructed as part o f the study showed that it was 
sensitive enough to detect effects in the three distinct areas o f  assessment i.e. 
performance, physiological assessment and psychological assessment. Indeed this 
covered the whole range o f effects that could be expected from the drugs chosen for 
investigation. The results also showed that there were no significant negative effects 
with any o f  the drugs assessed. This means two things, that the drugs were chosen 
with a sound technique for identifying truly usable putative PEs and that the test 
battery was suitable for testing such drugs in the future. However, some time effects 
and practice effects emerged which indicate that some methodological refinement 
would be useful, especially in the light o f  between subject variability in results.
One other aspect that was clear from looking at the literature as a whole, was 
that currently drug companies and academics are looking mainly at drugs which are 
used for cognitive replacement. As the results showed that the pharmacological 
approach to cognitive replacement is probably different to that for psychomotor 
enhancement, it is logical to suggest that true PEs will not be developed until the 
focus o f  scientific attention is turned towards enhancing performance above normal 
levels. This attention will probably not occur until there is a market demand for such 
substances to be widely available. Until that time caffeine and nicotine will be the 
substances which are nearest to providing true psychomotor enhancement.
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Not taking into account the general requirement for more specific animal models o f 
cognitive and psychomotor activity, and the need to target the actual requirement for a 
true PE, further work needs to be conducted to take this topic forward in the vein 
stalled by the present study. This could be:
i. Development of the methodology. The current range o f  tests need to be refined
to target the specific pails o f psychomotor performance which it is required to 
improve, indeed this latter point needs further refinement in itself. New 
technology for functional brain imaging needs to be incorporated, but the testing 
regimen needs to be standardised in order to provide accurate comparison o f 
different compounds. A  systematic programme o f assessment o f  the effects o f  all 
putative CEs and PEs, from both clinical and non-clinical application should be 
conducted in normal subjects. A wider range o f  tests to incorporate the assessment 
o f higher cognitive functions such as memory and learning should be used to do 
this. This would provide a library o f the effects which could be expected in normal 
subjects and which is sadly lacking at the present time.
ii. Assessment of novel PEs. New compounds which are constantly being improved
in terms o f selectivity and central action need to be assessed and compared using
this new refined methodology. Identification o f  an active control substance would 
be a large step forward, but will probably only be available once the topic is 
suitably targeted by the academic and pharmaceutical experts.
Further work
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iii. ResourceiActivity Ratio Theory. The use o f  more taxing psychomotor/cognitive 
tasks to test the ResourceiActivity Ratio Theory needs to be investigated. High 
level tasks may respond more to resource increasers, low level reactive/perceptive 
tasks may respond more to activators/stimulants.
iv. Operational relevance. The testing battery should automatically be linked to 
more operationally relevant tasks in order to illustrate the real benefit that can be 
achieved by the enhancement o f cognition. A  programme o f comparison o f drug 
effects in the laboratory and in a number o f  generic operational tasks needs to be 
conducted.
v. Quantification of psychomotor deterioration. A systematic quantification o f 
‘normal’ performance o f  laboratory tests to determine exactly how performance 
deteriorates over time should be conducted. This would give a baseline which is 
not yet available and against which the use o f  drugs could be recommended for 
safety purposes.
vi. Further investigation of caffeine and nicotine. The results o f the present study 
specifically suggest that the stimulant activity o f caffeine and nicotine requires 
isolation, both in terms o f its effect on functional brain activation and specific 
effects on psychomotor performance. Direct examination o f the effects o f  nicotinic 
and adenosinergic stimulation and inhibition on psychomotor performance in 
animals, followed by human studies will be required to do this. In turn this should 
elucidate the active aspects o f  each drug which may be more effective when
2 5 4
isolated, as opposed to being in combination as in the whole substance. This could 
lead to the development o f specific derivatives o f  the most ubiquitous 
psychoactive substances in use today.
2 5 5
Appendix A 
Analysis of Variance Tables
K ey: T =  Time
C =  Placebo or drug Condition 
CH =  EEG electrode Channel 
E =  Eyes Open or Closed 
O =  Order o f  run
N =  Number in Sternberg STM Test Group 
T a b le  A .  1 F u ll  A n a ly s is  o f  V a r ia n c e  resu lts  f o r  c a f fe in e  c o m p a r e d  to  p la c e b o  
Performance tests
PC =  Principal Component 
Op = Eyes Open only (in PC)
Cl =  Eyes Closed only (in PC)
M =  Geometric Mean o f  PC 
Dijf= Difference in Op and Cl scores 
R = Run order
T e s t V a r ia b le
j. - 7s v :y F
p <
C F F T 1 1 .3 7 3 4 ,4 4 * * *  0 .0 0 0 0
C 1 .2 6 7 f i l l 0 .2 8 4 1
T * C 0 .8 0 0 4 ,4 4 0 .5 3 1 6
R R T T 0 .9 9 4 4 ,4 4 0 .4 2 0 3
C 0 .3 7 7 1 ,11 0 .5 5 1 6
T * C 0 .3 4 6 4 ,4 4 0 .8 4 5 3
M R T T 1 .2 8 0 4 ,4 4 0 .2 9 1 7
C 1 .1 3 8 1 ,11 0 .3 0 8 9
T * C 1 .1 7 6 4 ,4 4 0 .3 3 3 7
T R T T 1 .3 6 1 4 ,4 4 0 .2 6 2 1
C 0 .0 1 2 1,11 0 .9 1 4 1
T * C 0 .7 9 9 4 ,4 4 0 .5 3 1 7
Mood State
T e s t F D e g r e e s  o f
Af r e e d o m
P <
P O M S  C A T 2 .2 0 3 4 ,4 4 0 .0 8 3 7
C 0 .8 5 2 1 ,1 1 0 .3 7 5 7
T * C 0 .5 0 2 4 ,4 4 0 .7 3 3 9
P O M S  A H T 0 .6 2 0 4 ,4 4 0 .6 5 0 1
C 2 .4 0 6 1 ,1 1 0 .1 4 9 1
T * C 0 .3 1 4 4 ,4 4 0 .8 6 7 2
P O M S  E D T 0 .1 9 3 4 ,4 4 0 .9 4 0 9
C 1 .2 8 2 1 ,1 1 0 .2 8 1 5
T * C 0 .6 7 8 4 ,4 4 0 .6 1 0 6
P O M S  C U T 2 .7 2 6 4 ,4 4 * 0 .0 4 0 9
C 8 .1 3 5 1 ,11 * 0 .0 1 5 8
T * C 0 .2 7 7 4 ,4 4 0 .8 9 1 2
P O M S  E T T 1 .2 7 2 4 ,4 4 0 .2 9 4 8
C 6 .3 7 3 1 ,11 * 0 .0 2 8 3
T * C 0 .1 3 2 4 ,4 4 0 .9 6 9 7
P O M S  C C T 0 .2 4 3 4 ,4 4 0 .9 1 2 5
C 1 .4 4 0 1 ,11 0 .2 5 5 2
T * C 0 .5 2 1 4 ,4 4 0 .7 2 0 2
2 5 7
EEG Power
T e s t F1 D e g r e e s  o f  
f r e e d o m
P <
D e lt a  P o w e r C H 4 6 .8 3 6 1 9 ,2 0 9 * * *  0 .0 0 0 0
T 1 .7 4 3 4 ,4 4 0 .1 5 7 1
E 2 6 .5 4 6 1,11 * * *  0 .0 0 0 3
C 1 .8 1 3 1,11 0 .2 0 5 2
C H * T 0 .9 6 2 7 6 ,8 3 6 0 .5 7 0 7
C H * E 6 .8 6 9 1 9 ,2 0 9 * * *  0 .0 0 0 0
C H * C 0 .5 3 0 1 9 ,2 0 9 0 .9 4 6 9
T * E 2 .8 9 2 4 ,4 4 * 0 .0 3 2 6
T * C 1 .9 8 4 4 ,4 4 0 .1 1 3 1
E * C 1 .3 5 8 1,11 0 .2 6 8 5
C H * T * E 1 .1 8 1 7 6 ,8 3 6 0 .1 4 6 7
C H * T * C 0 .7 0 2 7 6 ,8 3 6 0 .9 7 3 6
C H * E * C 1 .4 7 7 1 9 ,2 0 9 0 .0 9 6 2
T * E * C 0 .5 4 9 4 ,4 4 0 .7 0 0 1
C H * T * E * C 1 .4 7 0 7 6 ,8 3 6 * *  0 .0 0 7 3
T h e ta  P o w e r C H 5 0 .3 1 5 1 9 ,2 0 9 * * *  0 .0 0 0 0
T 1 2 .7 2 8 4 ,4 4 * * *  0 .0 0 0 0
E 1 6 .9 8 1 1 ,1 1 * *  0 .0 0 1 7
C 1 4 .2 2 9 1 ,1 1 * *  0 .0 0 3 1
C H * T 1 .2 8 9 7 6 ,8 3 6 0 .0 5 5 1
C H * E 6 .3 3 4 1 9 ,2 0 9 * * *  0 .0 0 0 0
C H * C 0 .1 0 4 1 9 ,2 0 9 1 .0 0 0 0
T * E 0 .3 4 0 4 ,4 4 0 .8 4 9 2
T * C 0 .5 2 9 4 ,4 4 0 .7 1 4 4
E * C 0 .6 3 8 1 ,1 1 0 .4 4 1 0
c h * t * e 0 .7 9 5 7 6 ,8 3 6 0 .8 9 6 9
c h * t * c 0 .7 1 2 7 6 ,8 3 6 0 .9 6 8 6
C H * E * C 0 .4 7 2 1 9 ,2 0 9 0 .9 7 1 2
T * E * C 0 .7 7 4 4 ,4 4 0 .5 4 7 5
C H * T * E * C 1 .5 0 7 7 6 ,8 3 6 * *  0 .0 0 4 6
A lp h a  P o w e r C H 8 9 .3 6 1 1 9 ,2 0 9 * * *  0 .0 0 0 0
T 1 5 .8 2 8 4 ,4 4 * * *  0 .0 0 0 0
E 4 3 .2 8 0 1 ,1 1 * * *  0 .0 0 0 0
C 1 0 .3 6 3 1 ,1 1 * *  0 .0 0 8 2
C H * T 0 .8 1 2 7 6 ,8 3 6 0 .8 7 3 5
C H * E 1 9 .0 8 0 1 9 ,2 0 9 * * *  0 .0 0 0 0
C H * C 0 .4 7 7 1 9 ,2 0 9 0 .9 6 9 4
T * E 0 .9 9 3 4 ,4 4 0 .4 2 0 8
T * C 3 .5 2 6 4 ,4 4 * 0 .0 1 3 9
E * C 7 .5 6 7 1 ,1 1 * 0 .0 1 8 9
C H * T * E 1 .3 4 5 7 6 ,8 3 6 * 0 .0 3 0 7
C H * T * C 0 .9 5 3 7 6 ,8 3 6 0 .5 9 2 3
C H * E * C 0 .7 1 5 1 9 ,2 0 9 0 .8 0 1 4
T * E * C 1 .2 7 3 4 ,4 4 0 .2 9 4 3
C H * T * E * C 0 .7 1 7 7 6 ,8 3 6 0 .9 6 6 1
B e t a l  P o w e r C H 7 0 .5 5 3 1 9 ,2 0 9 * * *  0 .0 0 0 0
T 3 .9 4 8 4 ,4 4 * *  0 .0 0 7 9
E 9 .0 5 7 1 ,1 1 * 0 .0 1 1 9
C 1 6 .9 8 2 1 ,1 1 * *  0 .0 0 1 7
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V a r ia b le F
f r e e d o m
P <
C H * T 1 .7 6 8 7 6 ,8 3 6 * * *  0 .0 0 0 1
C H * E 9 .1 0 6 1 9 ,2 0 9 * * *  0 .0 0 0 0
C H * C 0 .3 7 3 1 9 ,2 0 9 0 .9 9 2 8
T * E 0 .4 3 5 4 ,4 4 0 .7 8 2 3
T * C 0 .3 3 1 4 ,4 4 0 .8 5 5 6
E * C 0 .1 7 0 1,11 0 .6 8 8 2
C H * T * E 1 .2 1 4 7 6 ,8 3 6 0 .1 1 0 5
C H * T * C 0 .9 9 9 7 6 ,8 3 6 0 .4 8 3 5
C H * E * C 0 .8 2 3 1 9 ,2 0 9 0 .6 7 7 9
T * E * C 0 .4 1 5 4 ,4 4 0 .7 9 6 6
C H * T * E * C 1 .4 5 4 7 6 ,8 3 6 * *  0 .0 0 8 9
B e ta 2  P o w e r C H 4 5 .4 0 7 1 9 ,2 0 9 * * *  0 .0 0 0 0
T 4 .7 0 1 4 ,4 4 * *  0 .0 0 3 0
E 3 .0 6 7 1,11 0 .1 0 7 7
C 8 .8 3 9 1 ,11 * 0 .0 1 2 7
C H * T 1 .3 7 9 7 6 ,8 3 6 * 0 .0 2 1 1
C H * E 1 3 .7 7 5 1 9 ,2 0 9 * * *  0 .0 0 0 0
C H * C 0 .9 3 2 1 9 ,2 0 9 0 .5 4 4 2
T * E 0 .5 6 2 4 ,4 4 0 .6 9 0 9
T * C 0 .7 4 4 4 ,4 4 0 .5 6 7 1
E * C 0 .1 9 4 1 ,1 1 0 .6 6 8 1
C H * T * E 0 .7 6 3 7 6 ,8 3 6 0 .9 3 1 8
C H * T * C 1 .2 3 9 7 6 ,8 3 6 0 .0 8 8 6
C H * E * C 0 .8 8 7 1 9 ,2 0 9 0 .5 9 9 5
T * E * C 0 .8 9 2 4 ,4 4 0 .4 7 6 2
C H * T * E * C 1 .1 3 3 7 6 ,8 3 6 0 .2 3 1 4
B e ta 3  P o w e r C H 1 9 .0 2 4 1 9 ,2 0 9 * * *  0 .0 0 0 0
T 3 .2 0 2 4 ,4 4 * 0 .0 2 1 4
E 0 .8 4 8 1 ,11 0 .3 7 6 7
C 3 .0 5 9 1 ,11 0 .1 0 8 1
C H * T 1 .4 0 8 7 6 ,8 3 6 * 0 .0 1 5 3
C H * E 1 0 .1 0 0 1 9 ,2 0 9 * * *  0 .0 0 0 0
C H * C 1 .2 3 4 1 9 ,2 0 9 0 .2 3 2 3
T * E 0 .9 2 5 4 ,4 4 0 .4 5 7 8
T * C 0 .3 9 7 4 ,4 4 0 .8 0 9 3
E * C 0 .7 8 6 1 ,11 0 .3 9 4 1
C H * T * E 0 .7 6 9 7 6 ,8 3 6 0 .9 2 6 2
C H * T * C 1 .4 0 6 7 6 ,8 3 6 * 0 .0 1 5 6
C H * E * C 0 .8 8 0 1 9 ,2 0 9 0 .6 0 8 5
T * E * C 0 .6 6 9 4 ,4 4 0 .6 1 6 9
C H * T * E * C 1 .2 3 2 7 6 ,8 3 6 0 .0 9 4 4
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EEG Peak Frequency
T e s t V a r ia b le F D e g r e e s  o f  
f r e e d o m
P <
- i . r
D e l t a  P F C H 1 5 .8 1 5 1 9 ,2 0 9 * * *  0 .0 0 0 0
T 3 .1 4 6 4 ,4 4 * 0 .0 2 3 1
C 0 .8 2 6 1 ,1 1 0 .3 8 2 7
E 0 .0 5 9 1 ,11 0 .8 1 3 2
C H * T 1 .1 2 6 7 6 ,8 3 6 0 .2 2 3 7
C H * C 5 .0 6 0 1 9 ,2 0 9 * * *  0 .0 0 0 0
C H * E 0 .3 7 8 1 9 ,2 0 9 0 .9 9 2 1
T * C 0 .3 0 8 4 ,4 4 0 .8 7 1 1
T * E 0 .5 8 9 4 ,4 4 0 .6 7 1 9
C * E 3 .3 7 6 1 ,1 1 0 .0 9 3 3
C H * T * C 0 .8 8 3 7 6 ,8 3 6 0 .7 4 9 8
C H * T * E 0 .9 1 2 7 6 ,8 3 6 0 .6 8 8 0
C H * C * E 1 .4 2 6 1 9 ,2 0 9 0 .1 1 7 1
T * C * E 0 .6 0 7 4 ,4 4 0 .6 5 9 1
C H * T * C * E 1 .3 0 1 7 6 ,8 3 6 * 0 .0 4 8 9
T h e t a  P F C H 9 .1 1 1 1 9 ,2 0 9 * * *  0 .0 0 0 0
T 5 .5 0 0 4 ,4 4 * *  0 .0 0 1 1
C 8 .6 4 5 1 ,11 * 0 .0 1 3 5
E 9 .1 7 5 1 ,11 * 0 .0 1 1 5
C H * T 1 .1 5 0 7 6 ,8 3 6 0 .1 8 7 2
C H * C 3 .9 0 9 1 9 ,2 0 9 * * *  0 .0 0 0 0
C H * E 0 .4 9 9 1 9 ,2 0 9 0 .9 6 1 3
T * C 0 .4 7 2 4 ,4 4 0 .7 5 5 8
T * E 0 .6 3 3 4 ,4 4 0 .6 4 1 6
C * E 0 .0 7 2 1 ,11 0 .7 9 3 0
C H * T * C 1 .3 0 1 7 6 ,8 3 6 * 0 .0 4 8 8
C H * T * E 1 .2 0 4 7 6 ,8 3 6 0 .1 2 0 6
C H * C * E 0 .6 6 9 1 9 ,2 0 9 0 .8 4 6 5
T * C * E 1 .9 0 7 4 ,4 4 0 .1 2 5 7
C H * T * C * E 0 .7 9 8 7 6 ,8 3 6 0 .8 9 2 4
A lp h a  P F C H 8 .3 5 1 1 9 ,2 0 9 * * *  0 .0 0 0 0
T 0 .2 2 2 4 ,4 4 0 .9 2 4 5
C 1 .0 8 8 1 ,11 0 .3 1 9 2
E 5 .1 2 5 1 ,1 1 * 0 .0 4 4 8
C H * T 0 .8 3 0 7 6 ,8 3 6 0 .8 4 7 7
C H * C 1 .6 8 3 1 9 ,2 0 9 * 0 .0 4 1 0
C H * E 1 .2 8 2 1 9 ,2 0 9 0 .1 9 7 5
T * C 0 .3 3 0 4 ,4 4 0 .8 5 6 4
T * E 1 .6 7 4 4 ,4 4 0 .1 7 2 5
C * E 0 .9 7 4 1 ,11 0 .3 4 4 7
C H * T * C 0 .7 6 7 7 6 ,8 3 6 0 .9 2 7 6
c h * t * e 1 .2 6 4 7 6 ,8 3 6 0 .0 7 0 0
C H * C * E 1 .0 3 5 1 9 ,2 0 9 0 .4 2 2 4
T * C * E 1 .1 4 0 4 ,4 4 0 .3 4 9 9
C H * T * C * E 0 .9 1 6 7 6 ,8 3 6 0 .6 7 8 9
B e t a l  P F C H 5 .4 3 7 1 9 ,2 0 9 * * *  0 .0 0 0 0
T 0 .6 0 1 4 ,4 4 0 .6 6 3 5
C 2 .0 2 3 1 ,11 0 .1 8 2 6
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E 1 .4 6 0 1 ,11 0 .2 5 2 1
C H * T 1 .1 7 7 7 6 ,8 3 6 0 .1 5 2 1
C H * C 2 .4 1 0 1 9 ,2 0 9 * *  0 .0 0 1 3
C H * E 1 .1 4 9 1 9 ,2 0 9 0 .3 0 4 9
T * C 1 .2 1 8 4 ,4 4 0 .3 1 6 1
T * E 0 .5 8 3 4 ,4 4 0 .6 7 6 5
C * E 0 .2 6 5 1 ,1 1 0 .6 1 7 0
C H * T * C 0 .8 5 7 7 6 ,8 3 6 0 .8 0 1 4
C H * T * E 0 .9 7 2 7 6 ,8 3 6 0 .5 4 7 6
C H * C * E 0 .3 6 1 1 9 ,2 0 9 0 .9 9 4 1
T * C * E 0 .9 8 5 4 ,4 4 0 .4 2 5 2
c h * t * c * e 0 .9 1 0 7 6 ,8 3 6 0 .6 9 2 5
B e t a 2  P F C H 5 .4 1 0 1 9 ,2 0 9 * * *  0 .0 0 0 0
T 1 .2 3 2 4 ,4 4 0 .3 1 0 7
C 0 .9 7 8 1 ,11 0 .3 4 3 9
E 3 .7 4 0 1 ,1 1 0 .0 7 9 3
C H * T 0 .9 8 4 7 6 ,8 3 6 0 .5 2 0 2
C H * C 8 .7 7 5 1 9 ,2 0 9 * * *  0 .0 0 0 0
C H * E 1 .4 6 6 1 9 ,2 0 9 0 .1 0 0 3
T * C 0 .4 8 3 4 ,4 4 0 .7 4 7 5
T * E 0 .3 7 9 4 ,4 4 0 .8 2 2 0
C * E 0 .0 3 4 1 ,1 1 0 .8 5 6 3
c h * t * c 0 .9 8 4 7 6 ,8 3 6 0 .5 1 9 6
C H * T * E 0 .7 5 2 7 6 ,8 3 6 0 .9 4 1 3
C H * C * E 0 .6 3 0 1 9 ,2 0 9 0 .8 8 0 7
T * C * E 0 .8 2 1 4 ,4 4 0 .5 1 8 6
C H * T * C * E 1 .0 3 9 7 6 ,8 3 6 0 .3 9 2 5
B e ta 3  P F C H 1 4 .8 9 2 1 9 ,2 0 9 * * *  0 .0 0 0 0
T 0 .4 5 2 4 ,4 4 0 .7 7 0 5
C 9 .5 8 7 1 ,1 1 * 0 .0 1 0 2
E 0 .0 0 0 1 ,1 1 0 .9 9 6 4
C H * T 1 .1 6 3 7 6 ,8 3 6 0 .1 6 9 9
C H * C 1 .4 7 9 1 9 ,2 0 9 0 .0 9 5 3
C H * E 0 .9 6 1 1 9 ,2 0 9 0 .5 0 9 0
T * C 1 .6 3 0 4 ,4 4 0 .1 8 3 1
T * E 0 .5 4 6 4 ,4 4 0 .7 0 2 6
C * E 3 .6 6 3 1 ,1 1 0 .0 8 2 0
c h * t * c 1 .3 6 7 7 6 ,8 3 6 * 0 .0 2 4 2
C H * T * E 0 .5 6 3 7 6 ,8 3 6 0 .9 9 9 0
C H * C * E 0 .9 6 0 1 9 ,2 0 9 0 .5 0 9 6
T * C * E 2 .4 7 9 4 ,4 4 0 .0 5 7 4
C H * T * C * E 1 .1 6 5 7 6 ,8 3 6 0 .1 6 6 5
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EEG Peak Frequency Power
T e s t V a r ia b le p D e g r e e s  o f  
f r e e d o m
P <
D e lt a  P F P C H 3 9 .9 0 9 1 9 ,2 0 9 * * *  0 .0 0 0 0
T 0 .6 1 1 4 ,4 4 0 .6 5 6 9
C 3 1 .7 6 4 1 ,11 * * *  0 .0 0 0 2
E 0 .9 3 8 M l 0 .3 5 3 4
C H * T 1 .3 6 8 7 6 ,8 3 6 * 0 .0 2 3 9
C H * C 7 .4 2 7 1 9 ,2 0 9 * * *  0 .0 0 0 0
C H * E 0 .7 0 9 1 9 ,2 0 9 0 .8 0 7 6
T * C 2 .1 6 7 4 ,4 4 0 .0 8 8 0
T * E 1 .9 5 4 4 ,4 4 0 .1 1 7 7
C * E 2 .3 0 3 1 ,11 0 .1 5 7 3
C H * T * C 1 .4 2 4 7 6 ,8 3 6 *  0 .0 1 2 6
C H * T * E 0 .7 1 4 7 6 ,8 3 6 0 .9 6 7 9
C H * C * E 1 .2 0 7 1 9 ,2 0 9 0 .2 5 4 1
T * C * E 0 .6 3 0 4 ,4 4 0 .6 4 3 6
C H * T * C * E 1 .0 8 5 7 6 ,8 3 6 0 .2 9 7 7
T h e ta  P F P C H 5 0 .6 6 8 1 9 ,2 0 9 * * *  0 .0 0 0 0
T 1 0 .8 8 5 4 ,4 4 * * *  0 .0 0 0 0
C 1 2 .4 9 6 1 ,11 * *  0 .0 0 4 7
E 9 .8 1 8 1 ,11 * *  0 .0 0 9 6
C H * T 1 .0 0 1 7 6 ,8 3 6 0 .4 7 8 3
C H * C 4 .4 1 5 1 9 ,2 0 9 * * *  0 .0 0 0 0
C H * E 0 .2 4 1 1 9 ,2 0 9 0 .9 9 9 6
T * C 0 .5 0 7 4 ,4 4 0 .7 3 0 9
T * E 0 .6 2 5 4 ,4 4 0 .6 4 7 0
C * E 0 .3 4 7 1 ,11 0 .5 6 7 7
C H * T * C 1 .1 5 3 7 6 ,8 3 6 0 .1 8 3 6
C H * T * E 0 .8 6 8 7 6 ,8 3 6 0 .7 8 0 1
C H * C * E 0 .6 7 5 1 9 ,2 0 9 0 .8 4 1 3
T * C * E 0 .9 9 2 4 ,4 4 0 .4 2 1 2
C H * T * C * E 1 .4 4 0 7 6 ,8 3 6 * 0 .0 1 0 4
A lp h a  P F P C H 7 3 .0 8 2 1 9 ,2 0 9 * * *  0 .0 0 0 0
T 1 6 .8 7 4 4 ,4 4 * * *  0 .0 0 0 0
C 3 8 .9 0 6 1 ,1 1 * * *  0 .0 0 0 1
E 7 .1 0 4 1 ,1 1 * 0 .0 2 2 0
C H * T 0 .7 9 7 7 6 ,8 3 6 0 .8 9 3 8
C H * C 1 3 .0 6 9 1 9 ,2 0 9 * * *  0 .0 0 0 0
C H * E 0 .5 9 0 1 9 ,2 0 9 0 .9 1 1 5
T * C 0 .2 5 7 4 ,4 4 0 .9 0 3 5
T * E 4 .8 6 8 4 ,4 4 * *  0 .0 0 2 4
C * E 8 .7 4 1 1 ,11 * *  0 .0 1 3 1
C H * T * C 1 .4 5 4 7 6 ,8 3 6 * *  0 .0 0 8 8
C H * T * E 1 .4 4 4 7 6 ,8 3 6 * *  0 .0 0 9 9
C H * C * E 0 .5 1 3 1 9 ,2 0 9 0 .9 5 5 3
T * C * E 1 .3 2 7 4 ,4 4 0 .2 7 4 4
C H * T * C * E 1 .1 3 8 7 6 ,8 3 6 0 .2 0 4 7
B e t a l  P F P C H 6 3 .8 5 0 1 9 ,2 0 9 * * *  0 .0 0 0 0
T 3 .4 8 7 4 ,4 4 * 0 .0 1 4 6
C 6 .4 5 5 1 ,11 * 0 .0 2 7 5
E 1 2 .8 9 9 1 ,11 * *  0 .0 0 4 3
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3
V a r ia b le  | F
Df r S d o m f
P <
C H * T 1 .1 9 9 7 6 ,8 3 6 0 .1 2 6 1
C H * C 7 .1 1 0 1 9 ,2 0 9 * * *  0 .0 0 0 0
C H * E 0 .3 7 4 1 9 ,2 0 9 0 .9 9 2 7
T * C 0 .5 9 2 4 ,4 4 0 .6 6 9 6
T * E 0 .0 5 4 4 ,4 4 0 .9 9 4 3
C * E 0 .0 2 3 1 ,11 0 .8 8 2 2
C H * T * C 1 .2 9 2 7 6 ,8 3 6 0 .0 5 3 6
C H * T * E 0 .9 6 9 7 6 ,8 3 6 0 .5 5 5 1
C H * C * E 0 .7 9 4 1 9 ,2 0 9 0 .7 1 3 5
T * C * E 0 .3 6 5 4 ,4 4 0 .8 3 2 4
C H * T * C * E 1 .0 9 5 7 6 ,8 3 6 0 .2 7 8 1
B e ta 2  P o w e r C H 4 3 .6 8 3 1 9 ,2 0 9 * * *  0 .0 0 0 0
T 3 .1 4 5 4 ,4 4 * 0 .0 2 3 1
C 3 .5 7 4 1 ,11 0 .0 8 5 3
E 7 .5 3 8 1 ,11 * 0 .0 1 9 1
C H * T 1 .3 1 8 7 6 ,8 3 6 * 0 .0 4 1 0
C H * C 1 3 .0 3 2 1 9 ,2 0 9 * * *  0 .0 0 0 0
C H * E 0 .9 6 6 1 9 ,2 0 9 0 .5 0 2 3
T * C 0 .3 7 4 4 ,4 4 0 .8 2 5 6
T * E 0 .7 3 9 4 ,4 4 0 .5 7 0 0
C * E 0 .6 2 8 1 ,11 0 .4 4 4 8
C H * T * C 0 .9 0 0 7 6 ,8 3 6 0 .7 1 4 7
C H * T * E 1 .141 7 6 ,8 3 6 0 .2 0 0 9
C H * C * E 0 .9 6 9 1 9 ,2 0 9 0 .4 9 9 3
T * C * E 1 .1 4 0 4 ,4 4 0 .3 4 9 6
C H * T * C * E 1 .1 4 5 7 6 ,8 3 6 0 .1 9 5 0
B e ta S  P o w e r C H 2 1 .8 9 9 1 9 ,2 0 9 * * *  0 .0 0 0 0
T 2 .2 9 3 4 ,4 4 0 .0 7 4 1
C 0 .0 0 6 1 ,11 0 .9 3 7 6
E 2 .1 4 4 1 ,11 0 .1 7 1 1
C H * T 1 .3 3 9 7 6 ,8 3 6 * 0 .0 3 2 9
C H * C 1 0 .8 1 8 1 9 ,2 0 9 * * *  0 .0 0 0 0
C H * E 1 .1 5 7 1 9 ,2 0 9 0 .2 9 7 6
T * C 0 .9 8 6 4 ,4 4 0 .4 2 4 6
T * E 0 .2 4 7 4 ,4 4 0 .9 1 0 0
C * E 0 .0 0 7 1 ,1 1 0 .9 3 5 5
C H * T * C 0 .7 6 5 7 6 ,8 3 6 0 .9 2 9 6
C H * T * E 1 .1 6 9 7 6 ,8 3 6 0 .1 6 1 8
C H * C * E 0 .9 3 2 1 9 ,2 0 9 0 .5 4 4 6
T * C * E 0 .4 0 9 4 ,4 4 0 .8 0 1 2
C H * T * C * E 1 .1 6 0 7 6 ,8 3 6 0 .1 7 3 7
2 6 3
Table A.2 Complete results o f  Analysis o f  Variance for nicotine compared to placebo
T e s t
••
F  V a lu e D e g r e e s  o f  
F r e e d o m
P r o b a b il i t y
C F F C 0 .2 3 1 1 ,1 0 0 .6 4 1 0
T 5 .0 7 0 4 ,4 0 * *  0 .0 0 2 1
C * T 2 .1 6 2 4 ,4 0 0 .0 9 0 4
R R T C 4 .2 2 0 1 ,9 0 .0 7 0 0
T 1 .0 0 4 4 ,3 4 0 .4 1 8 6
0 2 5 .7 1 0 1 ,9 * * *  0 .0 0 0 7
C * T 0 .3 0 6 4 ,3 4 0 .8 7 1 7
T * 0 2 .3 2 5 4 ,3 4 0 .0 7 5 8
M R T C 0 .4 4 7 1 ,9 0 .8 3 7 0
T 3 .5 3 5 4 ,3 4 * 0 .0 1 6 0
0 0 .0 1 4 1 ,9 0 .9 0 9 0
C * T 0 .5 3 7 4 ,3 4 0 .9 9 4 0
T * 0 0 .6 9 4 4 ,3 4 0 .6 0 1 0
T R T C 2 .5 0 7 1 ,9 0 .1 4 7 8
T 2 .1 8 6 4 ,3 4 0 .0 9 2 0
0 2 3 .2 1 9 1 ,9 * * *  0 .0 0 0 9
C * T 0 .2 3 4 4 ,3 4 0 .9 1 7 3
T * 0 2 .3 0 2 4 ,3 4 0 .0 7 8 1
Mood State
T e s t V a r ia b le F  V a lu e D e g r e e s  o f
T”* JF r e e d o m
P r o b a b il i t y
P O M S  C A T 1 .2 0 1 4 ,4 0 0 .3 2 4 7
C 2 .4 3 4 1 ,1 0 0 .1 5 0 0
T * C 1 .1 7 5 4 ,4 0 0 .3 3 5 9
P O M S  A H T 2 .5 3 1 4 ,4 0 0 .0 5 5 0
C 1 .4 8 8 1 ,1 0 0 .2 5 1 0
T * C 1 .1 9 9 4 ,4 0 0 .3 2 5 6
P O M S  E D T 3 .5 2 2 4 ,4 0 * 0 .0 1 4 7
C 0 .0 0 7 1 ,1 0 0 .9 3 5 0
T * C 1 .0 5 2 4 ,4 0 0 .3 9 2 3
P O M S  C U T 0 .6 3 6 4 ,4 0 0 .6 3 9 5
C 0 .4 9 6 1 ,1 0 0 .4 9 7 0
T * C 0 .3 1 4 4 ,4 0 0 .8 6 6 6
P O M S  E T T 1 .2 3 3 4 ,4 0 0 .3 1 1 7
C 1 .3 9 7 1 ,1 0 0 .2 6 5 0
T * C 0 .9 0 6 4 ,4 0 0 .4 6 8 9
P O M S  C C T 0 .3 9 8 4 ,4 0 0 .8 0 8 7
C 0 .3 0 5 1 ,1 0 0 .5 9 3 0
T * D 0 .1 4 9 4 ,4 0 0 .9 6 2 2
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EEG
T e s t V a r ia b le F  V a lu e D e g r e e s  o f  
F r e e d o m
P r o b a b i l i t y
D e lt a  P F E 4 .8 8 5 1 ,1 0 0 .0 5 2 0
T 2 .7 2 2 4 ,4 0 * 0 .0 4 2 5
C 0 .2 0 7 1 ,1 0 0 .6 5 6 0
E * T 0 .6 1 7 4 ,4 0 0 .6 5 2 9
E * C 1 .1 0 5 1 ,1 0 0 .3 1 8 0
T * C 0 .2 7 7 4 ,4 0 0 .8 9 1 0
E * T * C 1 .2 5 4 4 ,4 0 0 .3 0 3 2
T h e ta  P F E 3 .1 5 4 1 ,1 0 0 .0 9 0 0
T 4 .3 1 5 4 ,4 0 0 .0 0 5 3
C 0 .2 6 6 1 ,1 0 0 .6 1 7 0
E * T 1 .0 7 3 4 ,4 0 0 .3 8 2 1
E * C 5 .6 9 7 1 ,1 0 0 .0 3 8 0
T * C 2 .1 1 7 4 ,4 0 0 .0 9 6 0
E * T * C 1 .1 7 9 4 ,4 0 0 .3 3 4 2
A lp h a  P F E 3 .4 4 2 1 ,1 0 0 .0 9 3 0
T 0 .1 0 9 4 ,4 0 0 .9 7 8 8
C 0 .0 1 2 1 ,1 0 0 .9 1 5 0
E * T 0 .2 6 7 4 ,4 0 0 .8 9 7 6
E * C 1 .0 6 4 1 ,1 0 0 .3 2 7 0
T * C 1 .6 4 1 4 ,4 0 0 .1 8 2 2
E * T * C 0 .5 5 6 4 ,4 0 0 .6 9 5 7
B e t a l  P F E 0 .1 5 7 1 ,1 0 0 .7 0 0 0
T 2 .7 6 5 4 ,4 0 * 0 .0 4 0 1
C 0 .0 8 7 1 ,1 0 0 .7 7 4 0
E * T 0 .2 1 1 4 ,4 0 0 .9 3 0 5
E * C 0 .8 5 8 1 ,1 0 0 .3 7 6 0
T * C 4 .7 6 3 4 ,4 0 * *  0 .0 0 3 0
E * T * C 0 .7 1 8 4 ,4 0 0 .5 8 4 4
B e ta 2  P F E 1 .2 6 9 1 ,1 0 0 .2 8 3 0
T 1 .1 6 4 4 ,4 0 0 .3 4 0 5
C 0 .0 1 2 1 ,1 0 0 .9 1 5 0
E * T 0 .3 1 4 4 ,4 0 0 .8 6 7 1
E * C 0 .6 6 0 1 ,1 0 0 .4 3 5 0
T * C 1 .2 5 3 4 ,4 0 0 .3 0 3 8
E * T * C 1 .6 6 8 4 ,4 0 0 .1 7 5 9
B e ta 3  P F E 9 .9 4 3 1 ,1 0 0 .0 1 0 0
T 0 .7 4 0 4 ,4 0 0 .5 6 9 9
C 3 .0 2 7 1 ,1 0 0 .1 1 3 0
E * T 0 .9 3 4 4 ,4 0 0 .4 5 3 3
E * C 0 .0 0 9 1 ,1 0 0 .9 2 6 0
T * C 2 .3 2 1 4 ,4 0 0 .0 7 2 9
E * T * C 0 .2 2 8 4 ,4 0 0 .9 2 0 9
2 6 5
EEG Power
T e s t V a r ia b le F  V a l u e
^ e d o m
P r o b a b il i t y
D e lt a  P o w e r E 1 3 .1 9 8 1 ,1 0 * *  0 .0 0 4 6
T 3 .0 6 3 4 ,4 0 * 0 .0 2 7 0
C 0 .1 5 5 1 ,1 0 0 .7 0 2 0
E * T 0 .5 8 5 4 ,4 0 0 .6 7 5 3
E * C 1 .6 2 8 1 ,1 0 0 .2 3 1 0
T * C 1 .3 1 7 4 ,4 0 0 .2 7 9 6
E * T * C 1 .9 1 6 4 ,4 0 0 .1 2 5 9
T h e ta  P o w e r E 2 1 .4 1 1 1 ,1 0 * * *  0 .0 0 0 9
T 1 1 .3 1 7 4 ,4 0 * * *  0 .0 0 0 0
C 1 .0 4 4 1 ,1 0 0 .3 3 1 0
E * T 0 .3 0 7 4 ,4 0 0 .8 7 1 4
E * C 2 .5 2 6 1 ,1 0 0 .1 4 3 0
T * C 1 .4 6 0 4 ,4 0 0 .2 3 1 9
E * T * C 2 .2 3 0 4 ,4 0 0 .0 8 2 5
A lp h a  P o w e r E 7 5 .1 9 6 1 ,1 0 * * *  0 .0 0 0 0
T 1 4 .0 2 0 4 ,4 0 * * *  0 .0 0 0 0
C 1 .6 5 6 1 ,1 0 0 .2 2 7 0
E * T 2 .4 3 3 4 ,4 0 0 .0 6 2 7
E * C 4 .7 1 3 1 ,1 0 0 .0 5 5 0
T * C 2 .0 9 6 4 ,4 0 0 .0 9 8 8
E * T * C 1 .4 6 4 4 ,4 0 0 .2 3 0 7
B e t a l  P o w e r E 1 2 .1 9 0 1 ,1 0 * *  0 .0 0 5 9
T 8 .5 7 7 4 ,4 0 * * *  0 .0 0 0 0
C 0 .9 1 0 1 ,1 0 0 .3 6 2 0
E * T 1 .6 9 6 4 ,4 0 0 .1 6 9 3
E * C 3 .6 6 2 1 ,1 0 0 .0 8 5 0
T * C 2 .4 1 8 4 ,4 0 0 .0 6 4 0
E * T * C 1 .0 3 1 4 ,4 0 0 .4 0 2 6
B e ta 2  P o w e r E 1 2 .6 2 7 1 ,1 0 * *  0 .0 0 5 2
T 1 2 .2 6 5 4 ,4 0 * * *  0 .0 0 0 0
C 1 .2 4 1 1 ,1 0 0 .2 9 1 0
E * T 0 .7 8 5 4 ,4 0 0 .5 4 1 4
E * C 2 .6 0 9 1 ,1 0 0 .1 3 7 0
T * C 1 .5 3 5 4 ,4 0 0 .2 0 9 9
E * T * C 0 .5 0 5 4 ,4 0 0 .7 3 1 6
B e ta 3  P o w e r E 3 .2 2 2 1 ,1 0 0 .1 0 3 0
T 3 .2 9 8 4 ,4 0 * 0 .0 1 9 8
C 0 .0 0 2 1 ,1 0 0 .9 6 5 0
E * T 1 .0 0 9 4 ,4 0 0 .4 1 3 7
E * C 0 .8 7 3 1 ,1 0 0 .3 7 2 0
T * C 0 .2 2 5 4 ,4 0 0 .9 2 3 0
E * T * C 0 .8 5 8 4 ,4 0 0 .4 9 6 9
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Principal Components EEG Power
T e s t V a r ia b le F  V a lu e D e g r e e s  o f P r o b a b il i t y
D e l t a  P C  1 O p T 1 0 .0 1 7 4 ,4 0 * * *  0 .0 0 0 0
C 0 .4 5 2 1 ,1 0 0 .5 1 6 6
T * C 1 .391 4 ,4 0 0 .2 5 3 8
D e l t a  P C 2  O p T 1 2 .4 7 4 4 ,4 0 * * *  0 .0 0 0 0
C 0 .3 4 0 1 ,1 0 0 .5 7 2 7
T * C 2 .2 5 1 4 ,4 0 0 .0 8 0 1
D e l t a  P C 3  O p T 1 2 .4 5 3 4 ,4 0 * * *  0 .0 0 0 0
C 0 .2 4 9 1 ,1 0 0 .6 2 8 6
T * C 1 .6 9 9 4 ,4 0 0 .1 6 8 6
D e l t a  P C I  C l T 1 .4 0 8 4 ,4 0 0 .2 4 8 3
C 0 .2 2 5 1 ,1 0 0 .6 4 5 4
T * C 1 .5 4 0 4 ,4 0 0 .2 0 8 6
D e l t a  P C 2  C l T 2 .3 2 3 4 ,4 0 0 .0 7 2 7
C 0 .0 8 1 1 ,1 0 0 .7 8 1 8
T * C 2 .8 1 6 4 ,4 0 0 .0 3 7 4
D e l t a  P C 3  C l T 1 .2 7 6 4 ,4 0 0 .2 9 4 8
C 0 .0 0 2 1 ,1 0 0 .2 9 4 8
T * C 1 .7 6 9 4 ,4 0 0 .1 5 3 6
D e l t a  P C I  M T 8 .2 0 2 4 ,4 0 * * *  0 .0 0 0 1
C 0 .9 7 2 1 ,1 0 0 .3 4 7 4
T * C 1 .8 6 4 4 ,4 0 0 .1 3 5 1
D e l t a  P C 2  M T 7 .4 6 0 4 ,4 0 * * *  0 .0 0 0 1
C 0 .2 1 4 1 ,1 0 0 .6 5 3 6
T * C 2 .8 1 3 4 ,4 0 0 .0 3 7 6
D e l t a  P C 3  M T 5 .3 5 7 4 ,4 0 * *  0 .0 0 1 5
C 0 .0 6 1 1 ,1 0 0 .8 0 9 9
T * C 1 .3 2 9 4 ,4 0 0 .2 7 5 2
D e l t a  P C I  D i f f T 8 .8 7 2 4 ,4 0 * * *  0 .0 0 0 0
C 0 .0 6 4 1 ,1 0 0 .8 0 5 4
T * C 1 .0 7 6 4 ,4 0 0 .3 8 0 7
D e l t a  P C 2  D i f f T 1 1 .4 6 3 4 ,4 0 * * *  0 .0 0 0 0
C 0 .1 0 2 1 ,1 0 0 .7 5 6 0
T * C 2 .0 1 9 4 ,4 0 0 .1 0 9 7
D e l t a  P C 3  D i f f T 1 0 .5 2 2 4 ,4 0 * * *  0 .0 0 0 0
C 0 .2 3 6 1 ,1 0 0 .6 3 7 6
T * C 2 .0 4 8 4 ,4 0 0 .1 0 5 4
T h e t a  P C I  O p T 1 0 .0 6 0 4 ,4 0 * * *  0 .0 0 0 0
C 0 .3 4 2 1 ,1 0 0 .5 7 1 6
T * C 1 .4 5 3 4 ,4 0 0 .2 3 3 8
T h e t a  P C 2  O p T 1 1 .8 0 4 4 ,4 0 * * *  0 .0 0 0 0
C 0 .4 7 3 1 ,1 0 0 .5 0 7 2
T * C 2 .4 6 9 4 ,4 0 0 .0 5 9 7
T h e t a  P C 3  O p T 1 2 .4 7 3 4 ,4 0 * * *  0 .0 0 0 0
C 0 .1 5 3 1 ,1 0 0 .7 0 3 9
T * C 1 .2 2 5 4 ,4 0 0 .3 1 5 1
T h e t a  P C I  C l T 7 .1 8 2 4 ,4 0 * * *  0 .0 0 0 2
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T e s t V a r ia b le D e g r e e s  o f  
F r e e d o m
P r o b a b il i t y
C 1 .4 9 4 1 ,1 0 0 .2 4 9 6
T * C 2 .0 0 9 4 ,4 0 0 .1 1 1 2
T h e ta  P C 2  C l T 7 .7 6 1 4 ,4 0 * * *  0 .0 0 0 1
C 1 .7 2 6 1 ,1 0 0 .2 1 8 3
T * C 1 .6 6 1 4 ,4 0 0 .1 7 7 5
T h e ta  P C 3  C l T 7 .8 3 4 4 ,4 0 * * *  0 .0 0 0 1
C 0 .9 2 7 1 ,1 0 0 .3 5 8 3
T * C 1 .6 9 9 4 ,4 0 0 .1 6 8 7
T h e ta  P C I  M T 1 4 .4 8 3 4 ,4 0 * * *  0 .0 0 0 0
C 0 .0 0 7 1 ,1 0 0 .9 3 5 0
T * C 1 .6 7 8 4 ,4 0 0 .1 7 3 5
T h e ta  P C 2  M T 1 5 .3 2 4 4 ,4 0 * * *  0 .0 0 0 0
C 1 .0 3 5 1 ,1 0 0 .3 3 3 0
T * C 2 .3 8 0 4 ,4 0 0 .0 6 7 4
T h e ta  P C 3  M T 1 7 .4 6 1 4 ,4 0 * * *  0 .0 0 0 0
C 0 .0 4 9 1 ,1 0 0 .8 2 9 3
T * C 1 .2 5 6 4 ,4 0 0 .3 0 2 5
T h e ta  P C I  D i f f T 4 .0 0 8 4 ,4 0 * *  0 .0 0 7 9
C 1 .6 2 2 1 ,1 0 0 .2 3 1 6
T * C 1 .4 6 1 4 ,4 0 0 .2 3 1 4
T h e ta  P C 2  D i f f T 3 .4 7 0 4 ,4 0 * 0 .0 1 5 8
C 1 .7 2 0 1 ,1 0 0 .2 1 9 0
T * C 2 .0 3 3 4 ,4 0 0 .1 0 7 6
T h e ta  P C 3  D i f f T 4 .6 1 7 4 ,4 0 * *  0 .0 0 3 7
C 1 .5 4 8 1 ,1 0 0 .2 4 1 8
T * C 1 .4 2 9 4 ,4 0 0 .2 4 1 4
A lp h a  P C I  O p T 1 0 .0 8 0 4 ,4 0 * * *  0 .0 0 0 0
C 0 .2 8 3 1 ,1 0 0 .6 0 6 4
T * C 1 .4 9 0 4 ,4 0 0 .2 2 2 8
A lp h a  P C 2  O p T 1 1 .5 5 4 4 ,4 0 * * *  0 .0 0 0 0
C 0 .3 8 1 1 ,1 0 0 .5 5 0 9
T * C 2 .2 6 7 4 ,4 0 0 .0 7 8 4
A lp h a  P C 3  O p T 1 2 .2 3 7 4 ,4 0 * * *  0 .0 0 0 0
C 0 .0 0 0 1 ,1 0 1 .0 0 0 0
T * C 0 .1 6 6 9 4 ,4 0 0 .1 7 5 5
A lp h a  P C I  C l T 1 .3 5 3 4 ,4 0 0 .2 6 6 6
C 2 .7 7 7 1 ,1 0 0 .1 2 6 6
T * C 1 .2 8 2 4 ,4 0 0 .2 9 2 5
A lp h a  P C 2  C l T 2 .2 8 0 4 ,4 0 0 .0 7 7 1
C 1 .9 9 6 1 ,1 0 0 .1 8 8 1
T * C 1 .7 4 7 4 ,4 0 0 .1 5 8 1
A lp h a  P C 3  C l T 1 .8 1 3 4 ,4 0 0 .1 4 4 8
C 2 .0 2 1 1 ,1 0 0 .1 8 5 6
T * C 1 .6 0 5 4 ,4 0 0 .1 9 1 2
A lp h a  P C I  M T 1 0 .5 9 8 4 ,4 0 * * *  0 .0 0 0 0
C 0 .4 2 3 1 ,1 0 0 .5 3 0 1
T * C 1 .4 3 9 4 ,4 0 0 .2 3 8 3
A lp h a  P C 2  M T 1 4 .1 1 2 4 ,4 0 * * *  0 .0 0 0 0
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T e s t V a r ia b le F  V a lu e D e g r e e s  o f  
F r e e d o m
P r o b a b i l i t y
c 1 .1 3 5 1 ,1 0 0 .3 1 1 8
T * C 2 .3 7 1 4 ,4 0 0 .0 6 8 1
A lp h a  P C S  M T 1 4 .6 8 3 4 ,4 0 * * *  0 .0 0 0 0
C 0 .6 0 6 1 ,1 0 0 .4 5 4 3
T * C 1 .9 5 5 4 ,4 0 0 .1 1 9 6
A lp h a  P C I  D i f f T 2 .5 9 8 4 ,4 0 0 .0 5 0 2
C 1 1 .2 3 5 1 ,1 0 * *  0 .0 0 7 3
T * C 1 .2 8 0 4 ,4 0 0 .2 9 3 5
A lp h a  P C 2  D i f f T 2 .5 3 7 4 ,4 0 0 .0 5 4 5
C 3 .3 8 9 1 ,1 0 0 .0 .9 5 5
T * C 1 .6 6 2 4 ,4 0 0 .1 7 7 3
A lp h a  P C 3  D i f f T 2 .6 9 8 4 ,4 0 0 .0 4 3 9
C 7 .2 7 2 1 ,1 0 * 0 .0 2 2 4
T * C 1 .3 7 9 4 ,4 0 0 .2 5 7 7
B e t a l  P C I  O p T 9 .9 4 5 4 ,4 0 * * *  0 .0 0 0 0
C 0 .3 2 6 1 ,1 0 0 .5 8 0 6
T * C 1 .5 0 1 4 ,4 0 0 .2 1 9 6
B e t a l  P C 2  O p T 1 1 .6 9 7 4 ,4 0 * * *  0 .0 0 0 0
C 0 .6 7 0 1 ,1 0 0 .4 3 2 1
T * C 2 .6 1 0 4 ,4 0 * 0 .0 4 9 4
B e t a l  P C S  O p T 1 2 .8 4 7 4 ,4 0 * * *  0 .0 0 0 0
C 0 .1 1 6 1 ,1 0 0 .7 4 0 5
T * C 1 .2 8 8 4 ,4 0 0 .2 9 0 2
B e t a l  P C I  C l T 2 .4 1 0 4 ,4 0 0 .0 6 4 7
C 1 .3 4 9 1 ,1 0 0 .2 7 2 4
T * C 2 .2 2 3 4 ,4 0 0 .0 8 3 2
B e t a l  P C 2  C l T 4 .7 1 4 4 ,4 0 * *  0 .0 0 3 2
C 1 .4 8 8 1 ,1 0 0 .2 5 0 5
T * C 2 .5 4 5 4 ,4 0 0 .0 5 3 9
B e t a l  P C 3  C l T 3 .6 2 7 4 ,4 0 * 0 .0 1 2 9
C 0 .2 9 1 1 ,1 0 0 .6 0 1 4
T * C 1 .3 9 2 4 ,4 0 0 .2 5 3 5
B e t a l  P C I  M T 1 1 .1 6 7 4 ,4 0 * * *  0 .0 0 0 0
C 0 .0 2 3 1 ,1 0 0 .8 8 2 5
T * C 2 .1 1 0 4 ,4 0 0 .0 9 6 9
B e t a l  P C 2  M T 1 3 .0 8 9 4 ,4 0 * * *  0 .0 0 0 0
C 1 .0 7 0 1 ,1 0 0 .3 2 5 3
T * C 3 .3 2 8 4 ,4 0 * 0 .0 1 9 0
B e t a l  P C 3  M T 1 4 .2 7 5 4 ,4 0 * * *  0 .0 0 0 0
C 0 .0 0 2 1 ,1 0 0 .9 6 5 2
T * C 1 .4 8 8 4 ,4 0 0 .2 2 3 2
B e t a l  P C I  D i f f T 6 .4 2 6 4 ,4 0 * * *  0 .0 0 0 4
C 2 .2 8 9 1 ,1 0 0 .1 6 1 2
T * C 1 .2 5 6 4 ,4 0 0 .3 0 2 5
B e t a l  P C 2  D i f f T 4 .4 3 7 4 ,4 0 * *  0 .0 0 4 6
C 2 .7 0 8 1 ,1 0 0 .1 3 0 9
T * C 1 .2 5 6 4 ,4 0 0 .3 0 2 7
B e t a l  P C S  D i f f T 7 .9 4 7 4 ,4 0 * * *  0 .0 0 0 1
2 6 9
T e s t V a r ia b le F  V a lu e P r o b a b il i t y
C 0 .8 8 0 1 ,1 0 0 .3 7 0 3
T * C 1 .1 1 8 4 ,4 0 0 .3 6 0 7
B e ta 2  P C I  O p T 9 .5 0 1 4 ,4 0 * * *  0 .0 0 0 0
C 0 .3 7 9 1 ,1 0 0 .5 5 1 9
T * C 1 .5 1 1 4 ,4 0 0 .2 1 6 6
B e ta 2  P C 2  O p T 1 1 .9 3 5 4 ,4 0 * * *  0 .0 0 0 0
C 0 .5 3 8 1 ,1 0 0 .4 8 0 1
T * C 2 .5 3 2 4 ,4 0 0 .0 5 4 9
B e ta 2  P C 3  O p T 1 3 .7 8 3 4 ,4 0 * * *  0 .0 0 0 0
C 0 .0 2 8 1 ,1 0 0 .8 7 0 4
T * C 1 .1 4 4 4 ,4 0 0 .3 4 9 1
B e ta 2  P C I  C l T 1 .9 0 4 4 ,4 0 0 .1 2 8 1
C 2 .2 6 4 1 ,1 0 0 .1 6 3 3
T * C 1 .4 4 8 4 ,4 0 0 .2 3 5 5
B e ta 2  P C 2  C l T 7 .0 2 6 4 ,4 0 * * *  0 .0 0 0 2
C 1 .8 9 0 1 ,1 0 0 .1 9 9 2
T * C 1 .8 7 0 4 ,4 0 0 .1 3 4 0
B e ta 2  P C 3  C l T 3 .4 3 8 4 ,4 0 * 0 .0 1 6 5
C 0 .1 5 2 1 ,1 0 0 .7 0 4 8
T * C 0 .7 9 7 4 ,4 0 0 .5 3 3 9
B e ta 2  P C I  M T 1 2 .0 8 7 4 ,4 0 * * *  0 .0 0 0 0
C 0 .0 8 0 1 ,1 0 0 .7 8 3 1
T * C 1 .8 4 5 4 ,4 0 0 .1 3 8 7
B e ta 2  P C 2  M T 1 5 .5 4 1 4 ,4 0 * * *  0 .0 0 0 0
C 1 .1 8 1 1 ,1 0 0 .3 0 2 7
T * C 3 .0 3 3 4 ,4 0 0 .0 2 8 1
B e ta 2  P C 3  M T 1 6 .3 2 3 4 ,4 0 * * *  0 .0 0 0 0
C 0 .0 1 0 1 ,1 0 0 .9 2 2 3
T * C 0 .8 4 7 4 ,4 0 0 .5 0 3 1
B e ta 2  P C I  D i f f T 4 .2 3 1 4 ,4 0 * *  0 .0 0 5 9
C 2 .3 7 5 1 ,1 0 0 .1 5 4 3
T * C 1 .1 9 0 4 ,4 0 0 .3 2 9 2
B e ta 2  P C 2  D i f f T 3 .9 2 0 4 ,4 0 * *  0 .0 0 8 8
C 1 .6 1 4 1 ,1 0 0 .2 3 2 7
T * C 1 .3 9 6 4 ,4 0 0 .2 5 2 3
B e ta 2  P C 3  D i f f T 5 .4 4 2 4 ,4 0 * *  0 .0 0 1 3
C 3 .4 4 4 1 ,1 0 0 .0 9 2 3
T * C 1 .5 1 8 4 ,4 0 0 .2 1 4 6
B e ta 3  P C I  O p T 9 .6 9 2 4 ,4 0 * * *  0 .0 0 0 0
C 0 .3 8 6 1 ,1 0 0 .5 4 8 3
T * C 1 .4 8 8 4 ,4 0 0 .2 2 3 5
B e ta 3  P C 2  O p T 1 2 .3 2 2 4 ,4 0 * * *  0 .0 0 0 0
C 0 .4 8 5 1 ,1 0 0 .5 0 2 0
T * C 2 .4 5 5 4 ,4 0 0 .6 0 8
B e ta 3  P C 3  O p T 1 2 .5 5 1 4 ,4 0 * * *  0 .0 0 0 0
C 0 .5 7 4 1 ,1 0 0 .4 6 6 2
T * C 2 .3 2 1 4 ,4 0 0 .0 7 2 9
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T e s t V a r ia b le F  V a lu e D e g r e e s  o f  
F r e e d o m
P r o b a b il i t y
B e ta 3  P C I  C l T 1 .5 7 0 4 ,4 0 0 .2 0 0 4
C 0 .1 0 6 1 ,1 0 0 .7 5 1 5
T * C 0 .4 0 9 4 ,4 0 0 .8 0 0 6
B e ta S  P C 2  C l T 4 .7 8 1 4 ,4 0 * *  0 .0 0 3 0
C 0 .3 4 2 1 ,1 0 0 .5 7 1 6
T * C 1 .0 3 2 4 ,4 0 0 .4 0 1 9
B e ta S  P C 3  C l T 4 .4 3 6 4 ,4 0 * *  0 .0 0 4 6
C 0 .0 2 5 1 ,1 0 0 .8 7 7 5
T * C 0 .1 1 9 4 ,4 0 0 .9 7 4 9
B e ta S  P C I  M T 1 0 .3 2 1 4 ,4 0 * * *  0 .0 0 0 0
C 0 .3 9 1 1 ,1 0 0 .5 4 5 8
T * C 0 .9 3 2 4 ,4 0 0 .4 5 4 5
B e ta S  P C 2  M T 1 3 .8 0 9 4 ,4 0 * * *  0 .0 0 0 0
C 0 .4 5 5 1 ,1 0 0 .5 1 5 3
T * C 2 .0 6 8 4 ,4 0 0 .1 0 2 6
B e ta S  P C 3  M T 1 0 .8 0 0 4 ,4 0 * * *  0 .0 0 0 0
C 0 .2 3 9 1 ,1 0 0 .6 3 5 5
T * C 1 .1 9 9 4 ,4 0 0 .3 2 5 5
B e ta S  P C I  D i f f T 5 .2 8 7 4 ,4 0 * *  0 .0 0 1 6
C 0 .0 6 3 1 ,1 0 0 .8 0 6 9
T * C 1 .5 5 3 4 ,4 0 0 .2 0 5 1
B e ta 3  P C 2  D i f f T 5 .3 8 8 4 ,4 0 * *  0 .0 0 1 4
C 0 .0 1 3 1 ,1 0 0 .9 1 1 5
T * C 1 .6 5 5 4 ,4 0 0 .1 7 8 9
B e ta S  P C 3  D i f f T 5 .6 9 5 4 ,4 0 * *  0 .0 0 1 0
C 1 .2 4 4 1 ,1 0 0 .2 9 0 8
T * C 1 .2 2 1 4 ,4 0 0 .3 1 6 7
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Principal Components EEG PF
T e s t
-
■
V a r ia b le F  V a lu e D e g r e e s  o f  
F r e e d o m
P r o b a b il i t y
D e l t a  P C  1 O p T 1 0 .0 1 7 4 ,4 0 * * *  0 .0 0 0 0
C 0 .4 5 2 1 ,1 0 0 .5 1 6
T * C 1 .3 9 1 4 ,4 0 0 .2 5 3 8
D e l t a  P C 2  O p T 1 2 .4 7 4 4 ,4 0 * * *  0 .0 0 0 0
C 0 .3 4 0 1 ,1 0 0 .5 7 2 7
T * C 2 .2 5 1 4 ,4 0 0 .0 8 0 1
D e l t a  P C 3  O p T 1 2 .4 5 3 4 ,4 0 * * *  0 .0 0 0 0
C 0 .2 4 9 1 ,1 0 0 .6 2 8 6
T * C 1 .6 9 9 4 ,4 0 0 .1 6 8 6
D e l t a  P C I  C l T 1 .4 0 8 4 ,4 0 0 .2 4 8 3
C 0 .2 2 5 1 ,1 0 0 .6 4 5 4
T * C 1 .5 4 0 4 ,4 0 0 .2 0 8 6
D e l t a  P C 2  C l T 2 .3 2 3 4 ,4 0 0 .0 7 2 7
C 0 .0 8 1 1 ,1 0 0 .7 8 1 8
T * C 2 .8 1 6 4 ,4 0 0 .0 3 7 4
D e l t a  P C 3  C l T 1 .2 7 6 4 ,4 0 0 .2 9 4 8
C 0 .0 0 2 1 ,1 0 0 .9 6 5 2
T * C 1 .7 6 9 4 ,4 0 0 .1 5 3 6
D e l t a  P C I  M T 8 .2 0 2 4 ,4 0 * * *  0 .0 0 0 1
C 0 .9 7 2 1 ,1 0 0 .3 4 7 4
T * C 1 .8 6 4 4 ,4 0 0 .1 3 5 1
D e l t a  P C 2  M T 7 .4 6 0 4 ,4 0 * * *  0 .0 0 0 1
C 0 .2 1 4 1 ,1 0 0 .6 5 3 6
T * C 2 .8 1 3 4 ,4 0 0 .0 3 7 6
D e l t a  P C 3  M T 5 .3 5 7 4 ,4 0 * *  0 .0 0 1 5
C 0 .0 6 1 1 ,1 0 0 .8 0 9 9
T * C 1 .3 2 9 4 ,4 0 0 .2 7 5 2
D e l t a  P C I  D i f f T 8 .8 7 2 4 ,4 0 * * *  0 .0 0 0 0
C 0 .0 6 4 1 ,1 0 0 .8 0 5 4
T * C 1 .0 7 6 4 ,4 0 0 .3 8 0 7
D e l t a  P C 2  D i f f T 1 1 .4 6 3 4 ,4 0 * * *  0 .0 0 0 0
C 0 .1 0 2 1 ,1 0 0 .7 5 6 0
T * C 2 .0 1 9 4 ,4 0 0 .1 0 9 7
D e lt a  P C 3  D i f f T 1 0 .5 2 2 4 ,4 0 * * *  0 .0 0 0 0
C 0 .2 3 6 1 ,1 0 0 .6 3 7 6
T * C 2 .0 4 8 4 ,4 0 0 .1 0 5 4
T h e t a  P C I  O p T 9 .4 7 3 4 ,4 0 * * *  0 .0 0 0 0
C 0 .6 8 1 1 ,1 0 0 .4 2 8 5
T * C 1 .4 8 2 4 ,4 0 0 .2 2 5 0
T h e t a  P C 2  O p T 9 .3 3 1 4 ,4 0 * * *  0 .0 0 0 0
C 1 .2 3 2 1 ,1 0 0 .2 9 3 0
T * C 2 .9 4 6 4 ,4 0 * 0 .0 3 1 5
T h e t a  P C 3  O p T 1 7 .6 5 5 4 ,4 0 * * *  0 .0 0 0 0
C 0 .0 0 1 1 ,1 0 0 .9 7 5 4
T * C 0 .3 6 0 4 ,4 0 0 .8 3 5 2
T h e t a  P C  1 C l T 5 .7 0 8 4 ,4 0 * *  0 .0 0 1 0
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T e s t V a r ia b le F  V a lu e
^ e e c t o m ^
P r o b a b il i t y
C 0 .6 3 5 1 ,1 0 0 .4 4 4 0
T * C 1 .9 8 4 4 ,4 0 0 .1 1 5 0
T h e ta  P C 2  C l T 6 .6 1 4 4 ,4 0 * * *  0 .0 0 0 3
C 1 .7 5 1 1 ,1 0 0 .2 1 5 2
T * C 1 .4 3 3 4 ,4 0 0 .2 4 0 0
T h e t a  P C S  C l T 6 .9 8 6 4 ,4 0 * * *  0 .0 0 0 2
C 0 .4 5 0 1 ,1 0 0 .5 1 7 5
T * C 0 .9 1 0 4 ,4 0 0 .4 6 6 7
T h e ta  P C I  M T 1 3 .0 7 6 4 ,4 0 * * *  0 .0 0 0 0
C 0 .1 0 7 1 ,1 0 0 .7 5 0 3
T * C 1 .7 3 5 4 ,4 0 0 .1 6 0 6
T h e ta  P C 2  M T 1 0 .9 5 8 4 ,4 0 * * *  0 .0 0 0 0
C 1 .4 8 8 1 ,1 0 0 .2 5 0 5
T * C 2 .4 9 3 4 ,4 0 0 .0 5 7 8
T h e ta  P C S  M T 1 9 .9 5 7 4 ,4 0 * * *  0 .0 0 0 0
C 0 .0 9 7 1 ,1 0 0 .7 6 1 9
T * C 0 .2 9 9 4 ,4 0 0 .8 7 6 7
T h e ta  P C I  D i f f T 3 .9 8 8 4 ,4 0 * *  0 .0 0 8 1
C 1 .6 0 9 1 ,1 0 0 .2 3 3 4
T * C 1 .4 5 7 4 ,4 0 0 .2 3 2 6
T h e ta  P C 2  D i f f T 2 .2 8 0 4 ,4 0 0 .0 7 7 1
C 0 .0 0 2 1 ,1 0 0 .9 6 5 2
T * C 2 .3 5 6 4 ,4 0 0 .0 6 9 6
T h e t a  P C 3  D i f f T 5 .6 3 1 4 ,4 0 * *  0 .0 0 1 1
C 0 .8 9 2 1 ,1 0 0 .3 6 7 2
T * C 0 .8 3 8 4 ,4 0 0 .5 0 8 9
A lp h a  P C  1 O p T 9 .2 6 8 4 ,4 0 * * *  0 .0 0 0 0
C 0 .7 4 5 1 ,1 0 0 .4 0 8 3
T * C 1 .2 2 2 4 ,4 0 0 .3 1 6 2
A lp h a  P C 2  O p T 7 .5 3 4 4 ,4 0 * * *  0 .0 0 0 1
C 1 .3 5 3 1 ,1 0 0 .2 7 1 8
T * C 3 .0 7 4 4 ,4 0 0 .0 2 6 6
A lp h a  P C 3  O p T 1 3 .5 5 6 4 ,4 0 * * *  0 .0 0 0 0
C 0 .0 6 3 1 ,1 0 0 .8 0 6 9
T * C 1 .6 5 7 4 ,4 0 0 .1 7 8 5
A lp h a  P C I  C l T 1 .1 0 7 4 ,4 0 0 .3 6 5 9
C 2 .0 4 0 1 ,1 0 0 .1 8 3 7
T * C 1 .1 0 1 4 ,4 0 0 .3 6 8 8
A lp h a  P C 2  C l T 2 .3 8 9 4 ,4 0 0 .0 6 6 6
C 1 .5 9 3 1 ,1 0 0 .2 3 5 5
T * C 1 .4 5 3 4 ,4 0 0 .2 3 4 1
A lp h a  P C 3  C l T 1 .8 2 3 4 ,4 0 0 .1 4 2 9
C 1 .2 4 4 1 ,1 0 0 .2 9 0 8
T * C 2 .3 8 5 4 ,4 0 0 .0 6 6 9
A lp h a  P C I  M T 8 .8 1 8 4 ,4 0 * * *  0 .0 0 0 0
C 0 .1 0 0 1 ,1 0 0 .7 5 8 3
T * C 1 .1 6 8 4 ,4 0 0 .3 3 8 8
A lp h a  P C 2  M T 6 .7 9 1 4 ,4 0 * * *  0 .0 0 0 3
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T e a V a r ia b le F  V a lu e
_
P r o b a b il i t y
C 1 .5 1 6 1 ,1 0 0 .2 4 6 4
T * C 2 .5 5 5 4 ,4 0 0 .0 5 3 2
A lp h a  P C 3  M T 1 7 .0 1 2 4 ,4 0 * * *  0 .0 0 0 0
C 0 .5 3 0 1 ,1 0 0 .4 8 3 3
T * C 2 .5 5 0 4 ,4 0 0 .0 5 3 5
A lp h a  P C I  D i f f T 2 .5 8 7 3 4 ,4 0 0 .0 5 1 9
C 1 7 .1 5 7 1 ,1 0 * *  0 .0 0 2 0
T * C 1 .1 1 3 4 ,4 0 0 .3 6 3 4
A lp h a  P C 2  D i f f T 1 .6 8 9 4 ,4 0 0 .1 7 1 0
C 0 .6 7 6 1 ,1 0 0 .4 3 0 1
T * C 2 .0 7 4 4 ,4 0 0 .1 0 1 8
A lp h a  P C 3  D i f f T 2 .6 5 5 4 ,4 0 * 0 .0 4 6 5
C 3 .1 8 7 1 ,1 0 0 .1 0 4 5
T * C 1 .5 7 8 4 ,4 0 0 .1 9 8 3
B e t a l  P C I  O p T 9 .6 2 6 4 ,4 0 * * *  0 .0 0 0 0
C 0 .4 5 6 1 ,1 0 0 .5 1 4 8
T * C 1 .4 5 6 4 ,4 0 0 .2 3 0 2
B e t a l  P C 2  O p T 7 .2 8 8 4 ,4 0 * * *  0 .0 0 0 2
C 1 .3 2 2 1 ,1 0 0 .2 7 7 0
T * C 3 .5 1 1 4 ,4 0 0 .0 1 5 0
B e t a l  P C 3  O p T 1 7 .6 5 5 4 ,4 0 * * *  0 .0 0 0 0
C 0 .0 0 1 1 ,1 0 0 .9 7 5 4
T * C 0 .3 6 0 4 ,4 0 0 .8 3 5 2
B e t a l  P C I  C l T 1 .9 0 7 4 ,4 0 0 .1 2 7 5
C 1 .2 1 5 1 ,1 0 0 .2 9 6 2
T * C 2 .1 4 7 4 ,4 0 0 .0 9 2 2
B e t a l  P C 2  C l T 4 .5 4 4 4 ,4 0 * *  0 .0 0 4 0
C 1 .4 8 1 1 ,1 0 0 .2 5 1 6
T * C 1 .7 8 3 4 ,4 0 0 .1 5 0 8
B e t a l  P C 3  C l T 3 .1 4 1 4 ,4 0 * 0 .0 2 4 3
C 0 .4 0 1 1 ,1 0 0 .5 4 0 8
T * C 0 .6 8 6 4 ,4 0 0 .6 0 5 2
B e t a l  P C I  M T 1 0 .5 7 4 4 ,4 0 * * *  0 .0 0 0 0
C 0 .0 0 0 1 ,1 0 1 .0 0 0 0
T * C 2 .0 6 1 4 ,4 0 0 .1 0 3 7
B e t a l  P C 2  M T 7 .5 3 5 4 ,4 0 * * *  0 .0 0 0 1
C 1 .4 1 6 1 ,1 0 0 .2 6 1 5
T * C 3 .2 3 1 4 ,4 0 0 .0 2 1 6
B e t a l  P C 3  M T 1 4 ..5 4 1 4 ,4 0 * * *  0 .0 0 0 0
C 0 .0 8 2 1 ,1 0 0 .7 8 0 4
T * C 0 .3 8 2 4 ,4 0 0 .8 1 9 8
B e t a l  P C I  D i f f T 6 .3 8 5 4 ,4 0 * * *  0 .0 0 0 4
C 2 .2 9 7 1 ,1 0 0 .1 6 0 6
T * C 1 .2 5 2 4 ,4 0 0 .3 0 4 0
B e t a l  P C 2  D i f f T 2 .3 1 3 4 ,4 0 0 .0 7 3 7
C 0 .0 0 6 1 ,1 0 0 .9 3 9 8
T * C 1 .5 1 4 4 ,4 0 0 .2 1 5 8
B e t a l  P C 3  D i f f T 1 0 .4 0 4 4 ,4 0 * * *  0 .0 0 0 0
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T e s t V a r ia b le F  V a lu e
DS m f
C 0 .2 4 5 1 ,1 0 0 .6 3 1 3
T * C 0 .6 8 5 4 ,4 0 0 .6 0 5 9
B e ta 2  P C  1 O p T 8 .7 3 0 4 ,4 0 * * *  0 .0 0 0 0
C 0 .7 1 9 1 ,1 0 0 .4 1 6 3
T * C 1 .4 1 1 4 ,4 0 0 .2 4 7 3
B e ta 2  P C 2  O p T 9 .3 3 1 4 ,4 0 * * *  0 .0 0 0 0
C 1 .2 3 2 1 ,1 0 0 .2 9 3 0
T * C 2 .9 4 6 4 ,4 0 * 0 .0 3 1 5
B e ta 2  P C 3  O p T 1 7 .6 5 5 4 ,4 0 * * *  0 .0 0 0 0
C 0 .0 0 1 1 ,1 0 0 .9 7 5 4
T * C 0 .3 6 0 4 ,4 0 0 .8 3 5 2
B e ta 2  P C I  C l T 1 .0 7 2 4 ,4 0 0 .3 8 2 3
C 0 .7 7 4 1 ,1 0 0 .3 9 9 6
T * C 1 .2 4 9 4 ,4 0 0 .3 0 5 5
B e ta 2  P C 2  C l T 7 .2 8 9 4 ,4 0 * * *  0 .0 0 0 2
C 1 .8 7 8 1 ,1 0 0 .2 0 0 5
T * C 1 .3 1 0 4 ,4 0 0 .2 8 2 2
B e ta 2  P C 3  C l T 2 .4 3 1 4 ,4 0 0 .0 6 2 9
C 0 .0 0 0 1 ,1 0 1 .0 0 0 0
T * C 0 .6 0 6 4 ,4 0 0 .6 6 0 3
B e ta 2  P C I  M T 9 .9 0 7 4 ,4 0 * * *  0 .0 0 0 0
C 0 .0 3 5 1 ,1 0 0 .8 5 5 3
T * C 1 .5 5 4 4 ,4 0 0 .2 0 4 7
B e ta 2  P C 2  M T 1 0 .7 0 4 4 ,4 0 * * *  0 .0 0 0 0
C 1 .5 9 7 1 ,1 0 0 .2 3 5 0
T * C 2 .7 6 4 4 ,4 0 0 .0 4 0 2
B e ta 2  P C 3  M T 1 4 .0 5 0 4 ,4 0 * * *  0 .0 0 0 0
C 0 .0 0 1 1 ,1 0 0 .9 7 5 4
T * C 0 .3 7 4 4 ,4 0 0 .8 2 5 9
B e ta 2  P C I  D i f f T 4 .1 6 2 4 ,4 0 * *  0 .0 0 6 5
C 2 .0 8 2 1 ,1 0 0 .1 7 9 6
T * C 1 .1 8 8 4 ,4 0 0 .3 3 0 1
B e ta 2  P C 2  D i f f T 3 .0 8 1 4 ,4 0 * 0 .0 2 6 3
C 0 .2 3 1 1 ,1 0 0 .6 4 1 1
T * C 1 .4 2 9 4 ,4 0 0 .2 4 1 3
B e ta 2  P C 3  D i f f T 5 .5 3 7 4 ,4 0 * *  0 .0 0 1 2
C 0 .0 0 0 1 ,1 0 1 .0 0 0 0
T * C 0 .7 0 3 4 ,4 0 0 .5 9 4 3
B e ta 3  P C I  O p T 9 .4 7 3 4 ,4 0 * * *  0 .0 0 0 0
C 0 .6 8 1 1 ,1 0 0 .4 2 8 5
T * C 1 .4 8 2 4 ,4 0 0 .2 2 5 0
B e ta 3  P C 2  O p T 1 0 .7 2 2 4 ,4 0 * * *  0 .0 0 0 0
C 1 .2 5 3 1 ,1 0 0 .2 8 9 1
T * C 2 .7 3 9 4 ,4 0 0 .0 1 6
B e ta 3  P C 3  O p T 6 .8 8 2 4 ,4 0 * * *  0 .0 0 0 0
C 1 .3 1 3 1 ,1 0 0 .2 7 8 5
T * C 2 .0 6 1 4 ,4 0 0 .6 2 0 1
2 7 5
T e s t V a r ia b le F  V a lu e D e g r e e s  o f  
F r e e d o m
P r o b a b i l i t y
B e ta 3  P C I  C l T 1 .0 8 8 4 ,4 0 0 .3 7 4 9
C 0 .1 8 0 1 ,1 0 0 .6 8 0 4
T * C 0 .4 2 8 4 ,4 0 0 .7 8 7 6
B e ta S  P C 2  C l T 3 .6 2 5 4 ,4 0 * 0 .0 1 2 9
C 0 .7 0 7 1 ,1 0 0 .4 2 0 1
T * C 1 .6 9 3 4 ,4 0 0 .1 7 0 1
B e ta 3  P C S  C l T 3 .7 0 4 4 ,4 0 * 0 .0 1 1 6
C 0 .0 2 0 1 ,1 0 0 .8 9 0 3
T * C 0 .1 5 5 4 ,4 0 0 .9 5 9 7
B e ta 3  P C I  M T 9 .2 5 4 4 ,4 0 * * *  0 .0 0 0 0
C 0 .6 5 1 1 ,1 0 0 .4 3 8 5
T * C 0 .8 2 1 4 ,4 0 0 .5 1 8 8
B e ta S  P C 2  M T 1 0 .3 8 0 4 ,4 0 * * *  0 .0 0 0 0
C 1 .0 4 5 1 ,1 0 0 .3 3 0 8
T * C 2 .5 8 1 4 ,4 0 0 .0 5 1 3
B e ta S  P C 3  M T 6 .0 0 6 4 ,4 0 * * *  0 .0 0 0 7
C 0 .5 2 7 1 ,1 0 0 .4 8 4 5
T * C 0 .9 6 1 4 ,4 0 0 .4 3 9 0
B e ta S  P C I  D i f f T 5 .3 0 7 4 ,4 0 * *  0 .0 0 1 6
C 0 .1 5 2 1 ,1 0 0 .7 0 4 8
T * C 1 .6 7 1 4 ,4 0 0 .1 7 5 1
B e ta 3  P C 2  D i f f T 4 .0 5 5 4 ,4 0 * *  0 .0 0 7 4
C 0 .3 6 1 1 ,1 0 0 .5 6 1 3
T * C 1 .2 0 2 4 ,4 0 0 .3 2 5 4
B e ta 3  P C S  D i f f T 2 .7 9 4 4 ,4 0 * 0 .0 3 8 6
C 5 .0 4 8 1 ,1 0 * 0 .0 4 8 4
T * C 0 .6 6 6 4 ,4 0 0 .6 1 9 2
2 7 6
T a b le  A .3  C o m p le t e  A n a ly s i s  o f  V a r ia n c e  r e s u lts  f o r  G B E  c o m p a r e d  w ith  p l a c e b o
T e s t; ■ , ' . > : • V a r ia b le F  v a lu e D e g r e e s  o f  
F r e e d o m
P r o b a b il i t y
C F F T 0 .7 4 8 3 ,3 0 0 .5 3 1 0
C 0 .0 1 5 1 ,1 0 0 .9 0 5 0
T * C 1 .1 9 4 3 ,3 0 0 .3 2 7 4
R R T T 1 .5 7 2 3 ,2 7 0 .2 1 7 8
C 1 .6 6 2 1 ,9 0 .2 2 9 0
T * C 2 .0 3 2 3 ,2 5 0 .1 3 4 0
M R T T 5 .2 1 1 3 ,2 7 * *  0 .0 0 5 6
C 3 .5 9 4 1 ,9 0 .0 9 0 0
T * C 0 .2 5 1 3 ,2 5 0 .8 5 9 8
T R T T 5 .7 9 6 3 ,2 7 * *  0 .0 0 3 3
C 0 .0 2 5 1 ,9 0 .8 7 8 0
T * C 2 .5 7 8 3 ,2 5 0 .0 7 5 4
C T T  S c o r e C 0 .0 1 2 1 ,1 0 0 .9 1 5 0
T 4 .7 2 4 3 ,3 0 * *  0 .0 0 8 0
C * T 0 .1 1 6 3 ,3 0 0 .9 4 9 9
C T T  R T C 3 .3 7 8 1 ,1 0 0 .0 9 6 0
T 3 .3 3 0 3 ,3 0 * 0 .0 3 2 2
C * T 0 .7 4 9 3 ,3 0 0 .5 3 0 5
S T M  A b s e n t  N u m b e r N 0 .8 5 9 2 ,2 0 0 .4 3 5 3
T 0 .8 6 5 3 ,3 0 0 .4 6 8 8
C 1 .0 0 3 1 ,1 0 0 .3 4 0 0
N * T 1 .5 8 0 6 ,6 1 0 .1 6 8 1
N * C 0 .4 7 0 2 ,2 1 0 .6 2 9 7
T * C 0 .4 2 0 3 ,3 1 0 .7 3 9 3
N * T * C 1 .3 4 3 6 ,6 8 0 .2 5 0 1
S T M  P r e s e n t  N u m b e r N 6 .5 3 9 2 ,2 0 * *  0 .0 0 6 3
T 0 .5 7 4 3 ,3 0 0 .6 3 5 7
C 6 .7 0 8 1 ,1 0 * 0 .0 2 7 0
N * T 1 .2 4 0 6 ,6 1 0 .2 9 8 6
N * C 1 .1 6 5 2 ,2 1 0 .3 2 7 6
T * C 2 .6 6 6 3 ,3 1 0 .0 6 4 3
N * T * C 0 .5 2 7 6 ,6 8 0 .7 8 6 1
S T M  P re s e n t  R T N 6 8 .9 0 4 2 ,2 2 * * *  0 .0 0 0 0
T 0 .1 8 0 3 ,3 3 0 .9 0 9 1
C 0 .0 5 0 1 ,9 0 .8 2 8 0
N * T 0 .3 1 2 6 ,6 6 0 .9 2 8 4
N * C 6 .0 7 1 2 ,1 8 * *  0 .0 0 9 3
T * C 0 .1 5 2 3 ,2 7 0 .9 2 7 6
N * T * C 0 .6 2 6 6 ,5 6 0 .7 0 8 3
S T M  A b s e n t  R T N 5 3 .7 6 4 2 ,2 0 * * * 0 . 0 0 0 0
T 0 .5 8 4 3 ,3 0 0 .6 2 9 3
C 1 .1 6 8 1 ,1 0 0 .3 0 5 0
N * T 0 .7 5 5 6 ,6 1 0 .6 0 7 9
N * C 2 .0 2 4 2 ,2 1 0 .1 5 4 0
T * C 1 .0 3 0 3 ,3 1 0 .3 9 1 7
N * T * C 1 .5 4 3 6 ,6 8 0 .1 7 7 3
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M ood State
r e s , V a r ia b le F  v a lu e D e g r e e s  o f  
F r e e d o m
P r o b a b i l i t y
P O M S  C A T 0 .4 7 7 3 ,3 0 0 .7 0 0 2
C 0 .0 2 0 1 ,1 0 0 .8 9 0 0
T * C 0 .2 1 7 3 ,2 9 0 .8 8 3 5
P O M S  A H T 3 .9 1 9 3 ,3 0 *  0 .0 1 7 6
C 0 .1 7 1 1 ,1 0 0 .6 8 8 0
T * C 0 .0 4 5 3 ,2 9 0 .9 8 6 9
P O M S  E D T 3 .8 8 7 3 ,3 0 * 0 .0 1 8 2
C 0 .1 8 4 1 ,1 0 0 .6 7 7 0
T * C 0 .1 0 6 3 ,2 9 0 .9 5 6 0
P O M S  C U T 4 .9 6 6 3 ,3 0 * *  0 .0 0 6 3
C 0 .0 0 3 1 ,1 0 0 .9 5 7 0
T * C 0 .2 5 1 3 ,2 9 0 .8 5 9 8
P O M S  E T T 3 .5 5 6 3 ,3 0 *  0 .0 2 5 2
C 0 .0 1 0 1 ,1 0 0 .9 2 2 0
T * C 0 .4 0 4 3 ,2 9 0 .7 5 0 8
P O M S  C C T 4 .8 8 5 3 ,3 0 * *  0 .0 0 6 9
C 0 .0 3 7 1 ,1 0 0 .8 5 1 0
T * C 0 .6 5 7 3 ,2 9 0 .5 8 4 1
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EEG Power
T e s t V a r ia b le F  v a lu e
^ r e e d o n T
A lp h a  P o w e r T 1 4 0 .0 9 9 3 ,3 0 * * *  0 .0 0 0 0
C 0 .5 0 6 1 ,1 0 0 .4 9 3 0
E 6 .8 4 3 1 ,1 0 * 0 .0 2 6 0
T * C 1 .9 5 8 3 ,3 0 0 .1 4 0 5
T * E 0 .7 0 1 3 ,3 0 0 .5 5 7 8
C * E 2 .3 0 0 1 ,1 0 0 .1 6 0 0
T * C * E 0 .1 6 2 3 ,3 0 0 .9 2 1 1
T h e ta  P o w e r T 2 4 .3 6 7 3 ,3 0 * * *  0 .0 0 0 0
C 0 .4 0 1 1 ,1 0 0 .5 4 1 0
E 9 .2 6 6 1 ,1 0 *  0 .0 1 2 0
T * C 2 .0 2 8 3 ,3 0 0 .1 3 0 0
T * E 1 .4 3 6 3 ,3 0 0 .2 5 0 5
C * E 0 .0 3 8 1 ,1 0 0 .8 4 9 0
T * C * E 5 .6 3 9 3 ,3 0 * *  0 .0 0 3 4
D e lt a  P o w e r T 1 0 .7 9 4 3 ,3 0 * * *  0 .0 0 0 1
C 1 .1 2 3 1 ,1 0 0 .3 1 4 0
E 5 .4 3 0 1 ,1 0 * 0 .0 4 2 0
T * C 0 .3 3 7 3 ,3 0 0 .7 9 8 2
T * E 1 .7 9 0 3 ,3 0 0 .1 6 9 1
C * E 0 .0 4 7 1 ,1 0 0 .8 3 3 0
T * C * E 4 .9 6 1 3 ,3 0 * *  0 .0 0 6 4
B e t a l  P o w e r T 1 8 .1 0 1 3 ,3 0 * * *  0 .0 0 0 0
C 0 .9 1 8 1 ,1 0 0 .3 6 1 0
E 3 .0 6 5 1 ,1 0 0 .1 1 1 0
T * C 0 .2 9 7 3 ,3 0 0 .8 2 7 0
T * E 0 .3 2 6 3 ,3 0 0 .8 0 6 5
C * E 0 .9 9 0 1 ,1 0 0 .3 4 3 0
T * C * E 0 .2 6 5 3 ,3 0 0 .8 4 9 7
B e ta  2  P o w e r T 2 9 .3 3 8 3 ,3 0 * * *  0 .0 0 0 0
C 0 .0 9 1 1 ,1 0 0 .7 6 9 0
E 3 .2 4 8 1 ,1 0 0 .1 0 2 0
T * C 2 .1 3 8 3 ,3 0 0 .1 1 5 3
T * E 1 .1 7 3 3 ,3 0 0 .3 3 5 1
C * E 1 .2 9 5 1 ,1 0 0 .2 8 2 0
T * C * E 1 .3 9 5 3 ,3 0 0 .2 6 2 3
B e ta 3  P o w e r T 4 .8 4 6 3 ,3 0 * *  0 .0 0 7 1
C 0 .0 1 6 1 ,1 0 0 .9 0 2 0
E 2 .9 6 8 1 ,1 0 0 .1 1 6 0
T * C 1 .3 5 0 3 ,3 0 0 .2 7 5 6
T * E 0 .9 2 2 3 ,3 0 0 .4 4 0 8
C * E 0 .1 8 4 1 ,1 0 0 .6 7 7 0
T * C * E 1 .0 6 2 3 ,3 0 0 .3 7 8 4
2 7 9
EEGPF
T e s t V a r ia b le F  v a lu e n  r
F r e e d o m
P r o b a b il i t y
D e lta  P F C H 1 5 .0 0 2 1 9 ,1 9 0 * * *  0 .0 0 0 0
T 1 .0 5 3 3 ,3 0 0 .3 8 2 1
E 6 .5 2 7 1 ,1 0 * 0 .0 2 9 0
C 0 .4 9 6 1 ,1 0 0 .4 9 7 0
C H * T 1 .1 7 5 5 7 ,5 7 0 0 .1 8 6 9
C H * E 3 .2 1 5 1 9 ,1 9 0 * * *  0 .0 0 0 0
C H * C 0 .7 1 8 1 9 ,1 9 0 0 .7 9 7 5
T * E 2 .2 0 4 3 ,3 0 0 .1 0 7 2
T * C 1 .1 8 2 3 ,3 0 0 .3 3 2 0
E * C 0 .0 6 8 1 ,1 0 0 .8 0 0 0
C H * T * E 1 .0 5 6 5 7 ,5 7 0 0 .3 7 0 6
C H * T * C 0 .5 9 2 5 7 ,5 7 0 0 .9 9 2 4
C H * E * C 0 .5 9 1 1 9 ,1 9 0 0 .9 1 0 1
T * E * C 0 .3 0 7 3 ,3 0 0 .8 2 0 2
C H * T * E * C 0 .6 7 3 5 7 ,5 7 0 0 .9 6 8 2
T h e ta  P F C H 8 .5 7 0 1 9 ,1 9 0 * * *  0 .0 0 0 0
T 4 .4 6 2 3 ,3 0 * 0 .0 1 0 3
E 1 1 .9 4 9 1 ,1 0 * *  0 .0 0 6 0
C 1 .0 2 0 1 ,1 0 0 .3 3 6 0
C H * T 0 .9 6 2 5 7 ,5 7 0 0 .5 5 6 7
C H * E 3 .3 5 2 1 9 ,1 9 0 * * *  0 .0 0 0 0
C H * C 0 .8 9 7 1 9 ,1 9 0 0 .5 8 7 5
T * E 0 .8 0 2 3 ,3 0 0 .5 0 1 6
T * C 0 .8 1 7 3 ,3 0 0 .4 9 3 4
E * C 8 .1 4 3 1 ,1 0 * 0 .0 1 7 0
C H * T * E 0 .7 6 2 5 7 ,5 7 0 0 .8 9 8 9
C H * T * C 1 .1 3 3 5 7 ,5 7 0 0 .2 4 2 2
C H * E * C 1 .1 0 7 1 9 ,1 9 0 0 .3 4 6 4
T * E * C 0 .8 1 4 3 ,3 0 0 .4 9 4 9
C H * T * E * C 1 .3 4 4 5 7 ,5 7 0 0 .0 5 2 6
A lp h a  P F C H 6 .1 1 1 1 9 ,1 9 0 * * *  0 .0 0 0 0
T 0 .9 8 8 3 ,3 0 0 .4 1 0 6
E 2 .0 9 3 1 ,1 0 0 .1 7 8 0
C 0 .0 9 5 1 ,1 0 0 .7 6 4 0
C H * T 1 .0 5 4 5 7 ,5 7 0 0 .3 7 3 4
C H * E 1 .3 5 1 1 9 ,1 9 0 0 .1 5 6 0
C H * C 1 .5 0 9 1 9 ,1 9 0 0 .0 8 5 8
T * E 0 .7 0 7 3 ,3 0 0 .5 5 4 4
T * C 0 .6 1 2 3 ,3 0 0 .6 1 2 0
E * C 0 .2 3 6 1 ,1 0 0 .6 3 8 0
C H * T * E 0 .8 2 8 5 7 ,5 7 0 0 .8 1 1 2
C H * T * C 1 .0 3 1 5 7 ,5 7 0 0 .4 1 7 7
C H * E * C 1 .3 1 1 1 9 ,1 9 0 0 .1 7 9 9
T * E * C 0 .7 9 3 3 ,3 0 0 .5 0 6 1
C H * T * E * C 0 .9 9 7 5 7 ,5 7 0 0 .4 8 3 9
B e t a l  P F C H 6 .7 4 7 1 9 ,1 9 0 * * *  0 .0 0 0 0
T 1 .6 4 4 3 ,3 0 0 .1 9 8 9
E 0 .0 7 9 1 ,1 0 0 .7 8 4 0
C 0 .1 5 0 1 ,1 0 0 .7 0 7 0
2 8 0
T e s t
V a r ia b le F  v a lu e D e g r e e s  o f  
F r e e d o m '
C H * T 1 .0 6 4 5 7 ,5 7 0 0 .3 5 5 9
C H * E 1 .0 9 6 1 9 ,1 9 0 0 .3 5 7 9
C H * C 0 .7 4 1 1 9 ,1 9 0 0 .7 7 3 1
T * E 0 .8 1 0 3 ,3 0 0 .4 9 7 0
T * C 0 .2 7 9 3 ,3 0 0 .8 4 0 0
E * C 0 .1 5 4 1 ,1 0 0 .7 0 3 0
C H * T * E 0 .7 6 9 5 7 ,5 7 0 0 .8 9 1 3
C H * T * C 0 .6 5 0 5 7 ,5 7 0 0 .9 7 7 9
C H * E * C 1 .0 1 2 1 9 ,1 9 0 0 .4 4 8 6
T * E * C 3 .7 6 4 3 ,3 0 * 0 .0 2 0 6
C H * T * E * C 0 .7 3 8 5 7 ,5 7 0 0 .9 2 3 6
B e ta 2  P F C H 1 .1 8 0 1 9 ,1 9 0 0 .2 7 8 3
T 1 .6 3 2 3 ,3 0 0 .2 0 1 5
E 1 .1 4 1 1 ,1 0 0 .7 1 5 0
C 0 .0 1 0 1 ,1 0 0 .9 2 2 0
C H * T 0 .9 1 1 5 7 ,5 7 0 0 .6 5 9 6
C H * E 4 .4 5 8 1 9 ,1 9 0 * * *  0 .0 0 0 0
C H * C 1 .0 4 8 1 9 ,1 9 0 0 .4 0 8 1
T * E 0 .4 2 9 3 ,3 0 0 .7 3 3 1
T * C 0 .3 6 7 3 ,3 0 0 .7 7 7 0
E * C 0 .9 4 0 1 ,1 0 0 .3 5 5 0
C H * T * E 0 .5 1 8 5 7 ,5 7 0 0 .9 9 8 7
C H * T * C 0 .7 4 9 5 7 ,5 7 0 0 .9 1 2 6
C H * E * C 0 .8 6 6 1 9 ,1 9 0 0 .6 2 5 7
T * E * C 0 .3 8 1 3 ,3 0 0 .7 6 7 1
c h * t * e * c 1 .3 6 7 5 7 ,5 7 0 * 0 .0 4 3 4
B e ta S  P F C H 1 0 .8 6 8 1 9 ,1 9 0 * * *  0 .0 0 0 0
T 1 .3 5 5 3 ,3 0 0 .2 7 3 9
E 1 0 .5 0 7 1 ,1 0 * *  0 .0 0 9 0
C 0 .0 1 3 1 ,1 0 0 .9 1 1 0
C H * T 0 .7 4 2 5 7 ,5 7 0 0 .9 1 9 4
C H * E 2 .2 4 9 1 9 ,1 9 0 * *  0 .0 0 3 1
C H * C 1 .1 2 4 1 9 ,1 9 0 0 .3 3 0 0
T * E 0 .0 7 0 3 ,3 0 0 .9 7 5 3
T * C 1 .1 5 5 3 ,3 0 0 .3 4 1 9
E * C 0 .1 4 1 1 ,1 0 0 .7 1 5 0
C H * T * E 0 .8 9 3 5 7 ,5 7 0 0 .6 9 6 2
C H * T * C 0 .9 6 1 5 7 ,5 7 0 0 .5 5 7 7
C H * E * C 0 .6 9 5 1 9 ,1 9 0 0 .8 2 1 4
T * E * C 0 .4 8 1 3 ,3 0 0 .6 9 7 2
C H * T * E * C 1 .4 6 6 5 7 ,5 7 0 *  0 .0 1 7 7
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Principal Components EEG
T e s t V a r ia b le F  V a lu e ftEtaf P r o b a b i l i t y
D e lta  P C I T 1 .3 5 0 2 ,2 2 0 .2 7 5 7
E 8 .1 7 5 1 ,1 1 * 0 .0 1 5 5
C 0 .6 4 0 2 ,2 2 0 .5 3 6 8
T * E 0 .2 1 6 1 ,11 0 .8 8 4 5
T * C 0 .8 1 5 2 ,2 2 0 .4 5 5 6
E * C 2 .5 7 5 1 ,11 0 .1 3 6 9
T * E * C 1 .0 5 0 2 ,2 2 0 .3 8 3 7
D e lta  P C 2 T 0 .2 0 2 2 ,2 2 0 .8 9 3 9
E 0 .3 3 7 1 ,11 0 .5 7 3 3
C 0 .5 1 6 2 ,2 2 0 .6 0 4 0
T * E 0 .2 8 2 1 ,11 0 .8 3 7 7
T * C 0 .3 1 8 2 ,2 2 0 .8 1 2 1
E * C 0 .0 7 0 1 ,1 1 0 .7 9 6 2
T * E * C 0 .2 1 1 2 ,2 2 0 .8 8 8 2
D e lta  P C 3 T 2 .4 7 2 2 ,2 2 0 .0 8 0 0
E 0 .3 5 4 1 ,11 0 .5 6 3 9
C 0 .0 6 3 2 ,2 2 0 .9 3 9 1
T * E 2 .1 7 1 1 ,11 0 .1 1 1 2
T * C 1 .3 7 6 2 ,2 2 0 .2 6 7 7
E * C 0 .5 1 6 1 ,11 0 .4 8 7 5
T * E * C 0 .3 5 6 2 ,2 2 0 .7 8 5 1
T h e ta  P C I T 1 .9 4 2 2 ,2 2 0 .1 4 3 0
E 1 0 .8 4 8 1 ,1 1 * *  0 .0 0 7 2
C 2 .9 9 2 2 ,2 2 0 .0 7 0 9
T * E 0 .1 4 9 1 ,1 1 0 .9 2 9 5
T * C 1 .5 0 3 2 ,2 2 0 .2 3 2 6
E * C 2 .8 5 3 1 ,1 1 0 .1 1 9 3
T * E * C 0 .7 5 6 2 ,2 2 0 .5 2 6 7
T h e ta  P C 2 T 0 .0 5 2 2 ,2 2 0 .9 8 4 2
E 2 .1 0 8 1 ,1 1 0 .1 7 4 4
C 0 .0 8 6 2 ,2 2 0 .9 1 7 9
T * E 0 .1 9 5 1 ,11 0 .8 9 8 7
T * C 1 .2 2 9 2 ,2 2 0 .3 1 5 0
E * C 6 .7 6 8 1 ,11 * 0 .0 2 4 6
T * E * C 0 .5 9 4 2 ,2 2 0 .6 2 2 8
T h e ta  P C 3 T 0 .7 7 4 2 ,2 2 0 .5 1 6 9
E 1 0 .3 2 9 1 ,11 * *  0 .0 0 8 2
C 0 .0 4 0 2 ,2 2 0 .9 6 0 9
T * E 1 .3 6 3 1 ,11 0 .2 7 1 7
T * C 0 .5 1 7 2 ,2 2 0 .6 7 2 9
E * C 1 .3 6 0 1 ,11 0 .2 6 8 2
T * E * C 0 .4 0 0 2 ,2 2 0 .7 5 3 5
A lp h a  P C I T 1 .0 4 3 2 ,2 2 0 .3 8 6 7
E 3 .4 4 6 1 ,11 0 .0 9 0 4
C 0 .7 0 1 2 ,2 2 0 .5 0 6 8
T * E 0 .3 3 1 1 ,1 1 0 .8 0 3 1
T * C 0 .3 6 6 2 ,2 2 0 .7 7 7 4
E * C 2 .0 3 1 1 ,11 0 .1 8 1 9
2 8 2
T e s t V a r ia b le F  V a lu e
' S o m ° f
P r o b a b i l i t y
T * E * C 0 .1 8 8 2 ,2 2 0 .9 0 3 4
A lp h a  P C 2 T 0 .2 8 1 2 ,2 2 0 .8 3 8 8
E 2 .3 2 7 1 ,11 0 .1 5 5 4
C 1 .0 6 3 2 ,2 2 0 .3 6 2 5
T * E 0 .1 9 0 1 ,1 1 0 .9 0 2 5
T * C 0 .9 5 6 2 ,2 2 0 .4 2 5 1
E * C 0 .2 1 3 1 ,1 1 0 .6 5 3 4
T * E * C 0 .6 2 1 2 ,2 2 0 .6 0 6 4
A lp h a  P C 3 T 1 .7 6 9 2 ,2 2 0 .1 7 3 0
E 4 .4 2 2 1 ,11 0 .0 5 9 3
C 5 .2 0 6 2 ,2 2 * 0 .0 1 4 1
T * E 0 .2 0 5 1 ,1 1 0 .8 9 2 0
T * C 0 .5 7 0 2 ,2 2 0 .6 3 8 6
E * C 3 .6 1 8 1 ,11 0 .0 8 3 7
T * E * C 0 .6 3 7 2 ,2 2 0 .5 9 6 1
B e t a l  P C I T 0 .6 9 1 2 ,2 2 0 .5 6 4 0
E 1 .1 4 8 1 ,11 0 .3 0 6 9
C 1 .6 0 4 2 ,2 2 0 .2 2 3 7
T * E 2 .0 2 6 1 ,11 0 .1 3 0 3
T * C 0 .1 9 8 2 ,2 2 0 .8 9 7 2
E * C 0 .1 6 0 1 ,1 1 0 .6 9 6 8
T * E * C 2 .2 8 3 2 ,2 2 0 .0 9 8 4
B e t a l  P C 2 T 0 .0 3 7 2 ,2 2 0 .9 9 0 3
E 0 .8 7 0 1 ,11 0 .3 7 1 0
C 0 .3 7 1 2 ,2 2 0 .6 9 4 3
T * E 0 .1 2 8 1 ,1 1 0 .9 4 2 7
T * C 1 .2 8 1 2 ,2 2 0 .2 9 7 4
E * C 0 .2 9 0 1 ,11 0 .6 0 0 9
T * E * C 0 .4 5 6 2 ,2 2 0 .7 1 4 7
B e t a l  P C 3 T 3 .3 4 2 2 ,2 2 0 .0 3 1 8
E 0 .2 2 3 1 ,1 1 0 .6 4 6 0
C 0 .4 2 6 2 ,2 2 0 .6 5 8 4
T * E 1 .2 5 0 1 ,11 0 .3 0 7 9
T * C 0 .4 1 9 2 ,2 2 0 .7 4 0 5
E * C 0 .0 2 1 1 ,11 0 .8 8 7 4
T * E * C 1 .1 2 2 2 ,2 2 0 .3 5 4 6
B e ta 2  P C I T 1 .3 6 4 2 ,2 2 0 .2 7 1 2
E 1 1 .3 4 3 1 ,11 * *  0 .0 0 6 3
C 0 .8 3 5 2 ,2 2 0 .4 4 7 2
T * E 0 .2 3 0 1 ,1 1 0 .8 7 4 9
T * C 0 .3 3 4 2 ,2 2 0 .8 0 0 5
E * C 0 .2 4 3 1 ,11 0 .6 3 1 7
T * E * C 4 .7 2 3 2 ,2 2 0 .0 0 8 0
B e ta 2  P C 2 T 0 .9 4 5 2 ,2 2 0 .4 3 0 3
E 1 .0 5 8 1 ,1 1 0 .3 2 5 8
C 0 .1 1 0 2 ,2 2 0 .8 9 6 3
T * E 0 .1 6 6 1 ,1 1 0 .9 1 8 2
T * C 0 .9 8 8 2 ,2 2 0 .4 1 0 5
E * C 0 .7 3 2 1 ,11 0 .4 1 0 5
T * E * C 0 .4 6 5 2 ,2 2 0 .7 0 8 3
283
B e ta 2  P C S
V a r ia b le
T
F  V a lu e
0 .1 5 9 2 ,2 2 0 .9 2 3 2
E 0 .3 7 7 1 ,11 0 .5 5 1 7
C 0 .6 0 6 2 ,2 2 0 .5 5 4 4
T * E 1 .1 3 7 1 ,1 1 0 .3 4 8 6
T * C 0 .1 6 6 2 ,2 2 0 .9 1 8 2
E * C 3 .3 7 1 1 ,1 1 0 .0 9 3 5
T * E * C 0 .0 0 5 2 ,2 2 1 .0 0 0 0
B e ta 3  P C I T 0 .0 7 6 2 ,2 2 0 .9 7 2 6
E 1 0 .9 6 2 1 ,1 1 * *  0 .0 0 6 9
C 0 .1 6 6 2 ,2 2 0 .8 4 8 1
T * E 0 .1 5 0 1 ,1 1 0 .9 2 9 0
T * C 0 .0 3 1 2 ,2 2 0 .9 9 2 4
E * C 0 .0 1 9 1 ,11 0 .8 9 2 9
T * E * C 0 .8 3 6 2 ,2 2 0 .4 8 3 5
B e ta S  P C 2 T 0 .3 7 7 2 ,2 2 0 .7 7 0 1
E 0 .0 7 9 1 ,11 0 .7 8 3 9
C 0 .3 5 7 2 ,2 2 0 .7 0 3 8
T * E 1 .2 4 0 1 ,1 1 0 .3 1 1 3
T * C 1 .4 9 3 2 ,2 2 0 .2 3 5 1
E * C 0 .4 9 0 1 ,1 1 0 .4 9 8 5
T * E * C 0 .9 2 2 2 ,2 2 0 .4 4 0 9
B e ta 3  P C S T 2 .9 5 9 2 ,2 2 0 .0 4 7 5
E 0 .9 7 5 1 ,1 1 0 .3 4 4 7
C 1 .9 5 6 2 ,2 2 0 .1 6 5 2
T * E 1 .2 9 6 1 ,11 0 .2 9 2 4
T * C 0 .3 8 0 2 ,2 2 0 .7 6 7 6
E * C 1 .4 7 0 1 ,1 1 0 .2 5 0 7
T * E * C 0 .5 3 7 2 ,2 2 0 .6 5 9 8
2 8 4
T a b le  A .4  F u ll  A n a ly s i s  o f  V a r ia n c e  r e s u lts  f o r  c i t a lo p r a m  h y d r o b r o m id e  c o m p a r e d  t o  p l a c e b o
Performance Tests
T e s t V a r ia b le F  V a lu e D e g r e e s  of 
F r e e d o m '
C F F T 0 .3 2 9 2 ,2 2 0 .7 2 2 0
C 1 .2 0 6 1 ,1 1 0 .2 9 5 5
T * C 0 .3 4 3 2 ,2 2 0 .7 1 2 4
M R T T 1 .2 0 8 2 ,2 2 0 .3 1 4 1
R 1 .2 8 8 1 9 ,2 0 9 0 .1 9 3 7
C 0 .5 0 9 1 ,1 1 0 .4 9 0 3
T * R 0 .7 4 6 3 8 ,4 1 7 0 .8 6 5 4
T * C 0 .2 3 8 2 ,2 2 0 .7 9 0 7
R * C 0 .9 4 3 1 9 ,2 0 9 0 .5 3 0 3
T * R * C 1 .2 9 9 3 8 ,3 8 1 0 .1 1 7 1
R R T T 1 .3 1 0 2 ,2 2 0 .2 8 6 4
R 0 .9 3 7 1 9 ,2 0 9 0 .5 3 7 6
C 1 .8 8 0 1 ,1 1 0 .1 9 7 6
T * R 0 .6 4 9 3 8 ,4 1 7 0 .9 4 8 3
T * C 0 .6 8 4 2 ,2 2 0 .5 1 1 9
R * C 1 .2 6 1 1 9 ,2 0 9 0 .2 1 2 3
T * R * C 0 .9 8 6 3 8 ,3 8 1 0 .4 9 7 7
T R T T 0 .2 6 1 2 ,2 2 0 .7 7 2 3
R 0 .8 8 6 1 9 ,2 0 9 0 .6 0 0 8
C 0 .3 2 2 1 ,1 1 0 .5 8 1 9
T * R 1 .0 1 9 3 8 ,4 1 7 0 .4 4 2 7
T * C 0 .8 1 7 2 ,2 2 0 .4 5 1 5
R * C 1 .6 5 2 1 9 ,2 0 9 0 .0 4 6 9
T * R * C 1 .2 5 6 3 8 ,3 8 1 0 .1 4 9 3
C T T  S c o r e T 0 .4 8 1 2 ,2 2 0 .6 2 2 7
C 1 .1 3 0 1 ,1 1 0 .3 1 0 5
T * C 0 .5 5 7 2 ,1 8 0 .5 7 9 8
C T T  R T T 4 .1 8 4 2 ,2 2 0 .0 2 7 9
C 0.111 1 ,1 1 0 .7 4 5 3
T * C 0 .9 4 1 2 ,1 6 0 .4 0 7 1
S T M  P re se n t  R T N 9 5 .6 7 7 2 ,2 2 * * *  0.0000
T 3 .4 5 2 2 ,2 2 * 0 .0 4 8 2
C 0 .5 1 4 1 ,1 1 0 .4 8 8 3
N * T 0 .1 9 0 4 ,4 4 0 .9 4 2 4
N * C 0 .3 4 1 2 ,2 2 0 .7 1 3 8
T * C 1 .0 1 2 2 ,1 8 0 .3 7 9 5
N * T * C 0 .8 6 3 4 ,3 6 0 .4 9 4 7
S T M  A b s e n t  R T N 4 3 .2 2 9 2 ,2 2 * * *  0.0000
T 3 .1 9 7 2 ,2 2 0 .5 8 7 0
C 0 .0 0 5 1 ,1 1 0 .9 4 4 5
N * T 3 .6 8 4 4 ,4 4 * 0 .0 1 1 2
N * C 0 .4 2 1 2 ,2 2 0 .6 6 0 0
T * C 0 .0 5 3 2 ,1 8 0 .9 5 0 4
N * T * C 1 .0 4 5 4 ,3 6 0 .3 9 7 3
S T M  P re s e n t  N u m b e r N 6 .0 5 2 2 ,2 2 * *  0 .0 0 7 7
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T 0 .2 5 2 2 ,2 2 0 .7 7 9 6
C 0 .0 6 1 1 ,1 1 0 .8 0 8 8
N * T 1 .7 2 7 4 ,4 4 0 .1 6 0 6
N * C 1 .4 5 4 2 ,2 2 0 .2 5 1 5
T * C 0 .0 1 7 2 ,1 8 0 .9 8 4 5
N * T * C 1 .1 4 2 4 ,3 6 0 .3 5 1 9
S T M  A b s e n t  N u m b e r N 2 .8 6 6 2 ,2 2 0 .0 7 6 3
T 0 .7 3 1 2 ,2 2 0 .4 8 9 4
C 0 .0 7 8 1 ,1 1 0 .7 8 4 5
N * T 1 .2 0 3 4 ,4 4 0 .3 2 2 2
N * C 1 .0 3 1 2 ,2 2 0 .3 6 9 6
T * C 1 .0 5 4 2 ,1 8 0 .3 6 5 5
N * T * C 0 .2 3 7 4 ,3 6 0 .9 1 5 4
Mood state
T e s t V a r ia b le F  V a lu e D e g r e e s  o f
P O M S  C A c 4 .1 9 5 mi 0 .0 6 5 2
T 1 .8 0 5 2,22 0 .1 8 4 7
C * T 1 .1 8 6 2,22 0 .3 2 0 6
P O M S  A H C 2 .6 3 1 1 ,11 0 .1 3 3 1
T 0 .0 6 1 2,22 0 .9 4 2 2
C * T 0 .7 0 7 2,22 0 .5 0 0 7
P O M S  E D C 1 .3 8 3 1 ,11 0 .2 6 4 3
T 2 .1 8 2 2,22 0 .1 3 3 8
C * T 0 .6 1 9 2,22 0 .5 4 5 0
P O M S  C U C 0 .7 3 0 1 ,11 0 .4 1 1 1
T 1 .0 2 9 2,22 0 .3 7 0 4
C * T 0 .0 2 3 2,22 0 .9 7 8 5
P O M S  E T C 1 .2 2 3 1 ,11 0 .2 9 2 3
T 3 .2 8 2 2,22 0 .0 5 5 0
C * T 0 .0 1 6 2,22 0 .9 8 5 4
P O M S  C C C 1 .3 9 3 1 ,11 0 .2 6 2 7
T 3 .7 2 8 2,22 * 0 .0 3 9 1
C * T 0 .5 3 3 2,22 0 .5 9 2 1
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EEG Power
T e s t V a r ia b le F  V a lu e
F r e e d o m
P r o b a b il i t y
D e lt a  P o w e r C H 1 0 .8 1 7 1 9 ,2 0 9 * * *  0 .0 0 0 0
T 1 .8 2 4 2 ,2 2 0 .1 8 1 6
E 1 9 .6 4 7 1 ,11 * * *  0 .0 0 1 0
C 0 .0 5 1 1,11 0 .8 2 5 5
C H * T 1 .4 5 5 3 8 ,4 1 8 * 0 .0 4 3 6
C H * E 5 .2 9 6 1 9 ,2 0 9 * * *  0 .0 0 0 0
C H * C 0 .6 2 0 1 9 ,2 0 9 0 .8 8 9 1
T * E 2 .0 0 3 2 ,2 2 0 .1 5 5 7
T * C 0 .4 8 1 2 ,2 2 0 .6 2 2 4
E * C 0 .0 2 8 1 ,11 0 .8 6 9 3
C H * T * E 0 .7 6 8 3 8 ,4 1 8 0 .8 4 0 3
C H * T * C 1 .1 8 5 3 8 ,4 1 8 0 .2 1 4 6
C H * E * C 0 .6 1 8 1 9 ,2 0 9 0 .8 9 0 4
T * E * C 0 .5 9 1 2 ,2 2 0 .5 5 9 7
C H * T * E * C 1 .0 9 0 3 8 ,4 1 8 0 .3 3 3 3
T h e ta  P o w e r C H 2 9 .0 8 9 1 9 ,2 0 9 * * *  0 .0 0 0 0
T 9 .5 8 2 2 ,2 2 * * *  0 .0 0 1 0
E 2 8 .5 6 6 1 ,11 * *  0 .0 0 0 2
C 0 .6 9 8 1,11 0 .4 2 1 1
C H * T 0 .8 1 4 3 8 ,4 1 8 0 .7 7 7 8
C H * E 3 .8 6 4 1 9 ,2 0 9 * * *  0 .0 0 0 0
C H * C 1 .0 2 5 1 9 ,2 0 9 0 .4 3 3 7
T * E 0 .1 2 1 2 ,2 2 0 .8 8 7 8
T * C 1 .0 8 8 2 ,2 2 0 .3 5 0 6
E * C 0 .8 2 5 1 ,11 0 .3 8 2 9
C H * T * E 1 .0 5 3 3 8 ,4 1 8 0 .3 8 8 8
c h * t * c 0 .8 3 8 3 8 ,4 1 8 0 .7 4 3 1
C H * E * C 0 .8 3 7 1 9 ,2 0 9 0 .6 6 1 7
T * E * C 0 .1 0 0 2 ,2 2 0 .9 0 6 5
C H * T * E * C 0 .9 9 2 3 8 ,4 1 8 0 .4 8 6 7
A lp h a  P o w e r C H 5 8 .6 7 0 1 9 ,2 0 9 * * *  0 .0 0 0 0
T 2 .2 3 7 2 ,2 2 0 .1 2 7 8
E 6 8 .8 0 6 1 ,11 * * *  0 .0 0 0 0
C 0 .3 9 4 1 ,11 0 .5 4 2 9
C H * T 1 .1 5 1 3 8 ,4 1 8 0 .2 5 3 5
C H * E 1 2 .8 4 4 1 9 ,2 0 9 * * *  0 .0 0 0 0
C H * C 0 .8 2 1 1 9 ,2 0 9 0 .6 8 0 4
T * E 3 .2 6 6 2 ,2 2 0 .0 5 5 7
T * C 1 .2 1 5 2 ,2 2 0 .3 1 2 2
E * C 0 .9 0 9 1,11 0 .3 6 0 7
C H * T * E 1 .1 8 7 3 8 ,4 1 8 0 .2 1 2 5
C H * T * C 1 .1 4 5 3 8 ,4 1 8 0 .2 6 0 9
C H * E * C 0 .9 4 7 1 9 ,2 0 9 0 .5 2 5 2
T * E * C 0 .9 2 9 2 ,2 2 0 .4 0 6 4
C H * T * E * C 1 .2 9 3 3 8 ,4 1 8 0 .1 1 9 9
B e t a l  P o w e r C H 4 7 .0 5 7 1 9 ,2 0 9 * * *  0 .0 0 0 0
T 7 .2 0 3 2 ,2 2 * *  0 .0 0 3 8
E 1 9 .2 6 6 U 1 * *  0 .0 0 1 1
2 8 7
C 1 .3 3 2 1 ,1 1 0 .2 7 2 7
C H * T 1 .5 2 2 3 8 ,4 1 8 *  0 .0 2 7 4
C H * E 8 .7 1 3 1 9 ,2 0 9 * * *  0 .0 0 0 0
C H * C 0 .7 1 3 1 9 ,2 0 9 0 .8 0 3 2
T * E 0 .4 5 6 2 ,2 2 0 .6 3 7 7
T * C 1 .1 8 2 2 ,2 2 0 .3 2 1 6
E * C 0 .0 7 7 1 ,1 1 0 .7 8 5 9
C H * T * E 0 .7 2 9 3 8 ,4 1 8 0 .8 8 3 2
C H * T * C 0 .9 5 7 3 8 ,4 1 8 0 .5 4 5 4
C H * E * C 0 .9 0 0 1 9 ,2 0 9 0 .5 8 3 0
T * E * C 1 .6 4 4 2 ,2 2 0 .2 1 2 5
c h * t * e * c 1 .1 8 6 3 8 ,4 1 8 0 .2 1 4 1
B e ta 2  P o w e r C H 1 6 .0 4 0 1 9 ,2 0 9 * * *  0 .0 0 0 0
T 6 .6 7 5 2 ,2 2 * *  0 .0 0 5 2
E 1 3 .4 2 6 1 ,1 1 * *  0 .0 0 3 7
C 1 .3 0 2 1 ,1 1 0 .2 7 7 9
C H * T 2 .1 5 7 3 8 ,4 1 8 * * *  0 .0 0 0 1
C H * E 8 .4 8 6 1 9 ,2 0 9 * * *  0 .0 0 0 0
C H * C 0 .8 3 3 1 9 ,2 0 9 0 .6 6 6 0
T * E 3 .0 8 2 2 ,2 2 0 .0 6 4 3
T * C 0 .9 0 1 2 ,2 2 0 .4 1 7 1
E * C 1 .5 2 8 1 ,1 1 0 .2 4 2 1
C H * T * E 1 .0 8 9 3 8 ,4 1 8 0 .3 3 5 0
c h * t * c 1 .3 0 3 3 8 ,4 1 8 0 .1 1 2 9
C H * E * C 0 .6 2 7 1 9 ,2 0 9 0 .8 8 3 3
T * E * C 1 .9 5 3 2 ,2 2 0 .1 6 2 6
C H * T * E * C 1 .1 6 6 3 8 ,4 1 8 0 .2 3 6 3
B e ta S  P o w e r C H 3 .4 5 2 1 9 ,2 0 9 * * *  0 .0 0 0 0
T 1 3 .1 2 2 2 ,2 2 * * *  0 .0 0 0 2
E 2 .9 5 8 1 ,11 0 .1 1 3 4
C 1 .5 9 3 1 ,1 1 0 .2 3 2 9
C H * T 2 .8 9 7 3 8 ,4 1 8 * * *  0 .0 0 0 0
C H * E 7 .5 7 7 1 9 ,2 0 9 * * *  0 .0 0 0 0
C H * C 0 .7 2 9 1 9 ,2 0 9 0 .7 8 6 1
T * E 2 .5 7 9 2 ,2 2 0 .0 9 6 3
T * C 0 .6 2 1 2 ,2 2 0 .5 4 3 6
E * C 1 .1 6 7 1 ,1 1 0 .3 0 3 1
c h * t * e 0 .7 3 6 3 8 ,4 1 8 0 .8 7 6 9
C H * T * C 1 .1 6 4 3 8 ,4 1 8 0 .2 3 8 3
C H * E * C 0 .9 4 4 1 9 ,2 0 9 0 .5 2 9 7
T * E * C 0 .3 2 0 2 ,2 2 0 .7 2 8 8
C H * T * E * C 0 .9 4 7 3 8 ,4 1 8 0 .5 6 3 3
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EEG PF
T e s t V a r ia b le F  V a lu e D e g r e e s  o f
TA J
F r e e d o m
P r o b a b i l i t y
D e lt a  P F C H 1 0 .6 1 6 1 9 ,2 0 9 * * *  0 .0 0 0 0
T 2 .7 3 9 2 ,2 2 0 .0 8 4 5
E 0 .7 2 6 1 ,11 0 .4 1 2 2
C 1 .1 9 9 1,11 0 .2 9 6 9
C H * T 0 .8 3 7 3 8 ,4 1 8 0 .7 4 4 4
C H * E 4 .8 0 2 1 9 ,2 0 9 * * *  0 .0 0 0 0
C H * C 0 .7 2 8 1 9 ,2 0 9 0 .7 8 7 6
T * E 2 .6 4 3 2 ,2 2 0 .0 9 1 4
T * C 0 .4 1 7 2 ,2 2 0 .6 6 2 3
E * C 0 .1 8 6 1 ,11 0 .6 7 4 4
C H * T * E 0 .9 6 6 3 8 ,4 1 8 0 .5 3 1 4
C H * T * C 0 .7 3 8 3 8 ,4 1 8 0 .8 7 4 4
C H * E * C 1 .3 2 5 1 9 ,2 0 9 0 .1 7 0 2
T * E * C 1 .2 7 3 2 ,2 2 0 .2 9 6 1
C H * T * E * C 0 .9 2 2 3 8 ,4 1 8 0 .6 0 6 1
T h e t a  P F C H 1 .3 0 4 1 9 ,2 0 9 0 .1 8 2 8
T 6 .2 4 5 2 ,2 2 * *  0 .0 0 6 8
E 6 .8 8 4 1 ,11 * 0 .0 2 3 7
C 0 .1 5 7 1 ,11 0 .6 9 9 2
C H * T 0 .6 7 5 3 8 ,4 1 8 0 .9 3 1 1
C H * E 0 .8 1 3 1 9 ,2 0 9 0 .6 9 0 2
C H * C 1 .3 8 9 1 9 ,2 0 9 0 .1 3 4 6
T * E 5 .7 8 6 2 ,2 2 * *  0 .0 0 9 2
T * C 1 .4 3 7 2 ,2 2 0 .2 5 5 4
E * C 1 .2 6 2 1 ,1 1 0 .2 8 5 0
C H * T * E 1 .7 7 5 3 8 ,4 1 8 * *  0 .0 0 4 0
C H * T * C 1 .9 3 8 3 8 ,4 1 8 0 .5 7 8 3
C H * E * C 0 .9 0 9 1 9 ,2 0 9 0 .5 7 2 5
T * E * C 0 .6 5 1 2 ,2 2 0 .5 2 8 5
C H * T * E * C 1 .2 0 5 3 8 ,4 1 8 0 .1 9 3 4
A lp h a  P F C H 6 .8 4 8 1 9 ,2 0 9 * * *  0 .0 0 0 0
T 0 .9 2 6 2 ,2 2 0 .4 0 7 6
E 1 .7 5 3 1 ,11 0 .2 1 2 3
C 1 .9 2 9 1 ,1 1 0 .1 9 2 3
C H * T 0 .6 3 3 3 8 ,4 1 8 0 .9 5 7 4
C H * E 1 .9 4 7 1 9 ,2 0 9 * 0 . 0 1 2 5
C H * C 1 .0 6 6 1 9 ,2 0 9 0 .3 8 7 9
T * E 0 .1 5 3 2 ,2 2 0 .8 6 0 2
T * C 1 .3 9 0 2 ,2 2 0 .2 6 6 5
E * C 1 .7 0 7 1 ,1 1 0 .2 1 8 0
C H * T * E 1 .0 3 1 3 8 ,4 1 8 0 .4 2 2 8
c h * t * c 1 .0 9 1 3 8 ,4 1 8 0 .3 3 1 7
C H * E * C 1 .0 4 1 1 9 ,2 0 9 0 .4 1 5 8
T * E * C 1 .8 4 3 2 ,2 2 0 .1 7 8 8
C H * T * E * C 1 .2 5 7 3 8 ,4 1 8 0 .1 4 7 1
B e t a l  P F C H 4 .4 6 2 1 9 ,2 0 9 * * *  0 .0 0 0 0
T 0 .0 4 8 2 ,2 2 0 .9 5 4 8
E 0 .5 7 2 1 ,1 1 0 .4 6 5 1
C 0 .2 5 7 1 ,1 1 0 .6 2 1 8
2 8 9
C H * T 1 .6 8 1 3 8 ,4 1 8 * *  0 .0 0 8 4
C H * E 1 .1 6 1 1 9 ,2 0 9 0 .2 9 3 7
C H * C 0 .7 1 1 1 9 ,2 0 9 0 .8 0 5 8
T * E 0 .7 4 0 2 ,2 2 0 .4 8 5 2
T * C 0 .4 5 5 2 ,2 2 0 .6 3 8 4
E * C 1 .5 0 7 1 ,11 0 .2 4 5 1
C H * T * E 0 .9 3 8 3 8 ,4 1 8 0 .5 7 8 7
c h * t * c 1 .2 3 8 3 8 ,4 1 8 0 .1 6 2 9
C H * E * C .0 6 1 7 1 9 ,2 0 9 0 .8 9 1 5
T * E * C 0 .9 5 5 2 ,2 2 0 .3 9 6 5
c h * t * e * c 1 .2 2 8 3 8 ,4 1 8 0 .1 7 1 4
B e ta 2  P F C H 1 .3 2 3 1 9 ,2 0 9 0 .1 7 1 0
T 2 .3 4 7 2 ,2 2 0 .1 1 6 6
E 0 .3 7 7 1 ,1 1 0 .5 5 1 4
C 1 .8 5 3 1 ,1 1 0 .2 0 0 6
C H * T 0 .9 8 7 3 8 ,4 1 8 0 .4 9 4 9
C H * E 2 .3 6 5 1 9 ,2 0 9 * *  0 .0 0 1 6
C H * C 0 .9 6 6 1 9 ,2 0 9 0 .5 0 2 3
T * E 0 .2 7 0 2 ,2 2 0 .7 6 5 8
T * C 0 .0 6 3 2 ,2 2 0 .9 4 0 9
E * C 1 .7 8 5 1 ,1 1 0 .2 0 8 5
c h * t * e 0 .7 3 9 3 8 ,4 1 8 0 .8 7 2 7
c h * t * c 1 .0 5 3 3 8 ,4 1 8 0 .3 8 8 6
C H * E * C 0 .8 1 9 1 9 ,2 0 9 0 .6 8 3 4
T * E * C 0 .9 0 7 2 ,2 2 0 .4 1 4 5
c h * t * e * c 1 .1 0 1 3 8 ,4 1 8 0 .3 1 8 0
B e ta 3  P F C H 8 .1 8 4 1 9 ,2 0 9 * * *  0 .0 0 0 0
T 2 .5 7 0 2 ,2 2 0 .0 9 7 0
E 3 .2 4 5 1 ,1 1 0 .0 9 9 1
C 0 .3 5 5 1 ,11 0 .5 6 3 3
C H * T 1 .0 9 2 3 8 ,4 1 8 0 .3 3 0 9
C H * E 1 .0 7 7 1 9 ,2 0 9 0 .3 7 6 4
C H * C 0 .9 0 9 1 9 ,2 0 9 0 .5 7 2 5
T * E 1 .3 5 2 2 ,2 2 0 .2 7 5 6
T * C 1 .4 8 2 2 ,2 2 0 .2 4 5 4
E * C 2 .1 9 9 1 ,1 1 0 .1 6 6 2
c h * t * e 1 .4 3 3 3 8 ,4 1 8 0 .0 5 0 2
C H * T * C 1 .0 4 1 3 8 ,4 1 8 0 .4 0 6 6
C H * E * C 1 .0 8 9 1 9 ,2 0 9 0 .3 6 3 9
T * E * C 0 .7 0 1 2 ,2 2 0 .5 0 3 8
c h * t * e * c 0 .9 5 7 3 8 ,4 1 8 0 .5 4 5 4
2 9 0
Principal Components EEG Power
T e s t V a r ia b le F  V a lu e
F r e S b m
D e lt a  P C I T 0 .6 8 4 2 ,2 2 0 .5 1 1 8
E 3 .5 5 6 1 ,1 1 0 .0 8 6 0
C 1 .9 9 4 2 ,2 2 0 .1 8 5 5
T * E 0 .4 3 3 1 ,11 0 .6 5 2 0
T * C 0 .8 4 7 2 ,2 2 0 .4 2 8 5
E * C 1 .7 0 2 1 ,11 0 .2 1 8 6
T * E * C 2 .0 0 4 2 ,2 2 0 .1 5 5 6
D e lt a  P C 2 T 0 .9 4 0 2 ,2 2 0 .4 0 2 2
E 3 .1 4 7 1 ,11 0 .1 0 3 7
C 0 .1 2 8 2 ,2 2 0 .7 2 7 0
T * E 4 .3 1 4 1 ,11 * 0 .0 2 5 4
T * C 0 .7 6 9 2 ,2 2 0 .4 7 2 1
E * C 0 .8 4 9 1 ,11 0 .3 7 6 5
T * E * C 0 .7 6 4 2 ,2 2 0 .4 7 4 4
D e lt a  P C S T 1 .8 3 4 2 ,2 2 0 .1 8 0 1
E 8 .6 2 9 1 ,11 * 0 . 0 1 3 6
C 1 .3 0 8 2 ,2 2 0 .2 7 7 0
T * E 0 .6 3 4 1 ,11 0 .5 3 6 9
T * C 0 .2 8 4 2 ,2 2 0 .7 5 5 3
E * C 0 .1 6 9 1 ,11 0 .6 8 8 8
T * E * C 0 .6 1 5 2 ,2 2 0 .5 4 7 0
D e lt a  P C 4 T 0 .5 2 5 2 ,2 2 0 .5 9 6 4
E 1 7 .6 6 7 1 ,11 * * 0 . 0 0 1 5
C 1 .4 2 1 2 ,2 2 0 .2 5 8 2
T * E 0 .6 0 8 1 ,11 0 .5 5 0 6
T * C 1 .9 9 4 2 ,2 2 0 .1 5 7 0
E * C 0 .4 1 6 1 ,11 0 .5 3 2 1
T * E * C 0 .6 9 4 2 ,2 2 0 .5 0 7 2
T h e t a  P C  1 T 3 .9 1 4 2 ,2 2 * 0 .0 3 4 0
E 1 4 .8 8 0 1 ,11 * *  0 .0 0 2 7
C 1 .8 9 0 2 ,2 2 0 .1 9 6 5
T * E .0 1 8 3 1 ,11 0 .8 3 4 4
T * C 1 .1 8 6 2 ,2 2 0 .3 2 0 4
E * C 1 .5 3 8 1 ,11 0 .2 4 0 6
T * E * C 0 .7 6 7 2 ,2 2 0 .4 7 3 2
T h e t a  P C 2 T 2 .4 6 4 2 ,2 2 0 .1 0 5 8
E 5 .7 1 8 1 ,11 * 0 .0 3 5 8
C 1 .0 5 5 2 ,2 2 0 .3 2 6 3
T * E 1 .0 3 7 1 ,11 0 .3 6 7 5
T * C 0 .2 2 6 2 ,2 2 0 .7 9 9 6
E * C 0 .5 5 5 1,11 0 .4 7 1 7
T * E * C 0 .8 8 0 2 ,2 2 0 .4 2 5 3
A lp h a  P C  1 T 1 .4 6 3 2 ,2 2 0 .2 4 9 6
E 1 4 .1 3 1 1,11 * *  0 .0 0 3 2
C 0 .9 5 1 2 ,2 2 0 .3 5 0 3
T * E 0 .6 0 8 1 ,11 0 .5 5 0 7
T * C 1 .3 6 7 2 ,2 2 0 .2 7 1 9
E * C 0 .0 9 1 1 ,11 0 .7 6 8 5
2 9 1
T e s t V a r ia b le F  V a lu e D e g r e e s  o f  
F r e e d o m
P r o b a b i l i t y
T * E * C 0 .7 8 3 2 ,2 2 0 .4 6 5 9
A lp h a  P C 2 T 1 .0 6 7 2 ,2 2 0 .3 5 7 4
E 3 2 .6 3 5 1 ,1 1 * * *  0 .0 0 0 1
C 0 .5 3 6 2 ,2 2 0 .4 7 9 4
T * E 1 .7 1 1 1 ,1 1 0 .2 0 0 4
T * C 0 .8 5 6 2 ,2 2 0 .4 3 5 0
E * C 0 .0 0 2 1 ,1 1 0 .9 6 5 4
T * E * C 0 .8 9 8 2 ,2 2 0 .4 1 8 0
B e t a l  P C I T 4 .8 1 7 2 ,2 2 * 0 .0 1 7 7
E 1 .1 8 3 1 ,1 1 0 .2 9 9 9
C 0 .4 0 0 2 ,2 2 0 .5 4 0 0
T * E 0 .2 6 5 1 ,1 1 0 .7 6 9 8
T * C 0 .6 9 7 2 ,2 2 0 .5 0 5 9
E * C 0 .4 2 4 1 ,1 1 0 .5 2 8 3
T * E * C 1 .1 8 1 2 ,2 2 0 .3 2 1 8
B e t a l  P C 2 T 0 .5 1 6 2 ,2 2 0 .6 0 1 9
E 1 7 .2 7 2 1 ,1 1 * *  0 .0 0 1 6
C 0 .1 6 9 2 ,2 2 0 .6 8 8 9
T * E 1 .0 9 9 1 ,1 1 0 .3 4 7 1
T * C 1 .2 3 9 2 ,2 2 0 .6 0 5 4
E * C 0 .2 3 7 1 ,1 1 0 .6 3 6 0
T * E * C 0 .4 1 0 2 ,2 2 0 .2 6 1 6
B e ta 2  P C I T 0 .6 2 8 2 ,2 2 0 .5 3 9 9
E 7 4 .0 9 9 1 ,1 1 * * *  0 .0 0 0 0
C 1 .3 2 5 2 ,2 2 0 .2 7 4 0
T * E 5 .0 5 4 1 ,1 1 * 0 .0 1 5 1
T * C 1 .6 5 4 2 ,2 2 0 .2 1 0 8
E * C 0 .4 0 6 1 ,1 1 0 .5 3 6 8
T * E * C 0 .8 3 5 2 ,2 2 0 .4 4 3 7
B e ta 2  P C 2 T 7 .9 6 0 2 ,2 2 * *  0 .0 0 2 4
E 2 .7 9 7 1 ,1 1 0 .1 2 2 6
C 1 .0 1 4 2 ,2 2 0 .3 3 5 4
T * E 0 .3 6 1 1 ,1 1 0 .7 0 0 3
T * C 1 .6 5 1 2 ,2 2 0 .2 1 1 2
E * C 0 .9 5 8 1 ,11 0 .3 4 8 5
T * E * C 0 .7 3 4 2 ,2 2 0 .4 8 8 2
B e ta 3  P C I T 0 .2 7 3 2 ,2 2 0 .7 6 3 2
E 1 1 .7 5 2 1 ,1 1 * *  0 .0 0 5 7
C 0 .7 0 3 2 ,2 2 0 .4 1 9 4
T * E 2 .2 3 1 1 ,11 0 .1 2 8 4
T * C 0 .9 2 6 2 ,2 2 0 .4 0 7 2
E * C 2 .1 7 6 1 ,1 1 0 .1 6 8 2
T * E * C 1 .8 2 2 2 ,2 2 0 .1 8 2 0
B e ta S  P C 2 T 5 .4 1 7 2 ,2 2 * 0 .0 1 1 8
E 2 .6 7 8 1 ,1 1 0 .1 3 0 0
C 1 .9 7 0 2 ,2 2 0 .1 8 8 0
T * E 0 .3 2 9 1 ,1 1 0 .7 2 2 3
T * C 1 .6 1 1 2 ,2 2 0 .2 1 8 8
E * C 0 .0 6 6 1 ,1 1 0 .8 0 2 6
T * E * C 1 .0 3 2 2 ,2 2 0 .3 6 9 0
2 9 2
T e s t V a r ia b le F  V a lu e
F r e e d o m
P r o b a b i l i t y
B eta S  P C S T 1 .3 9 8 2 ,2 2 0 .2 6 4 5
E 1 2 .4 6 4 1 .1 1 * *  0 .0 0 4 7
C 0 .0 3 0 2 ,2 2 0 .8 6 4 5
T * E 2 .8 5 0 1 .1 1 0 .0 7 7 3
T * C 0 .8 7 9 2 ,2 2 0 .4 2 5 6
E * C 0 .8 1 6 1 .1 1 0 .3 8 5 5
T * E * C 0 .3 4 0 2 ,2 2 0 .7 1 4 7
B eta S  P C 4 T 2 .4 0 5 2 ,2 2 0 .1 1 1 1
E 0 .1 3 6 1 .1 1 0 .7 1 8 9
C 0 .0 3 6 2 ,2 2 0 .8 5 2 2
T * E 2 .0 4 0 1 ,1 1 0 .1 5 0 9
T * C 0 .8 5 4 2 ,2 2 0 .4 3 5 9
E * C 0 .5 4 8 1 .1 1 0 .4 7 4 4
T * E * C 1 .6 4 3 2 ,2 2 0 .2 1 2 7
Principal Components EEG PF
T e s t V a r ia b le F  V a lu e
DFerfe d o Sm f
D e lt a  P C I T 0 .2 5 9 2 ,2 2 0 .7 7 4 4
E 1 .3 0 9 1 ,1 1 0 .2 7 6 7
C 1 .1 4 6 2 ,2 2 0 .3 0 7 3
T * E 1 .1 9 7 1 ,1 1 0 .3 1 7 1
T * C 1 .8 4 2 2 ,2 2 0 .1 7 8 8
E * C 2 .1 0 3 1 ,1 1 0 .1 7 4 9
T * E * C 0 .7 9 5 2 ,2 2 0 .4 6 0 6
D e lt a  P C 2 T 1 .3 3 8 2 ,2 2 0 .2 7 9 0
E 3 .7 7 6 1 ,1 1 0 .0 7 8 0
C 0 .0 2 6 2 ,2 2 0 .8 7 4 9
T * E 0 .0 8 3 1 ,11 0 .9 2 1 8
T * C 0 .0 0 1 2 ,2 2 1 .0 0 0 0
E * C 1 .4 6 0 1 ,11 0 .2 5 2 1
T * E * C 0 .1 1 6 2 ,2 2 0 .8 9 2 4
D e lta  P C S T 1 .0 5 8 2 ,2 2 0 .3 6 0 5
E 0 .0 5 5 1 ,11 0 .8 1 9 5
C 2 .1 8 8 2 ,2 2 0 .1 6 7 1
T * E 2 .4 3 8 1 ,1 1 0 .1 0 8 0
T * C 1 .0 2 3 2 ,2 2 0 .3 7 2 4
E * C 0 .0 5 2 1 ,1 1 0 .8 2 4 1
T * E * C 0 .5 8 2 2 ,2 2 0 .5 6 4 5
D e lta  P C 4 T 1 .3 0 7 2 ,2 2 0 .2 8 7 0
E 3 .7 8 5 1 ,11 0 .0 7 7 8
C 2 .1 6 2 2 ,2 2 0 .1 6 9 4
T * E 0 .8 8 1 1 ,1 1 0 .4 2 4 9
T * C 0 .8 0 8 0 2 ,2 2 0 .4 5 4 9
E * C 0 .5 7 8 1 ,1 1 0 .4 6 2 9
T * E * C 1 .4 1 9 2 ,2 2 0 .2 5 9 6
T h e ta  P C I T 1 .4 6 0 2 ,2 2 0 .5 2 0 2
2 9 3
' ..............T e s t  ' T V a r ia b le  ....  F  V a lu e
1 1
P r o b a b il i t y
E 3 .3 9 6 1 ,11 0 .0 9 2 5
C 0 .1 0 6 2 ,2 2 0 .7 5 1 1
T * E 9 .5 1 6 1 ,11 * *  0 .0 0 1 0
T * C 1 .6 6 6 2 ,2 2 0 .2 0 8 6
E * C 2 .0 8 5 1 ,1 1 0 .1 7 6 5
T * E * C 0 8 1 8 2 ,2 2 0 .4 5 1 0
T h e t a  P C 2 T 1 .5 1 3 2 ,2 2 0 .2 3 8 7
E 0 .0 3 0 1 ,11 0 .8 6 5 8
C 1 .7 9 7 2 ,2 2 0 .2 0 7 0
T * E 3 .3 6 6 1 ,11 0 .0 5 1 5
T * C 1 .3 3 5 2 ,2 2 0 .2 7 9 8
E * C 0 .6 0 6 1 ,11 0 .4 5 2 6
T * E * C 0 .7 5 4 2 ,2 2 0 .4 7 9 0
A lp h a  P C I T 0 .9 4 2 2 ,2 2 0 .4 0 1 2
E 5 .2 7 1 1 ,1 1 * 0 .0 4 2 4
C 1 .0 6 1 2 ,2 2 0 .3 2 5 0
T * E 0 .5 1 0 1 ,11 0 .6 0 5 5
T * C 1 .2 4 2 2 ,2 2 0 .3 0 4 4
E * C 1 .1 6 3 1 ,11 0 .3 0 3 7
T * E * C 1 .5 1 5 2 ,2 2 0 .2 3 8 2
A lp h a  P C 2 T 0 .6 9 7 2 ,2 2 0 .5 0 5 8
E 0 .1 9 3 1 ,11 0 .6 6 8 6
C 0 .2 3 2 2 ,2 2 0 .6 3 9 5
T * E 0 .3 1 5 1 ,11 0 .7 3 2 5
T * C 2 .0 5 0 2 ,2 2 0 .1 4 9 6
E * C 0 .2 4 6 1 ,1 1 0 .6 2 9 8
T * E * C 1 .8 9 5 2 ,2 2 0 .1 7 0 9
B e t a l  P C I T 1 .6 5 4 2 ,2 2 0 .2 1 0 8
E 3 .0 1 2 1 ,1 1 0 .1 1 0 5
C 2 .1 8 5 2 ,2 2 0 .1 6 7 3
T * E 0 .4 9 8 1 ,11 0 .6 1 2 3
T * C 0 .1 7 5 2 ,2 2 0 .8 4 1 4
E * C 0 .3 7 5 1 ,11 0 .5 5 2 8
T * E * C 1 .3 5 7 2 ,2 2 0 .2 7 4 5
B e t a l  P C 2 T 4 .2 5 7 2 ,2 2 * 0 .0 2 6 5
E 0 .3 2 5 1 ,1 1 0 .5 7 9 8
C 1 .1 3 8 2 ,2 2 0 .3 0 8 8
T * E 0 .4 0 2 1 ,11 0 .6 7 2 5
T * C 0 .4 7 0 2 ,2 2 0 .6 2 9 2
E * C 0 .6 6 1 1 ,11 0 .4 3 3 2
T * E * C 1 .2 0 5 2 ,2 2 0 .3 1 5 0
B e ta 2  P C I T 0 .4 2 6 2 ,2 2 0 .6 5 7 0
E 9 .7 3 9 1 ,11 * *  0 .0 0 9 8
C 2 .0 0 9 2 ,2 2 0 .1 8 4 0
T * E 0 .4 6 8 1 ,1 1 0 .6 3 0 5
T * C 0 .8 6 7 2 ,2 2 0 .4 3 0 5
E * C 0 .5 9 1 1 ,11 0 .4 5 8 2
T * E * C 1 .0 8 3 2 ,2 2 0 .3 5 2 2
B e ta 2  P C 2 T 4 .4 5 1 2 ,2 2 * 0 .0 2 3 0
E 1 .1 5 2 1 ,11 0 .3 0 6 0
2 9 4
T e s t V a r ia b le F  V a lu e
S o u f
P r o b a b i l i t y
C 0 .9 2 1 2 ,2 2 0 .3 5 7 7
T * E 0 .1 9 4 1 ,1 1 0 .8 2 5 3
T * C 1 .7 8 9 2 ,2 2 0 .1 8 7 3
E * C 1 .8 4 1 1 ,1 1 0 .2 0 2 0
T * E * C 2 .0 0 4 2 ,2 2 0 .1 5 5 6
B e ta S  P C I T 1 .3 5 7 2 ,2 2 0 .2 7 4 3
E 0 .0 4 0 1 ,1 1 0 .8 4 4 9
C 0 .6 2 9 2 ,2 2 0 .4 4 4 3
T * E 0 .0 8 8 1 ,1 1 0 .9 1 7 5
T * C 1 .3 1 9 2 ,2 2 0 .2 8 4 0
E * C 0 .7 6 0 1 ,1 1 0 .4 0 1 8
T * E * C 1 .2 2 6 2 ,2 2 0 .3 0 9 0
B e ta S  P C 2 T 3 .4 6 5 2 ,2 2 * 0 .0 4 7 8
E 1 .3 8 0 1 ,1 1 0 .2 6 4 9
C 1 .7 4 5 2 ,2 2 0 .2 1 3 2
T * E 1 .2 7 4 1 ,1 1 0 .2 9 5 7
T * C 1 .6 6 6 2 ,2 2 0 .2 0 8 5
E * C 1 .2 9 9 1 ,1 1 0 .2 7 8 4
T * E * C 0 .9 1 9 2 ,2 2 0 .4 1 0 2
B e ta S  P C 3 T 0 .7 3 8 2 ,2 2 0 .4 8 6 2
E 0 .4 5 9 1 ,1 1 0 .5 1 1 8
C 0 .6 4 5 2 ,2 2 0 .4 3 8 9
T * E 4 .2 8 0 1 ,1 1 * 0 .0 2 6 0
T * C 0 .6 3 0 2 ,2 2 0 .5 3 9 1
E * C 0 .7 5 7 1 ,1 1 0 .4 0 2 6
T * E * C 1 .4 7 0 2 ,2 2 0 .2 4 8 1
B e ta S  P C 4 T 0 .1 7 6 2 ,2 2 0 .8 4 0 6
E 0 .0 9 0 1 ,1 1 0 .7 6 9 2
C 0 .8 8 2 2 ,2 2 0 .3 6 7 7
T * E 1 .2 9 9 1 ,1 1 0 .2 8 9 2
T * C 0 .2 2 6 2 ,2 2 0 .7 9 9 5
E * C 1 .0 1 6 1 ,1 1 0 .3 3 5 1
T * E * C 1 .0 0 3 2 ,2 2 0 .3 7 9 2
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